Skip to main content

Publications

What type of publication do you want to show?

2024

Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics

De Block, C., Peleshok, J., Wilding, J. P. H., Kwan, A. Y. M., Rasouli, N., Maldonado, J. M., . . . Benneyworth, B. D. (n.d.). Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics. Diabetes Therapy. doi:10.1007/s13300-024-01660-0

DOI
10.1007/s13300-024-01660-0
Journal article

Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on diabetic eye complications. Reply to Tsai Y-H, Hemphill NO, Kurth T.

Eleftheriadou, A., Riley, D., Zhao, S. S., Austin, P., Hernández, G., Lip, G. Y. H., . . . Alam, U. (2024). Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on diabetic eye complications. Reply to Tsai Y-H, Hemphill NO, Kurth T.. Diabetologia. doi:10.1007/s00125-024-06314-1

DOI
10.1007/s00125-024-06314-1
Journal article

Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes: A systematic review with multiple network meta-regressions

Zhu, J. -J., Wilding, J. P. H., & Gu, X. -S. (n.d.). Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes: A systematic review with multiple network meta-regressions. World Journal of Diabetes, 15(10), 2135-2146. doi:10.4239/wjd.v15.i10.2135

DOI
10.4239/wjd.v15.i10.2135
Journal article

Early findings from the NHS Type 2 Diabetes Path to Remission Programme: a prospective evaluation of real-world implementation.

Valabhji, J., Gorton, T., Barron, E., Safazadeh, S., Earnshaw, F., Helm, C., . . . Bakhai, C. (2024). Early findings from the NHS Type 2 Diabetes Path to Remission Programme: a prospective evaluation of real-world implementation.. The lancet. Diabetes & endocrinology, 12(9), 653-663. doi:10.1016/s2213-8587(24)00194-3

DOI
10.1016/s2213-8587(24)00194-3
Journal article

Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study.

Anson, M., Henney, A. E., Broadwell, N., Zhao, S. S., Ibarburu, G. H., Lip, G. Y. H., . . . Alam, U. (2024). Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study.. EClinicalMedicine, 75, 102777. doi:10.1016/j.eclinm.2024.102777

DOI
10.1016/j.eclinm.2024.102777
Journal article

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.

Deanfield, J., Verma, S., Scirica, B. M., Kahn, S. E., Emerson, S. S., Ryan, D., . . . SELECT Trial Investigators. (2024). Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.. Lancet (London, England), 404(10454), 773-786. doi:10.1016/s0140-6736(24)01498-3

DOI
10.1016/s0140-6736(24)01498-3
Journal article

1896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 58

MI KANG, Y. U., MELLONI, G. E. M., CAHN, A., RAZ, I., MOURA, F., BHATT, D. L., . . . WIVIOTT, S. D. (2024). 1896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 58. Diabetes, 73(Supplement_1). doi:10.2337/db24-1896-lb

DOI
10.2337/db24-1896-lb
Journal article

Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.

Eleftheriadou, A., Riley, D., Zhao, S. S., Austin, P., Hernández, G., Lip, G. Y. H., . . . Alam, U. (2024). Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.. Diabetologia. doi:10.1007/s00125-024-06132-5

DOI
10.1007/s00125-024-06132-5
Journal article

SGLT2 Inhibitors - The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review.

Seidu, S., Alabraba, V., Davies, S., Newland-Jones, P., Fernando, K., Bain, S. C., . . . Wilding, J. P. H. (2024). SGLT2 Inhibitors - The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review.. Diabetes therapy : research, treatment and education of diabetes and related disorders. doi:10.1007/s13300-024-01550-5

DOI
10.1007/s13300-024-01550-5
Journal article

Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in weight management services (STRIVE study): a multicentre, open-label, parallel-group, randomized controlled trial.

Papamargaritis, D., Al-Najim, W., Lim, J. Z. M., Crane, J., Bodicoat, D. H., Barber, S., . . . Davies, M. J. (2024). Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in weight management services (STRIVE study): a multicentre, open-label, parallel-group, randomized controlled trial.. The Lancet regional health. Europe, 39, 100853. doi:10.1016/j.lanepe.2024.100853

DOI
10.1016/j.lanepe.2024.100853
Journal article

SOLUBLE SUPPRESSION OF TUMORIGENICITY 2 (SST2) AND CARDIOVASCULAR OUTCOMES IN PERSONS WITH TYPE 2 DIABETES MELLITUS RANDOMIZED TO DAPAGLIFLOZIN OR PLACEBO: ANALYSES FROM THE DECLARE-TIMI 58 TRIAL

Haller, P., Wiviott, S., Jarolim, P., Goodrich, E. L., Bhatt, D. L., Gause-Nilsson, I., . . . Morrow, D. A. (2024). SOLUBLE SUPPRESSION OF TUMORIGENICITY 2 (SST2) AND CARDIOVASCULAR OUTCOMES IN PERSONS WITH TYPE 2 DIABETES MELLITUS RANDOMIZED TO DAPAGLIFLOZIN OR PLACEBO: ANALYSES FROM THE DECLARE-TIMI 58 TRIAL. Journal of the American College of Cardiology, 83(13), 378. doi:10.1016/s0735-1097(24)02368-4

DOI
10.1016/s0735-1097(24)02368-4
Journal article

Changing the global obesity narrative to recognize and reduce weight stigma: A position statement from the World Obesity Federation.

Nutter, S., Eggerichs, L. A., Nagpal, T. S., Ramos Salas, X., Chin Chea, C., Saiful, S., . . . Yusop, S. (2024). Changing the global obesity narrative to recognize and reduce weight stigma: A position statement from the World Obesity Federation.. Obesity reviews : an official journal of the International Association for the Study of Obesity, 25(1), e13642. doi:10.1111/obr.13642

DOI
10.1111/obr.13642
Journal article

Evaluating the impact of differing completion rates of a face-to-face DIABETES self-management education programme on Patient Reported Outcome measures (DIABETES PRO): A feasibility trial protocol.

Lewis, G., Irving, G., Wilding, J., & Hardy, K. (2024). Evaluating the impact of differing completion rates of a face-to-face DIABETES self-management education programme on Patient Reported Outcome measures (DIABETES PRO): A feasibility trial protocol.. Diabetic medicine : a journal of the British Diabetic Association, e15430. doi:10.1111/dme.15430

DOI
10.1111/dme.15430
Journal article

2023

Drugs That Affect Body Weight

Asswad, R. G., & Wilding, J. P. H. (2023). Drugs That Affect Body Weight. In Handbook of Obesity - Volume 2 (pp. 367-375). CRC Press. doi:10.1201/9781003432807-39

DOI
10.1201/9781003432807-39
Chapter

No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE)

Rajeev, S., Roberts, C., Brown, E., Sprung, V., Harrold, J., Halford, J., . . . Wilding, J. (2023). No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE). Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics. doi:10.1111/dom.15257

DOI
10.1111/dom.15257
Journal article

Corneal Confocal Microscopy Predicts Cardiovascular and Cerebrovascular Events and Demonstrates Greater Peripheral Neuropathy in Patients with Type 1 Diabetes and Foot Ulcers

Lim, J. Z. M., Burgess, J., Ooi, C., Ferdousi, M., Azmi, S., Kalteniece, A., . . . Alam, U. (2023). Corneal Confocal Microscopy Predicts Cardiovascular and Cerebrovascular Events and Demonstrates Greater Peripheral Neuropathy in Patients with Type 1 Diabetes and Foot Ulcers. DIAGNOSTICS, 13(17). doi:10.3390/diagnostics13172793

DOI
10.3390/diagnostics13172793
Journal article

Obesity: medical management

Henney, A. E., & Wilding, J. P. H. (2023). Obesity: medical management. Medicine, 51(7), 509-514. doi:10.1016/j.mpmed.2023.04.009

DOI
10.1016/j.mpmed.2023.04.009
Journal article

Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes A Secondary Analysis of the DECLARE-TIMI 58 Trial

Zelniker, T. A., Wiviott, S. D., Mosenzon, O., Goodrich, E. L., Jarolim, P., Cahn, A., . . . Morrow, D. A. (2023). Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes A Secondary Analysis of the DECLARE-TIMI 58 Trial. JAMA CARDIOLOGY, 8(5), 503-509. doi:10.1001/jamacardio.2023.0019

DOI
10.1001/jamacardio.2023.0019
Journal article

Tirzepatide Induces Weight Loss in participants with Type 2 Diabetes Regardless of Baseline BMI: A Post Hoc Analysis of SURPASS-1 through -5 Studies

Kwan, A. Y. M., Maldonado, J. M., Wang, H., Rasouli, N., Wilding, J. P. H., & Aberle, J. (2023). Tirzepatide Induces Weight Loss in participants with Type 2 Diabetes Regardless of Baseline BMI: A Post Hoc Analysis of SURPASS-1 through -5 Studies. In Diabetologie und Stoffwechsel. Georg Thieme Verlag. doi:10.1055/s-0043-1767995

DOI
10.1055/s-0043-1767995
Conference Paper

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Schnell, O., Battelino, T., Bergenstal, R., Birkenfeld, A. L., Ceriello, A., Cheng, A., . . . Standl, E. (2023). CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes. CARDIOVASCULAR DIABETOLOGY, 22(1). doi:10.1186/s12933-023-01788-6

DOI
10.1186/s12933-023-01788-6
Journal article

RELATIONSHIP BETWEEN CYSTATIN C, CREATININE-BASED EGFR, CARDIOVASCULAR EVENTS AND KIDNEY OUTCOMES IN DECLARETIMI 58

Small, A. M., Berg, D., Raz, I., Goodrich, E. L., Moura, F., Mosenzon, O., . . . Wiviott, S. D. (2023). RELATIONSHIP BETWEEN CYSTATIN C, CREATININE-BASED EGFR, CARDIOVASCULAR EVENTS AND KIDNEY OUTCOMES IN DECLARETIMI 58. Journal of the American College of Cardiology, 81(8), 1816. doi:10.1016/s0735-1097(23)02260-x

DOI
10.1016/s0735-1097(23)02260-x
Journal article

Etiopathogenesis of Obesity

Rajeev, S. P., & Wilding, J. P. H. (2023). Etiopathogenesis of Obesity. In Obesity, Bariatric and Metabolic Surgery (pp. 15-26). Springer International Publishing. doi:10.1007/978-3-030-60596-4_2

DOI
10.1007/978-3-030-60596-4_2
Chapter

2022

Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation

Lopez-Jimenez, F., Almahmeed, W., Bays, H., Cuevas, A., Di Angelantonio, E., le Roux, C. W., . . . Wilding, J. P. H. (2022). Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 29(17), 2218-2237. doi:10.1093/eurjpc/zwac187

DOI
10.1093/eurjpc/zwac187
Journal article

Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program

Perreault, L., Davies, M., Frias, J. P., Laursen, P. N., Lingvay, I., Machineni, S., . . . le Roux, C. W. (2022). Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. DIABETES CARE, 45(10), 2396-2405. doi:10.2337/dc21-1785

DOI
10.2337/dc21-1785
Journal article

A group-based behavioural intervention for weight management (PROGROUP) versus usual care in adults with severe obesity: a feasibility randomised controlled trial protocol

Swancutt, D., Tarrant, M., Ingram, W., Baldrey, S., Burns, L., Byng, R., . . . Pinkney, J. (2022). A group-based behavioural intervention for weight management (PROGROUP) versus usual care in adults with severe obesity: a feasibility randomised controlled trial protocol. PILOT AND FEASIBILITY STUDIES, 8(1). doi:10.1186/s40814-022-01167-0

DOI
10.1186/s40814-022-01167-0
Journal article

Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes A Prespecified Secondary Analysis of a Randomized Clinical Trial

Oyama, K., Raz, I., Cahn, A., Goodrich, E. L., Bhatt, D. L., Leiter, L. A., . . . Wiviott, S. D. (2022). Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA CARDIOLOGY, 7(9), 914-923. doi:10.1001/jamacardio.2022.2006

DOI
10.1001/jamacardio.2022.2006
Journal article

Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial

Oyama, K., Raz, I., Cahn, A., Kuder, J., Murphy, S. A., Bhatt, D. L., . . . Wiviott, S. D. (2022). Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. EUROPEAN HEART JOURNAL, 43(31), 2958-2967. doi:10.1093/eurheartj/ehab530

DOI
10.1093/eurheartj/ehab530
Journal article

Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial

Furtado, R. H. M., Raz, I., Goodrich, E. L., Murphy, S. A., Bhatt, D. L., Leiter, L. A., . . . Wiviott, S. D. (2022). Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. CIRCULATION, 145(21), 1581-1591. doi:10.1161/CIRCULATIONAHA.121.058103

DOI
10.1161/CIRCULATIONAHA.121.058103
Journal article

The UK's U-turn on obesity is a failure of leadership

Buse, K., Wilding, J., Bryant, M., Halford, J. C. G., & Ralston, J. (2022). The UK's U-turn on obesity is a failure of leadership. BMJ-BRITISH MEDICAL JOURNAL, 377. doi:10.1136/bmj.o1285

DOI
10.1136/bmj.o1285
Journal article

The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial

Sargeant, J. A., King, J. A., Yates, T., Redman, E. L., Bodicoat, D. H., Chatterjee, S., . . . Davies, M. J. (2022). The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial. DIABETES OBESITY & METABOLISM. doi:10.1111/dom.14721

DOI
10.1111/dom.14721
Journal article

The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review

Wilding, J. P. H., Evans, M., Fernando, K., Luis Gorriz, J., Cebrian, A., Diggle, J., . . . Del Prato, S. (2022). The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review. DIABETES THERAPY, 13(5), 847-872. doi:10.1007/s13300-022-01228-w

DOI
10.1007/s13300-022-01228-w
Journal article

Association of Baseline HbA<sub>1c</sub> With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

Cahn, A., Wiviott, S. D., Mosenzon, O., Goodrich, E. L., Murphy, S. A., Yanuv, I., . . . Raz, I. (2022). Association of Baseline HbA<sub>1c</sub> With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. DIABETES CARE, 45(4), 938-946. doi:10.2337/dc21-1744

DOI
10.2337/dc21-1744
Journal article

Adjunctive Therapy, Including Pharmacotherapy

Al‐Bazz, D., & Wilding, J. P. H. (2022). Adjunctive Therapy, Including Pharmacotherapy. In Unknown Book (pp. 279-296). Wiley. doi:10.1002/9781119695257.ch21

DOI
10.1002/9781119695257.ch21
Chapter

Clinical Obesity in Adults and Children

Kopelman, P. G., Caterson, I. D., Dietz, W. H., Armstrong, S., Sweeting, A. N., & Wilding, J. P. H. (Eds.) (2022). Clinical Obesity in Adults and Children. Wiley. doi:10.1002/9781119695257

DOI
10.1002/9781119695257
Book

FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58

Berg, D., Wiviott, S. D., Raz, I., Jarolim, P., Goodrich, E. L., Mosenzon, O., . . . Morrow, D. A. (2022). FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58. In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Vol. 79 (pp. 1526). Retrieved from https://www.webofscience.com/

Conference Paper

Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58

Kolkailah, A. A., Wiviott, S. D., Raz, I., Murphy, S. A., Mosenzon, O., Bhatt, D. L., . . . McGuire, D. K. (2022). Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. DIABETES CARE, 45(2), E27-E29. doi:10.2337/dc21-1668

DOI
10.2337/dc21-1668
Journal article

Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy

Frias, J. P., Maaske, J., Suchower, L., Johansson, L., Hockings, P. D., Iqbal, N., & Wilding, J. P. H. (2022). Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy. DIABETES OBESITY & METABOLISM, 24(1), 61-71. doi:10.1111/dom.14548

DOI
10.1111/dom.14548
Journal article

2021

PARIS: protocol for a prospective single arm, theory-based, group-based feasibility intervention study to increase Physical Activity and reduce sedentary behaviouR after barIatric Surgery

James, J., Hardeman, W., Eborall, H., Goodall, M., & Wilding, J. (2021). PARIS: protocol for a prospective single arm, theory-based, group-based feasibility intervention study to increase Physical Activity and reduce sedentary behaviouR after barIatric Surgery. BMJ OPEN, 11(12). doi:10.1136/bmjopen-2021-051638

DOI
10.1136/bmjopen-2021-051638
Journal article

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

Mosenzon, O., Wiviott, S. D., Heerspink, H. J. L., Dwyer, J. P., Cahn, A., Goodrich, E. L., . . . Raz, I. (2021). The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. DIABETES CARE, 44(8), 1805-1815. doi:10.2337/dc21-0076

DOI
10.2337/dc21-0076
Journal article

Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data

Khunti, K., Kosiborod, M., Kim, D. J., Kohsaka, S., Lam, C. S. P., Goh, S. -Y., . . . Fenici, P. (2021). Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. CARDIOVASCULAR DIABETOLOGY, 20(1). doi:10.1186/s12933-021-01345-z

DOI
10.1186/s12933-021-01345-z
Journal article

A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol

Brown, E., Wilton, M. M., Sprung, V. S., Harrold, J. A., Halford, J. C. G., Stancak, A., . . . Cuthbertson, D. J. (2021). A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol. BMJ open, 11(7), e045663. doi:10.1136/bmjopen-2020-045663

DOI
10.1136/bmjopen-2020-045663
Journal article

Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Srivastava, G., & Kumar, R. B. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity.. The New England journal of medicine, 385(1), e4. doi:10.1056/nejmc2106918

DOI
10.1056/nejmc2106918
Journal article

Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Javor, E., Lucijanić, M., & Skelin, M. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity.. The New England journal of medicine, 385(1), e4. doi:10.1056/nejmc2106918

DOI
10.1056/nejmc2106918
Journal article

Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Nadolsky, K. Z., & Agarwal, M. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity.. The New England journal of medicine, 385(1), e4. doi:10.1056/nejmc2106918

DOI
10.1056/nejmc2106918
Journal article

Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Khoo, T. K., & Lin, J. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity.. The New England journal of medicine, 385(1), e4. doi:10.1056/nejmc2106918

DOI
10.1056/nejmc2106918
Journal article

Once-Weekly Semaglutide in Adults with Overweight or Obesity. Reply.

Rosen, C. J., & Ingelfinger, J. R. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. Reply.. The New England journal of medicine, 385(1), e4. doi:10.1056/nejmc2106918

DOI
10.1056/nejmc2106918
Journal article

Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors

Evans, M., Morgan, A. R., Yousef, Z., Ellis, G., Dashora, U., Patel, D. C., . . . Bain, S. C. (2021). Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. DRUGS, 81(11), 1243-1255. doi:10.1007/s40265-021-01538-6

DOI
10.1007/s40265-021-01538-6
Journal article

Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58

Zelniker, T. A., Morrow, D. A., Mosenzon, O., Goodrich, E. L., Jarolim, P., Murphy, S. A., . . . Wiviott, S. D. (2021). Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58. EUROPEAN JOURNAL OF HEART FAILURE, 23(6), 1026-1036. doi:10.1002/ejhf.2073

DOI
10.1002/ejhf.2073
Journal article

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58

Cahn, A., Raz, I., Leiter, L. A., Mosenzon, O., Murphy, S. A., Goodrich, E. L., . . . Wiviott, S. D. (2021). Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. DIABETES CARE, 44(5), 1159-1167. doi:10.2337/dc20-2492

DOI
10.2337/dc20-2492
Journal article

Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data

Wharton, S., Astrup, A., Endahl, L., Lean, M. E. J., Satylganova, A., Skovgaard, D., . . . Wilding, J. P. H. (2021). Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data. INTERNATIONAL JOURNAL OF OBESITY, 45(5), 923-933. doi:10.1038/s41366-020-00733-x

DOI
10.1038/s41366-020-00733-x
Journal article

Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.

Zelniker, T. A., Raz, I., Mosenzon, O., Dwyer, J. P., Heerspink, H. H. J. L., Cahn, A., . . . Wiviott, S. D. (2021). Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.. JAMA Cardiology. doi:10.1001/jamacardio.2021.0660

DOI
10.1001/jamacardio.2021.0660
Journal article

The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial

McEwan, P., Morgan, A. R., Boyce, R., Bergenheim, K., Gause-Nilsson, I. A. M., Bhatt, D. L., . . . Wilding, J. P. H. (2021). The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. DIABETES OBESITY & METABOLISM, 23(4), 1020-1029. doi:10.1111/dom.14308

DOI
10.1111/dom.14308
Journal article

Once-weekly semaglutide 2.4 mg improved glucose metabolism and prediabetes in adults with overweight or obesity in the STEP 1 trial

Perreault, L., Davies, M., Frias, J. P., Laursen, P. N., Lingvay, I., Machineni, S., . . . Le Roux, C. W. (2021). Once-weekly semaglutide 2.4 mg improved glucose metabolism and prediabetes in adults with overweight or obesity in the STEP 1 trial. In DIABETOLOGIA Vol. 64 (pp. 234). Retrieved from https://www.webofscience.com/

Conference Paper

2020

Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence

McEwan, P., Bennett, H., Khunti, K., Wilding, J., Edmonds, C., Thuresson, M., . . . Kosiborod, M. (2020). Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence. DIABETES OBESITY & METABOLISM, 22(12), 2364-2374. doi:10.1111/dom.14162

DOI
10.1111/dom.14162
Journal article

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

Lingvay, I., Hansen, T., Macura, S., Marre, M., Nauck, M. A., de la Rosa, R., . . . Wilding, J. (2020). Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. BMJ OPEN DIABETES RESEARCH & CARE, 8(2). doi:10.1136/bmjdrc-2020-001706

DOI
10.1136/bmjdrc-2020-001706
Journal article

Cardiovascular outcome trials in obesity: A review.

Wilding, J. P. H., & Jacob, S. (2020). Cardiovascular outcome trials in obesity: A review.. Obesity reviews : an official journal of the International Association for the Study of Obesity. doi:10.1111/obr.13112

DOI
10.1111/obr.13112
Journal article

Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI)

Sprung, V. S., Kemp, G. J., Wilding, J. P., Adams, V., Murphy, K., Burgess, M., . . . Cuthbertson, D. J. (2020). Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI). BMJ OPEN, 10(7). doi:10.1136/bmjopen-2020-038856

DOI
10.1136/bmjopen-2020-038856
Journal article

Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial

Bajaj, H. S., Raz, I., Mosenzon, O., Murphy, S. A., Rozenberg, A., Yanuv, I., . . . Cahn, A. (2020). Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial. DIABETES OBESITY & METABOLISM, 22(7), 1122-1131. doi:10.1111/dom.14011

DOI
10.1111/dom.14011
Journal article

Cover Image, Volume 22, Issue 7

Johansson, L., Hockings, P. D., Johnsson, E., Dronamraju, N., Maaske, J., Garcia‐Sanchez, R., & Wilding, J. P. H. (2020). Cover Image, Volume 22, Issue 7. Diabetes, Obesity and Metabolism, 22(7). doi:10.1111/dom.14113

DOI
10.1111/dom.14113
Journal article

Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study

Kohsaka, S., Lam, C. S. P., Kim, D. J., Cavender, M. A., Norhammar, A., Jorgensen, M. E., . . . Kosiborod, M. (2020). Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. LANCET DIABETES & ENDOCRINOLOGY, 8(7), 606-615. Retrieved from https://www.webofscience.com/

Journal article

Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58

Cahn, A., Wiviott, S. D., Mosenzon, O., Murphy, S., Goodrich, E. L., Yanuv, I., . . . Raz, I. (2020). Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58. In DIABETES Vol. 69. doi:10.2337/db20-1101-P

DOI
10.2337/db20-1101-P
Conference Paper

Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial

Raz, I., Wiviott, S. D., Heerspink, H. L., Dwyer, J. P., Cahn, A., Goodrich, E. L., . . . Mosenzon, O. (2020). Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial. In DIABETES Vol. 69. doi:10.2337/db20-303-OR

DOI
10.2337/db20-303-OR
Conference Paper

The 1α,25(OH)2D3 Analogs ZK159222 and ZK191784 Show Anti-Inflammatory Properties in Macrophage-Induced Preadipocytes via Modulating the NF-κB and MAPK Signaling.

Zhu, J., & Wilding, J. P. H. (2020). The 1α,25(OH)2D3 Analogs ZK159222 and ZK191784 Show Anti-Inflammatory Properties in Macrophage-Induced Preadipocytes via Modulating the NF-κB and MAPK Signaling.. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13, 1715-1724. doi:10.2147/dmso.s245080

DOI
10.2147/dmso.s245080
Journal article

Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus Insights From the DECLARE-TIMI 58 Trial

Zelniker, T. A., Bonaca, M. P., Furtado, R. H. M., Mosenzon, O., Kuder, J. F., Murphy, S. A., . . . Wiviott, S. D. (2020). Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus Insights From the DECLARE-TIMI 58 Trial. CIRCULATION, 141(15), 1227-1234. doi:10.1161/CIRCULATIONAHA.119.044183

DOI
10.1161/CIRCULATIONAHA.119.044183
Journal article

Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus

Freemantle, N., Mauricio, D., Giaccari, A., Bailey, T., Roussel, R., Franco, D., . . . Investigator, R. E. G. A. I. N. (2020). Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus. Current Medical Research and Opinion, 36(4), 571-581. doi:10.1080/03007995.2019.1708287

DOI
10.1080/03007995.2019.1708287
Journal article

EFFECTS OF DAPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS BODY MASS INDEX CATEGORIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE DECLARE TIMI 58 TRIAL

Oyama, K., Raz, I., Cahn, A., Kuder, J., Murphy, S., Bhatt, D., . . . Wiviott, S. D. (2020). EFFECTS OF DAPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS BODY MASS INDEX CATEGORIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE DECLARE TIMI 58 TRIAL. In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Vol. 75 (pp. 660). Retrieved from https://www.webofscience.com/

Conference Paper

Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial

Papamargaritis, D., Al-Najim, W., Lim, J., Crane, J., Lean, M., Le Roux, C., . . . Davies, M. J. (2020). Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial. BMJ OPEN, 10(2). doi:10.1136/bmjopen-2019-034137

DOI
10.1136/bmjopen-2019-034137
Journal article

Accessible indices of insulin resistance: exploring the associations with hepatic and intramuscular fat accumulation

Davies, K. B., Sprung, V. S., Norman, J. A., Thompson, A., Wilding, J. P. H., Kemp, G. J., & Cuthbertson, D. J. (2020). Accessible indices of insulin resistance: exploring the associations with hepatic and intramuscular fat accumulation. In DIABETOLOGIA Vol. 63 (pp. S224-S225). Retrieved from https://www.webofscience.com/

Conference Paper

Cardiorenal and metabolic outcomes of dapagliflozin vs placebo in patients at high cardiovascular risk without established cardiovascular disease: analyses from the DECLARE-TIMI 58 study

Cahn, A., Raz, I., Leiter, L. A., Mosenzon, O., Murphy, S. A., Bhatt, D. L., . . . Wiviott, S. D. (2020). Cardiorenal and metabolic outcomes of dapagliflozin vs placebo in patients at high cardiovascular risk without established cardiovascular disease: analyses from the DECLARE-TIMI 58 study. In DIABETOLOGIA Vol. 63 (pp. S269). Retrieved from https://www.webofscience.com/

Conference Paper

DAPAGLIFLOZIN PLUS SAXAGLIPTIN ADD-ON TO METFORMIN MAINTAINS REDUCED LIVER FAT AND ADIPOSE TISSUE VOLUMES IN PATIENTS WITH TYPE 2 DIABETES OVER 122 WEEKS

Johansson, L., Hockings, P., Frias, J. P., Suchower, L., Maaske, J., Iqbal, N., & Wilding, J. P. H. (2020). DAPAGLIFLOZIN PLUS SAXAGLIPTIN ADD-ON TO METFORMIN MAINTAINS REDUCED LIVER FAT AND ADIPOSE TISSUE VOLUMES IN PATIENTS WITH TYPE 2 DIABETES OVER 122 WEEKS. In HEPATOLOGY Vol. 72 (pp. 1048). Retrieved from https://www.webofscience.com/

Conference Paper

Effects of empagliflozin, diet, or both on physical activity and sedentary behaviour in people with type 2 diabetes: analyses from the SEESAW trial

Sargeant, J. A., King, J. A., Baldry, E. L., Bodicoat, D. H., Edwardson, C. L., Khunti, K., . . . Davies, M. J. (2020). Effects of empagliflozin, diet, or both on physical activity and sedentary behaviour in people with type 2 diabetes: analyses from the SEESAW trial. In DIABETOLOGIA Vol. 63 (pp. S270-S271). Retrieved from https://www.webofscience.com/

Conference Paper

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

Heerspink, H. J. L., Karasik, A., Thuresson, M., Melzer-Cohen, C., Chodick, G., Khunti, K., . . . Kosiborod, M. (2020). Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. LANCET DIABETES & ENDOCRINOLOGY, 8(1), 27-35. Retrieved from https://www.webofscience.com/

Journal article

Multiparametric magnetic resonance imaging of the liver demonstrates the prevalence of steatohepatitis in patients with type 2 diabetes

Brown, E., Waddell, T., Mouchti, S., Roca-Fernandez, A., Thomaides-Brears, H., Wilton, M., . . . Banerjee, R. (2020). Multiparametric magnetic resonance imaging of the liver demonstrates the prevalence of steatohepatitis in patients with type 2 diabetes. In DIABETOLOGIA Vol. 63 (pp. S420-S421). Retrieved from https://www.webofscience.com/

Conference Paper

2019

Selecting Core Outcomes for Randomised Effectiveness Trials in Type 2 Diabetes (SCORE-IT) - a Patient and Healthcare Professional Consensus on a Core Outcome Set for Type 2 Diabetes

Harman, N., Wilding, J., Curry, D., Harris, J., Logue, J., Pemberton, R. J., . . . Team, S. C. O. R. E. -I. T. S. (2019). Selecting Core Outcomes for Randomised Effectiveness Trials in Type 2 Diabetes (SCORE-IT) - a Patient and Healthcare Professional Consensus on a Core Outcome Set for Type 2 Diabetes. BMJ Open Diabetes Research and Care.

Journal article

Cardiac Autonomic Neuropathy in Obesity, Metabolic Syndrome and Prediabetes: A Narrative Review (vol 10, pg 1995, 2019)

Williams, S. M., Eleftheriadou, A., Alam, U., Cuthbertson, D. J., & Wilding, J. P. H. (2019). Cardiac Autonomic Neuropathy in Obesity, Metabolic Syndrome and Prediabetes: A Narrative Review (vol 10, pg 1995, 2019). DIABETES THERAPY, 10(6), 2023. doi:10.1007/s13300-019-00705-z

DOI
10.1007/s13300-019-00705-z
Journal article

SGLT2 inhibitors and urinary tract infections

Wilding, J. (2019). SGLT2 inhibitors and urinary tract infections. NATURE REVIEWS ENDOCRINOLOGY, 15(12), 687-688. doi:10.1038/s41574-019-0275-6

DOI
10.1038/s41574-019-0275-6
Journal article

The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)

Thondam, S. K., Cuthbertson, D. J., & Wilding, J. P. H. (2019). The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD). Peptides, 170208. doi:10.1016/j.peptides.2019.170208

DOI
10.1016/j.peptides.2019.170208
Journal article

Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus

Berg, D. D., Wiviott, S. D., Scirica, B. M., Gurmu, Y., Mosenzon, O., Murphy, S. A., . . . Sabatine, M. S. (2019). Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. CIRCULATION, 140(19), 1569-1577. doi:10.1161/CIRCULATIONAHA.119.042685

DOI
10.1161/CIRCULATIONAHA.119.042685
Journal article

Semaglutide in weight management reply

Wilding, J. P. H. (2019). Semaglutide in weight management reply. LANCET, 394(10205), 1226-1227. doi:10.1016/S0140-6736(19)31904-X

DOI
10.1016/S0140-6736(19)31904-X
Journal article

SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice (vol 10, pg 1595, 2019)

Ali, A., Bain, S., Hicks, D., Jones, P. N., Patel, D. C., Evans, M., . . . Wilding, J. (2019). SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice (vol 10, pg 1595, 2019). DIABETES THERAPY, 10(5), 1623-1624. doi:10.1007/s13300-019-0670-y

DOI
10.1007/s13300-019-0670-y
Journal article

Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus

Wilding, J. P. H., Rigney, U., Blak, B. T., Nolan, S. T., Fenici, P., & Medina, J. (2019). Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus. DIABETES RESEARCH AND CLINICAL PRACTICE, 155. doi:10.1016/j.diabres.2019.107791

DOI
10.1016/j.diabres.2019.107791
Journal article

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial

Mosenzon, O., Wiviott, S. D., Cahn, A., Rozenberg, A., Yanuv, I., Goodrich, E. L., . . . Raz, I. (2019). Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. LANCET DIABETES & ENDOCRINOLOGY, 7(8), 606-617. doi:10.1016/S2213-8587(19)30180-9

DOI
10.1016/S2213-8587(19)30180-9
Journal article

Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARETIMI 58 Randomised, Placebo-Controlled Trial

Raz, I., Wiviott, S. D., Yanuv, I., Rozenberg, A., Zelniker, T. A., Cahn, A., . . . Mosenzon, O. (2019). Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARETIMI 58 Randomised, Placebo-Controlled Trial. In DIABETES Vol. 68. doi:10.2337/db19-244-OR

DOI
10.2337/db19-244-OR
Conference Paper

Semaglutide-Induced Weight Loss Is Associated with Improved Health-Related Quality of Life and Treatment Satisfaction

Uusinarkaus, K. T., Rodbard, H. W., Van Gaal, L., Wilding, J. P., Hansen, T., Sandberg, A., . . . Davies, M. J. (2019). Semaglutide-Induced Weight Loss Is Associated with Improved Health-Related Quality of Life and Treatment Satisfaction. In DIABETES Vol. 68. doi:10.2337/db19-1020-P

DOI
10.2337/db19-1020-P
Conference Paper

Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial

Furtado, R. H. M., Bonaca, M. P., Raz, I., Zelniker, T. A., Mosenzon, O., Cahn, A., . . . Wiviott, S. D. (2019). Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial. In CIRCULATION Vol. 139 (pp. 2516-2527). doi:10.1161/CIRCULATIONAHA.119.039996

DOI
10.1161/CIRCULATIONAHA.119.039996
Conference Paper

A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors

Brown, E., Rajeev, S. P., Cuthbertson, D. J., & Wilding, J. P. H. (2019). A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors. DIABETES OBESITY & METABOLISM, 21, 9-18. doi:10.1111/dom.13650

DOI
10.1111/dom.13650
Journal article

DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL

de Mendonca Furtado, R. H., Bonaca, M., Raz, I., Zelniker, T., Mosenzon, O., Cahn, A., . . . Wiviott, S. (2019). DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL. Journal of the American College of Cardiology, 73(9), 1. doi:10.1016/s0735-1097(19)30610-2

DOI
10.1016/s0735-1097(19)30610-2
Journal article

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials.

Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., . . . Sabatine, M. S. (2019). Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials.. Circulation. doi:10.1161/circulationaha.118.038868

DOI
10.1161/circulationaha.118.038868
Journal article

1,25(OH)(2)D-3 attenuates IL-6 and IL-1-mediated inflammatory responses in macrophage conditioned medium-stimulated human white preadipocytes by modulating p44/42 MAPK and NF-B signaling pathways

Zhu, J., Bing, C., & Wilding, J. P. H. (2019). 1,25(OH)(2)D-3 attenuates IL-6 and IL-1-mediated inflammatory responses in macrophage conditioned medium-stimulated human white preadipocytes by modulating p44/42 MAPK and NF-B signaling pathways. DIABETOLOGY & METABOLIC SYNDROME, 11. doi:10.1186/s13098-019-0405-2

DOI
10.1186/s13098-019-0405-2
Journal article

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., . . . Sabatine, M. S. (2019). SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. LANCET, 393(10166), 31-39. doi:10.1016/S0140-6736(18)32590-X

DOI
10.1016/S0140-6736(18)32590-X
Journal article

A Pragmatic Phase 4 Randomised Trial to evaluate the Effectiveness of Dapagliflozin compared to Standard of Care in patients with Type 2 Diabetes in Routine Primary Care (DECIDE: NCT02616666)

Williams, R., Beatty, S., Williamson, P., Fenici, P., Dodd, S., Medina, J., & Wilding, J. (2019). A Pragmatic Phase 4 Randomised Trial to evaluate the Effectiveness of Dapagliflozin compared to Standard of Care in patients with Type 2 Diabetes in Routine Primary Care (DECIDE: NCT02616666). In TRIALS Vol. 20. Retrieved from https://www.webofscience.com/

Conference Paper

Change in categorical urinary albumin creatinine ratio in the DECLARE-TIMI 58 trial

Raz, I., Wiviott, S. D., Rozenberg, A., Zelniker, T. A., Cahn, A., Heerspink, H. J. L., . . . Mosenzon, O. (2019). Change in categorical urinary albumin creatinine ratio in the DECLARE-TIMI 58 trial. In DIABETOLOGIA Vol. 62 (pp. S330). Retrieved from https://www.webofscience.com/

Conference Paper

DOES THE APPLICATION OF UKPDS RISK EQUATIONS UNDERESTIMATE THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN TYPE 2 DIABETES MELLITUS?

McEwan, P., Bennett, H., Kartman, B., Edmonds, C., Gause-Nilsson, I., & Wilding, J. (2019). DOES THE APPLICATION OF UKPDS RISK EQUATIONS UNDERESTIMATE THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN TYPE 2 DIABETES MELLITUS?. In VALUE IN HEALTH Vol. 22 (pp. S581). Retrieved from https://www.webofscience.com/

Conference Paper

Effect of Dapagliflozin in Reducing Recurrent Myocardial Infarction of Different Infarct Types and Sizes: Insights From Declare-Timi 58

Furtado, R. H., Bonaca, M. P., Zelniker, T. A., Raz, I., Goodrich, E., Mosenzon, O., . . . Wiviott, S. (2019). Effect of Dapagliflozin in Reducing Recurrent Myocardial Infarction of Different Infarct Types and Sizes: Insights From Declare-Timi 58. In CIRCULATION Vol. 140. Retrieved from https://www.webofscience.com/

Conference Paper

Effect of Dapagliflozin on Atrial Fibrillation/Flutter in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial

Zelniker, T. A., Bonaca, M. P., Mosenzon, O., Kuder, J. F., Murphy, S. A., Furtado, R. H., . . . Wiviott, S. D. (2019). Effect of Dapagliflozin on Atrial Fibrillation/Flutter in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. In CIRCULATION Vol. 140. Retrieved from https://www.webofscience.com/

Conference Paper

Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58

Zelniker, T. A., Raz, I., Mosenzon, O., Dwyer, J. P., Heerspink, H. J. L., Cahn, A., . . . Wiviott, S. D. (2019). Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58. In EUROPEAN HEART JOURNAL Vol. 40 (pp. 54). Retrieved from https://www.webofscience.com/

Conference Paper

Estimating healthcare resource implications associated with use of dapagliflozin: model predictions using data from the DECLARE-TIMI 58 trial

McEwan, P., Bennett, H., Kartman, B., Edmonds, C., Gause-Nilsson, I., & Wilding, J. (2019). Estimating healthcare resource implications associated with use of dapagliflozin: model predictions using data from the DECLARE-TIMI 58 trial. In DIABETOLOGIA Vol. 62 (pp. S396-S397). Retrieved from https://www.webofscience.com/

Conference Paper

Heart failure risk stratification and efficacy of dapagliflozin in patients with type 2 diabetes mellitus

Berg, D., Wiviott, S., Scirica, B., Gurmu, Y., Mosenzon, O., Murphy, S., . . . Sabatine, M. (2019). Heart failure risk stratification and efficacy of dapagliflozin in patients with type 2 diabetes mellitus. In EUROPEAN HEART JOURNAL Vol. 40 (pp. 153). Retrieved from https://www.webofscience.com/

Conference Paper

Metabolic health, rather than obesity status, contributes to endothelial dysfunction: a comparison of obesity/metabolic health related phenotypes

Sprung, V. S., Davies, K. A. B., Norman, J. A., Mitchell, K. L., Wilding, J. P. H., Kemp, G. J., & Cuthbertson, D. J. (2019). Metabolic health, rather than obesity status, contributes to endothelial dysfunction: a comparison of obesity/metabolic health related phenotypes. In DIABETOLOGIA Vol. 62 (pp. S552). Retrieved from https://www.webofscience.com/

Conference Paper

Obesity and Obstructive Sleep Apnea Syndrome

Seetho, I. W., & Wilding, J. P. H. (2019). Obesity and Obstructive Sleep Apnea Syndrome. In Endocrinology (pp. 243-271). Springer International Publishing. doi:10.1007/978-3-319-46933-1_24

DOI
10.1007/978-3-319-46933-1_24
Chapter

Pooled cohort analysis of non-alcoholic fatty liver disease in patients with and without type 2 diabetes: time to take action

Brown, E., Sprung, V., Bowden-Davies, K., Wilton, M., Harrold, J., Rajeev, S., . . . Cuthbertson, D. J. (2019). Pooled cohort analysis of non-alcoholic fatty liver disease in patients with and without type 2 diabetes: time to take action. In DIABETOLOGIA Vol. 62 (pp. S536). Retrieved from https://www.webofscience.com/

Conference Paper

Relationship Between Baseline Cardiac Biomarkers and Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58

Zelniker, T. A., Morrow, D. A., Mosenzon, O., Goodrich, E., Murphy, S. A., Bhatt, D. L., . . . Wiviott, S. D. (2019). Relationship Between Baseline Cardiac Biomarkers and Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58. In CIRCULATION Vol. 140. Retrieved from https://www.webofscience.com/

Conference Paper

Safety and efficacy of dapagliflozin in the elderly: analysis from the DECLARE TIMI 58 study

Cahn, A., Wiviott, S. D., Mosenzon, O., Yanuv, I., Rozenberg, A., Murphy, S. A., . . . Raz, I. (2019). Safety and efficacy of dapagliflozin in the elderly: analysis from the DECLARE TIMI 58 study. In DIABETOLOGIA Vol. 62 (pp. S360). Retrieved from https://www.webofscience.com/

Conference Paper

Severe insulin resistance and childhood obesity: A familial disorder in two siblings

Lim, J. Z., Mon, A., Brown, E., Alam, U., & Wilding, J. P. (2019). Severe insulin resistance and childhood obesity: A familial disorder in two siblings. In DIABETIC MEDICINE Vol. 36 (pp. 140). Retrieved from https://www.webofscience.com/

Conference Paper

Short-term physical inactivity, with increased sedentary behaviour, causes a decline in endothelial function

Davies, K. A. B., Norman, J. A., Thompson, A., Mitchell, K. L., Halford, J. C. G., Harrold, J. A., . . . Sprung, V. S. (2019). Short-term physical inactivity, with increased sedentary behaviour, causes a decline in endothelial function. In DIABETOLOGIA Vol. 62 (pp. S552). Retrieved from https://www.webofscience.com/

Conference Paper

The Efficacy and Safety of Dapagliflozin in Women and Men With Type 2 Diabetes Mellitus: Insights From The DECLARE-TIMI 58 Trial

O'Donoghue, M. L., Kato, E. T., Mosenzon, O., Murphy, S. A., Cahn, A., Marmolejo, M. H., . . . Wiviott, S. D. (2019). The Efficacy and Safety of Dapagliflozin in Women and Men With Type 2 Diabetes Mellitus: Insights From The DECLARE-TIMI 58 Trial. In CIRCULATION Vol. 140. Retrieved from https://www.webofscience.com/

Conference Paper

Therapeutic effect of improved glycaemic control with concomitant use of cannabis oil

Lim, J. Z., Abdelrahim, S., Alam, U., Wilding, J. P., & Mon, A. (2019). Therapeutic effect of improved glycaemic control with concomitant use of cannabis oil. In DIABETIC MEDICINE Vol. 36 (pp. 19-20). Retrieved from https://www.webofscience.com/

Conference Paper

2018

A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus

Shestakova, M. V., Wilding, J. P. H., Wilpshaar, W., Tretter, R., Orlova, V. L., & Verbovoy, A. F. (2018). A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. DIABETES RESEARCH AND CLINICAL PRACTICE, 146, 240-250. doi:10.1016/j.diabres.2018.10.018

DOI
10.1016/j.diabres.2018.10.018
Journal article

Patients' Perspectives of Oral and Injectable Type 2 Diabetes Medicines, Their Body Weight and Medicine-Taking Behavior in the UK: A Systematic Review and Meta-Ethnography

Psarou, A., Cooper, H., & Wilding, J. P. H. (2018). Patients' Perspectives of Oral and Injectable Type 2 Diabetes Medicines, Their Body Weight and Medicine-Taking Behavior in the UK: A Systematic Review and Meta-Ethnography. DIABETES THERAPY, 9(5), 1791-1810. doi:10.1007/s13300-018-0490-5

DOI
10.1007/s13300-018-0490-5
Journal article

Vitamin D receptor ligands attenuate the inflammatory profile of IL-1 beta-stimulated human white preadipocytes via modulating the NF-kappa B and unfolded protein response pathways

Zhu, J., Bing, C., & Wilding, J. P. H. (2018). Vitamin D receptor ligands attenuate the inflammatory profile of IL-1β-stimulated human white preadipocytes via modulating the NF-κB and unfolded protein response pathways. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 503(2), 1049-1056. doi:10.1016/j.bbrc.2018.06.115

DOI
10.1016/j.bbrc.2018.06.115
Journal article

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

Ahren, B., Atkin, S. L., Charpentier, G., Warren, M. L., Wilding, J. P. H., Birch, S., . . . Leiter, L. A. (2018). Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. DIABETES OBESITY & METABOLISM, 20(9), 2210-2219. doi:10.1111/dom.13353

DOI
10.1111/dom.13353
Journal article

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., . . . Wilding, J. P. H. (2018). Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. LANCET, 392(10148), 637-649. doi:10.1016/S0140-6736(18)31773-2

DOI
10.1016/S0140-6736(18)31773-2
Journal article

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study

Kosiborod, M., Birkeland, K. I., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., . . . Fenici, P. (2018). Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. DIABETES OBESITY & METABOLISM, 20(8), 1983-1987. doi:10.1111/dom.13299

DOI
10.1111/dom.13299
Journal article

Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink

Wilding, J., Godec, T., Khunti, K., Pocock, S., Fox, R., Smeeth, L., . . . Medina, J. (2018). Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. BMC Medicine, 16. doi:10.1186/s12916-018-1085-8

DOI
10.1186/s12916-018-1085-8
Journal article

A Phase 3 Study to Assess the Efficacy and Safety of Ipragliflozin in Russian Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Metformin

Shestakova, M. V., Wilding, J. P., Wilpshaar, W., Tretter, R. N., Orlova, V. L., & Verbovoy, A. F. (2018). A Phase 3 Study to Assess the Efficacy and Safety of Ipragliflozin in Russian Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Metformin. In DIABETES Vol. 67. doi:10.2337/db18-1131-P

DOI
10.2337/db18-1131-P
Conference Paper

Changes in Energy Balance during Dapagliflozin Therapy in Type 2 Diabetes-The Energize Study

Rajeev, S. P., Roberts, C. A., Cuthbertson, D. J., Sprung, V. S., Brown, E., Halford, J. C. J., . . . Wilding, J. P. (2018). Changes in Energy Balance during Dapagliflozin Therapy in Type 2 Diabetes-The Energize Study. In DIABETES Vol. 67. doi:10.2337/db18-1163-P

DOI
10.2337/db18-1163-P
Conference Paper

Dapagliflozin plus Saxagliptin Add-On to Metformin Reduces Liver Fat and Adipose Tissue Volume in Patients with Type 2 Diabetes

Wilding, J. P., Hockings, P., Johnsson, E. K., Maaske, J., Garcia-Sanchez, R., & Johansson, L. (2018). Dapagliflozin plus Saxagliptin Add-On to Metformin Reduces Liver Fat and Adipose Tissue Volume in Patients with Type 2 Diabetes. In DIABETES Vol. 67. doi:10.2337/db18-1175-P

DOI
10.2337/db18-1175-P
Conference Paper

Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes

Johanssoni, I., Hockings, P., Johnsson, E. K., Maaskes, J., Garcia-Sanchez, R., & Wilding, J. P. (2018). Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. In DIABETOLOGIA Vol. 61 (pp. S314). Retrieved from https://www.webofscience.com/

Conference Paper

HbA1c, Weight, and Blood Pressure Changes Associated with Early vs. Late Treatment Intensification with Dapagliflozin in UK Primary Care Patients with Type 2 Diabetes

Wilding, J. P., Rigney, U., Blak, B. T., Nolan, S. T., Fenici, P., & Medina, J. (2018). HbA1c, Weight, and Blood Pressure Changes Associated with Early vs. Late Treatment Intensification with Dapagliflozin in UK Primary Care Patients with Type 2 Diabetes. In DIABETES Vol. 67. doi:10.2337/db18-1186-P

DOI
10.2337/db18-1186-P
Conference Paper

Relatively Consistent Effects of Canagliflozin (CANA) on Outcomes Regardless of Baseline HbA1c in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program

Rosenstock, J., Bantwal, G., Wilding, J. P., Dumas, R., Gonzalez-Galvez, G., Slee, A., . . . Matthews, D. R. (2018). Relatively Consistent Effects of Canagliflozin (CANA) on Outcomes Regardless of Baseline HbA1c in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program. In DIABETES Vol. 67. doi:10.2337/db18-1191-P

DOI
10.2337/db18-1191-P
Conference Paper

Semaglutide treatment and renal function in the SUSTAIN 6 trial

Silver, R., Gumprecht, J., Vilsboll, T., Hansen, T., Pettersson, J., Vrazic, H., & Wilding, J. (2018). Semaglutide treatment and renal function in the SUSTAIN 6 trial. In DIABETOLOGIA Vol. 61 (pp. S40-S41). Retrieved from https://www.webofscience.com/

Conference Paper

Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.

Thuresson, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., . . . Kosiborod, M. (2018). Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10. DIABETES CARE, 41(6), E106-E108. doi:10.2337/dc18-0338

DOI
10.2337/dc18-0338
Journal article

Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10

Nystrom, T., Bodegard, J., Nathanson, D., Thuresson, M., Norhammar, A., & Eriksson, J. W. (2018). Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10. DIABETES CARE, 41(6), E104-E105. doi:10.2337/dc18-0339

DOI
10.2337/dc18-0339
Journal article

Short-term decreased physical activity with increased sedentary behaviour causes metabolic derangements and altered body composition: effects in individuals with and without a first-degree relative with type 2 diabetes

Bowden Davies, K. A., Sprung, V. S., Norman, J. A., Thompson, A., Mitchell, K. L., Halford, J. C. G., . . . Cuthbertson, D. J. (2018). Short-term decreased physical activity with increased sedentary behaviour causes metabolic derangements and altered body composition: effects in individuals with and without a first-degree relative with type 2 diabetes. Diabetologia, 61(6), 1282-1294. doi:10.1007/s00125-018-4603-5

DOI
10.1007/s00125-018-4603-5
Journal article

Metabolically healthy and unhealthy obesity: Metabolic health status rather than obesity is a more accurate prognostic marker for cardiovascular health

Sprung, V. S., Davies, K. A. B., Norman, J. A., Thompson, A., Wilding, J. P. H., Jones, H., . . . Cuthbertson, D. J. (2018). Metabolically healthy and unhealthy obesity: Metabolic health status rather than obesity is a more accurate prognostic marker for cardiovascular health. In DIABETIC MEDICINE Vol. 35 (pp. 53). Retrieved from https://www.webofscience.com/

Conference Paper

Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".

Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., . . . Fenici, P. (2018). Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)". CIRCULATION, 137(9), 989-991. doi:10.1161/CIRCULATIONAHA.117.031847

DOI
10.1161/circulationaha.117.031847
Journal article

A randomised, phase 2, placebo- and active-controlled dose-ranging study of semaglutide for treatment of obesity in subjects without diabetes

Wilding, J., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., . . . O'Neil, P. M. (2018). A randomised, phase 2, placebo- and active-controlled dose-ranging study of semaglutide for treatment of obesity in subjects without diabetes. In DIABETOLOGIA Vol. 61 (pp. S273-S274). Retrieved from https://www.webofscience.com/

Conference Paper

Age no impediment to effective weight loss with liraglutide 3.0mg: Data from two randomised trials

Wilding, J. P. H., Rubino, D. M., Kahan, S., Kushner, R., Jepsen, C. H., Smolarz, B. G., & Wyatt, H. (2018). Age no impediment to effective weight loss with liraglutide 3.0mg: Data from two randomised trials. In DIABETIC MEDICINE Vol. 35 (pp. 109-110). Retrieved from https://www.webofscience.com/

Conference Paper

Clinical inertia: The patient's perspective in delays of Type 2 diabetes treatment(s)

Psarou, A., Wilding, J. P. H., & Cooper, H. (2018). Clinical inertia: The patient's perspective in delays of Type 2 diabetes treatment(s). In DIABETIC MEDICINE Vol. 35 (pp. 202). Retrieved from https://www.webofscience.com/

Conference Paper

HbA<sub>1c</sub> changes in subjects with obesity without diabetes receiving semaglutide for weight management

Mosenzon, O., Wilding, J., Birkenfeld, A. L., McGowan, B., Pedersen, S. D., Wharton, S., . . . O'Neil, P. M. (2018). HbA<sub>1c</sub> changes in subjects with obesity without diabetes receiving semaglutide for weight management. In DIABETOLOGIA Vol. 61 (pp. S352-S353). Retrieved from https://www.webofscience.com/

Conference Paper

High number of responders with pharmacotherapy-induced weight loss ≥15% in a placebo-controlled dose-ranging study of semaglutide in subjects with obesity

Birkenfeld, A. L., Wilding, J., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., . . . O'Neil, P. M. (2018). High number of responders with pharmacotherapy-induced weight loss ≥15% in a placebo-controlled dose-ranging study of semaglutide in subjects with obesity. In DIABETOLOGIA Vol. 61 (pp. S272-S273). Retrieved from https://www.webofscience.com/

Conference Paper

Late-Breaking Clinical Trial: Novel Approaches to CV Prevention

Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., . . . Sabatine, M. S. (2018). Late-Breaking Clinical Trial: Novel Approaches to CV Prevention. In CIRCULATION Vol. 138 (pp. E754-E755). Retrieved from https://www.webofscience.com/

Conference Paper

Metabolic decompensation and altered body composition after short-term physical inactivity in first-degree relatives of patients with Type 2 diabetes vs healthy controls

Davies, K. A. B., Sprung, V. S., Norman, J. A., Thompson, A., Mitchell, K. L., Halford, J. C. G., . . . Cuthbertson, D. J. (2018). Metabolic decompensation and altered body composition after short-term physical inactivity in first-degree relatives of patients with Type 2 diabetes vs healthy controls. In DIABETIC MEDICINE Vol. 35 (pp. 31-32). Retrieved from https://www.webofscience.com/

Conference Paper

Minimal contribution of nausea or vomiting to superior semaglutide-mediated weight loss vs exenatide and dulaglutide in type 2 diabetes

Lingvay, I., de la Rosa, R., Marre, M., Nauck, M., Woo, V., Hansen, T., . . . Wilding, J. (2018). Minimal contribution of nausea or vomiting to superior semaglutide-mediated weight loss vs exenatide and dulaglutide in type 2 diabetes. In DIABETOLOGIA Vol. 61 (pp. S375-S376). Retrieved from https://www.webofscience.com/

Conference Paper

Relatively consistent effects of canagliflozin on outcomes regardless of baseline HbA<sub>1c</sub> in the CANVAS Program

Matthews, D. R., Rosenstock, J., Bantwal, G., Wilding, J., Dumas, R., Gonzalez-Galvez, G., . . . Fulcher, G. (2018). Relatively consistent effects of canagliflozin on outcomes regardless of baseline HbA<sub>1c</sub> in the CANVAS Program. In DIABETOLOGIA Vol. 61 (pp. S321). Retrieved from https://www.webofscience.com/

Conference Paper

Type 2 diabetes individuals' perspectives and needs for improved healthcare in medication management

Psarou, A., Wilding, J. P. H., & Cooper, H. (2018). Type 2 diabetes individuals' perspectives and needs for improved healthcare in medication management. In DIABETIC MEDICINE Vol. 35 (pp. 201). Retrieved from https://www.webofscience.com/

Conference Paper

2017

The impact of gastrointestinal adverse events on weight loss with semaglutide in subjects with type 2 diabetes

Atkin, S., Woo, V., de la Rosa, R., Wilding, J., Yamada, Y., Birch, S., . . . Ahren, B. (2017). The impact of gastrointestinal adverse events on weight loss with semaglutide in subjects with type 2 diabetes. In DIABETOLOGIA Vol. 60 (pp. S379-S380). Retrieved from https://www.webofscience.com/

Conference Paper

Combination therapy for obesity

Wilding, J. P. H. (2017). Combination therapy for obesity. JOURNAL OF PSYCHOPHARMACOLOGY, 31(11), 1503-1508. doi:10.1177/0269881117737401

DOI
10.1177/0269881117737401
Journal article

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial

Petrie, J. R., Chaturvedi, N., Ford, I., Brouwers, M. C. G. J., Greenlaw, N., Tillin, T., . . . Colhoun, H. M. (2017). Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. LANCET DIABETES & ENDOCRINOLOGY, 5(8), 597-609. doi:10.1016/S2213-8587(17)30194-8

DOI
10.1016/S2213-8587(17)30194-8
Journal article

OBSERVATIONAL STUDY ON THE EFFECTS OF IL-6 INHIBITOR THERAPY ON MYOSTATIN IN PATIENTS WITH RHEUMATOID ARTHRITIS

Chapman, M. J., Narayanan, R. P., Cross, A., Moots, R., Wilding, J., & Goodson, N. (2017). OBSERVATIONAL STUDY ON THE EFFECTS OF IL-6 INHIBITOR THERAPY ON MYOSTATIN IN PATIENTS WITH RHEUMATOID ARTHRITIS. In ANNALS OF THE RHEUMATIC DISEASES Vol. 76 (pp. 852). doi:10.1136/annrheumdis-2017-eular.5831

DOI
10.1136/annrheumdis-2017-eular.5831
Conference Paper

What have human experimental overfeeding studies taught us about adipose tissue expansion and susceptibility to obesity and metabolic complications?

Cuthbertson, D., Steele, T., Wilding, J., Halford, J. C. G., Harrold, J. A., Hamer, M., & Karpe, F. (2017). What have human experimental overfeeding studies taught us about adipose tissue expansion and susceptibility to obesity and metabolic complications?. International Journal of Obesity, 41, 853-865. doi:10.1038/ijo.2017.4

DOI
10.1038/ijo.2017.4
Journal article

Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study.

Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., . . . Fenici, P. (2017). Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study.. Circulation, 136(3), 249-259. doi:10.1161/circulationaha.117.029190

DOI
10.1161/circulationaha.117.029190
Journal article

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., . . . NN8022, S. C. A. L. E. O. P. (2017). 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. LANCET, 389(10077), 1399-1409. doi:10.1016/S0140-6736(17)30069-7

DOI
10.1016/S0140-6736(17)30069-7
Journal article

Consensus recommendations on exploring effective solutions for the rising cost of diabetes

Sadikot, S. M., Das, A. K., Wilding, J., Siyan, A., Zargar, A. H., Saboo, B., . . . Kesavadev, J. (2017). Consensus recommendations on exploring effective solutions for the rising cost of diabetes. DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 11(2), 141-147. doi:10.1016/j.dsx.2017.03.002

DOI
10.1016/j.dsx.2017.03.002
Journal article

Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response

Thondam, S. K., Daousi, C., Wilding, J. P. H., Holst, J. J., Ameen, G. I., Yang, C., . . . Cuthbertson, D. J. (2017). Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 312(3), E224-E233. doi:10.1152/ajpendo.00347.2016

DOI
10.1152/ajpendo.00347.2016
Journal article

Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: A randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)- study protocol

Rajeev, S., Sprung, V. S., Roberts, C., Harrold, J. A., Halford, J. C. G., Stancak, A., . . . Wilding, J. (2017). Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: A randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)- study protocol. BMJ Open, 7(1). doi:10.1136/bmjopen-2016-013539

DOI
10.1136/bmjopen-2016-013539
Journal article

Baseline characteristics of the DECLARE-TIMI 58 trial population

Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., . . . Wiviott, S. D. (2017). Baseline characteristics of the DECLARE-TIMI 58 trial population. In DIABETOLOGIA Vol. 60 (pp. S519-S520). Retrieved from https://www.webofscience.com/

Conference Paper

DECLARE-TIMI 58: Design and Baseline Characteristics

Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., . . . Wiviott, S. D. (2017). DECLARE-TIMI 58: Design and Baseline Characteristics. In DIABETES Vol. 66 (pp. A333). Retrieved from https://www.webofscience.com/

Conference Paper

Dapagliflozin in Renal Impairment: The Association of British Clinical Diabetologists Nationwide Dapagliflozin Audit

Yadagiri, M., Bain, S. C., Robinson, T., Wilding, J. P. H., Pang, T., Mcgowan, B., . . . Ryder, R. E. J. (2017). Dapagliflozin in Renal Impairment: The Association of British Clinical Diabetologists Nationwide Dapagliflozin Audit. In DIABETES Vol. 66 (pp. A45). Retrieved from https://www.webofscience.com/

Conference Paper

Dapagliflozin therapy for Type 2 diabetes in primary care: effects on HbA1c, weight and blood pressure over two years follow-up

Wilding, J., Bailey, C., Rigney, U., Blak, B., Kok, M., & Emmas, C. (2017). Dapagliflozin therapy for Type 2 diabetes in primary care: effects on HbA1c, weight and blood pressure over two years follow-up. In DIABETIC MEDICINE Vol. 34 (pp. 189). Retrieved from https://www.webofscience.com/

Conference Paper

Early weight loss responders to liraglutide 3.0mg had greater weight loss, regression to normoglycaemia, and reduced Type 2 diabetes development at three years vs early non-responders: SCALE Obesity and Prediabetes

Le Roux, C. W., Lau, D. C. W., Fujioka, K., Greenway, F., Wilding, J. P. H., Jacobsen, P. B., . . . Madsbad, S. (2017). Early weight loss responders to liraglutide 3.0mg had greater weight loss, regression to normoglycaemia, and reduced Type 2 diabetes development at three years vs early non-responders: SCALE Obesity and Prediabetes. In DIABETIC MEDICINE Vol. 34 (pp. 57). Retrieved from https://www.webofscience.com/

Conference Paper

Early weight loss with liraglutide 3.0 mg is a good predictor of clinically meaningful weight loss after 56 weeks

Le Roux, C., Bluher, M., Hermansen, K., Greenway, F., Fujioka, K., Donsmark, M., . . . Wilding, J. (2017). Early weight loss with liraglutide 3.0 mg is a good predictor of clinically meaningful weight loss after 56 weeks. In BRITISH JOURNAL OF SURGERY Vol. 104 (pp. 14). Retrieved from https://www.webofscience.com/

Conference Paper

Hospitalization for Heart Failure and Death in New Users of SGLT2 Inhibitors in Patients With and Without Cardiovascular Disease: CVD-REAL Study

Cavender, M. A., Norhammar, A., Birkeland, K. I., Jorgensen, M. E., Wilding, J. P. H., Khunti, K., . . . Kosiborod, M. N. (2017). Hospitalization for Heart Failure and Death in New Users of SGLT2 Inhibitors in Patients With and Without Cardiovascular Disease: CVD-REAL Study. In DIABETES Vol. 66 (pp. A99-A100). Retrieved from https://www.webofscience.com/

Conference Paper

Nutrition and Cardiometabolic Health

Bergeron, N., Siri-Tarino, P. W., Bray, G. A., & Krauss, R. M. (Eds.) (n.d.). Nutrition and Cardiometabolic Health. In . CRC Press. doi:10.1201/9781315119410

DOI
10.1201/9781315119410
Chapter

Pre-emptive diabetes medicines management to reduce first hypoglycaemic episodes facilitated by IT systems and nurse prescribing

Akiboye, F., Wilding, J., Wilson, S., Kerry, C., Round, R., & Rayman, G. (2017). Pre-emptive diabetes medicines management to reduce first hypoglycaemic episodes facilitated by IT systems and nurse prescribing. In DIABETIC MEDICINE Vol. 34 (pp. 143-144). Retrieved from https://www.webofscience.com/

Conference Paper

The Merseyside and Greater Manchester regional genetic diabetes nursing service: increasing recognition of monogenic diabetes

Navein, P., Samad, S., Wilding, J., Hattersley, A., Colclough, K., & Shepherd, M. (2017). The Merseyside and Greater Manchester regional genetic diabetes nursing service: increasing recognition of monogenic diabetes. In DIABETIC MEDICINE Vol. 34 (pp. 181). Retrieved from https://www.webofscience.com/

Conference Paper

The efficacy and safety of liraglutide 3.0mg for weight management are similar across baseline Edmonton Obesity Staging System (EOSS) categories: post-hoc analysis at 56 weeks

Wilding, J. P. H., Sharma, A. M., Finer, N., Padwal, R. S., Skjoth, T., Jensen, C. B., & Kushner, R. (2017). The efficacy and safety of liraglutide 3.0mg for weight management are similar across baseline Edmonton Obesity Staging System (EOSS) categories: post-hoc analysis at 56 weeks. In DIABETIC MEDICINE Vol. 34 (pp. 57). Retrieved from https://www.webofscience.com/

Conference Paper

2016

Greater weight loss and regression to normoglycaemia, and reduced risk of T2D, at 3 years in early weight loss responders to liraglutide 3.0 mg vs early non-responders

Wilding, J. P. H., Fujioka, K., Greenway, F., Lau, D. C. W., O'Neil, P., Jacobsen, P. B., . . . Madsbad, S. (2016). Greater weight loss and regression to normoglycaemia, and reduced risk of T2D, at 3 years in early weight loss responders to liraglutide 3.0 mg vs early non-responders. In DIABETOLOGIA Vol. 59 (pp. S330). Retrieved from https://www.webofscience.com/

Conference Paper

Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin

White, W. B., Wilson, C. A., Bakris, G. L., Bergenstal, R. M., Cannon, C. P., Cushman, W. C., . . . Zebrack, J. (2016). Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. HYPERTENSION, 68(3), 606-+. doi:10.1161/HYPERTENSIONAHA.116.07797

DOI
10.1161/HYPERTENSIONAHA.116.07797
Journal article

Set individualized targets for patients with type 2 diabetes.

Rajeev, S. P., & Wilding, J. (2016). Set individualized targets for patients with type 2 diabetes.. In The Practitioner Vol. 260 (pp. 23-26).

Conference Paper

Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial

White, W. B., Kupfer, S., Zannad, F., Mehta, C. R., Wilson, C. A., Lei, L., . . . Knapp, B. (2016). Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. DIABETES CARE, 39(7), 1267-1273. doi:10.2337/dc16-0303

DOI
10.2337/dc16-0303
Journal article

Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition

Rajeev, S. P., Cuthbertson, D. J., & Wilding, J. P. H. (2016). Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. DIABETES OBESITY & METABOLISM, 18(2), 125-134. doi:10.1111/dom.12578

DOI
10.1111/dom.12578
Journal article

Obesity and cardiovascular risk in type 2 diabetes

Whitmore, C., & Wilding, J. (2016). Obesity and cardiovascular risk in type 2 diabetes. In ADVANCED NUTRITION AND DIETETICS IN DIABETES (pp. 119-128). Retrieved from https://www.webofscience.com/

Chapter

A baseline assessment of individuals with and without a family history of Type 2 diabetes: the effects of 14 day step reduction

Davies, K. A. B., Sprung, V. S., Norman, J. A., Wilding, J. P., Kemp, G. J., & Cuthbertson, D. J. (2016). A baseline assessment of individuals with and without a family history of Type 2 diabetes: the effects of 14 day step reduction. In DIABETIC MEDICINE Vol. 33 (pp. 74). Retrieved from https://www.webofscience.com/

Conference Paper

A rare case of PICA syndrome post bariatric-surgery

Rajeev, S. P., McQuaid, P., Cowell, A., & Wilding, J. (2016). A rare case of PICA syndrome post bariatric-surgery. In BRITISH JOURNAL OF SURGERY Vol. 103 (pp. 9). Retrieved from https://www.webofscience.com/

Conference Paper

Characteristics of Individuals Developing Type 2 Diabetes in the SCALE Obesity and Prediabetes Randomized, Double-Blind, Liraglutide vs. Placebo Trial

Lau, D. C. W., Blueher, M., Van Gaal, L., Rubino, D. M., Guerrero, G., Manning, L. S., & Wilding, J. P. H. (2016). Characteristics of Individuals Developing Type 2 Diabetes in the SCALE Obesity and Prediabetes Randomized, Double-Blind, Liraglutide vs. Placebo Trial. In DIABETES Vol. 65 (pp. A510). Retrieved from https://www.webofscience.com/

Conference Paper

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: Efficacy and safety over 2 years. Diabetes Obes Metab

Wilding, J. P. H. (2016). Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: Efficacy and safety over 2 years. Diabetes Obes Metab. Therapeutic Research, 37(4), 386-387.

Journal article

Does dapagliflozin affect the metabolic response in patients with elevated alanine aminotransferase and Type 2 diabetes? The Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit

Yadagiri, M., Sen Gupta, P., Stephens, J. W., Robinson, A., Phylactou, M., Kennedy, A., . . . Ryder, R. E. J. (2016). Does dapagliflozin affect the metabolic response in patients with elevated alanine aminotransferase and Type 2 diabetes? The Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit. In DIABETIC MEDICINE Vol. 33 (pp. 30-31). Retrieved from https://www.webofscience.com/

Conference Paper

Early weight loss with liraglutide 3.0 mg is a good predictor of clinically meaningful weight loss after 56 weeks

Wilding, J. P. H., Hermansen, K., Greenway, F., Fujioka, K., Donsmark, M., Nzeakor, N., & Blueher, M. (2016). Early weight loss with liraglutide 3.0 mg is a good predictor of clinically meaningful weight loss after 56 weeks. DIABETIC MEDICINE, 33, 83. Retrieved from https://www.webofscience.com/

Journal article

Increased self-efficacy in taking Type 2 diabetes medicines can improve adherence

Psarou, A., Wilding, J. H. P., & Cooper, H. (2016). Increased self-efficacy in taking Type 2 diabetes medicines can improve adherence. In DIABETIC MEDICINE Vol. 33 (pp. 190). Retrieved from https://www.webofscience.com/

Conference Paper

Surgical cancellation rates in people with diabetes: passport to surgery

Akiboye, F., Page, E., Gardener, H., Wilding, J., & Rayman, G. (2016). Surgical cancellation rates in people with diabetes: passport to surgery. In DIABETIC MEDICINE Vol. 33 (pp. 182-183). Retrieved from https://www.webofscience.com/

Conference Paper

The Glycemic Response to Dapagliflozin According to Intensity of Background Diabetes Treatment or Duration of Type 2 Diabetes: The Association of British Clinical Diabetologists Nationwide Dapagliflozin Audit

Thong, K. Y., Yadagiri, M., Sen Gupta, P., Winocour, P., Joshi, M., Wilding, J., . . . Ryder, R. E. J. (2016). The Glycemic Response to Dapagliflozin According to Intensity of Background Diabetes Treatment or Duration of Type 2 Diabetes: The Association of British Clinical Diabetologists Nationwide Dapagliflozin Audit. In DIABETES Vol. 65 (pp. A307). Retrieved from https://www.webofscience.com/

Conference Paper

2015

Effect of CPAP on arterial stiffness in severely obese patients with obstructive sleep apnoea

Seetho, I. W., Asher, R., Parker, R. J., Craig, S., Duffy, N., Hardy, K. J., & Wilding, J. P. H. (2015). Effect of CPAP on arterial stiffness in severely obese patients with obstructive sleep apnoea. SLEEP AND BREATHING, 19(4), 1155-1165. doi:10.1007/s11325-015-1131-0

DOI
10.1007/s11325-015-1131-0
Journal article

Cerebral activations during viewing of food stimuli in adult patients with acquired structural hypothalamic damage: a functional neuroimaging study

Steele, C. A., Powell, J., Kemp, G., Halford, J., Wilding, J., Harrold, J., . . . Daousi, C. (2015). Cerebral activations during viewing of food stimuli in adult patients with acquired structural hypothalamic damage: a functional neuroimaging study. International Journal of Obesity, 39, 1376-1382. doi:10.1038/ijo.2015.82

DOI
10.1038/ijo.2015.82
Journal article

Serum urate and obstructive sleep apnoea in severe obesity

Seetho, I., Parker, R. J., Craig, S., Duffy, N., Hardy, K., Wilding, J., & Goodson, N. (2015). Serum urate and obstructive sleep apnoea in severe obesity. Chronic Respiratory Disease, 12(03), 238-246. doi:10.1177/1479972315586197

DOI
10.1177/1479972315586197
Journal article

Urinary proteomic profiling in severe obesity and obstructive sleep apnoea with CPAP treatment

Seetho, I. W., Ramírez-Torres, A., Albalat, A., Mullen, W., Mischak, H., Parker, R. J., . . . Wilding, J. P. (2015). Urinary proteomic profiling in severe obesity and obstructive sleep apnoea with CPAP treatment. Sleep Science, 8(2), 58-67. doi:10.1016/j.slsci.2015.06.004

DOI
10.1016/j.slsci.2015.06.004
Journal article

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., . . . NN, S. O. P. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11-22. doi:10.1056/NEJMoa1411892

DOI
10.1056/NEJMoa1411892
Journal article

Effects of canagliflozin on body weight and relationship to HbA(1c) and blood pressure changes in patients with type 2 diabetes

Cefalu, W. T., Stenlof, K., Leiter, L. A., Wilding, J. P. H., Blonde, L., Polidori, D., . . . Meininger, G. (2020). Effects of canagliflozin on body weight and relationship to HbA(1c) and blood pressure changes in patients with type 2 diabetes. Diabetologia, 58(6), 1183-1187. doi:10.1007/s00125-015-3547-2

DOI
10.1007/s00125-015-3547-2
Journal article

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., . . . Knapp, B. (2015). Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. LANCET, 385(9982), 2067-2076. doi:10.1016/S0140-6736(14)62225-X

DOI
10.1016/S0140-6736(14)62225-X
Journal article

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

Bentley-Lewis, R., Aguilar, D., Riddle, M. C., Claggett, B., Diaz, R., Dickstein, K., . . . Pfeffer, M. A. (2015). Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. AMERICAN HEART JOURNAL, 169(5), 631-U75. doi:10.1016/j.ahj.2015.02.002

DOI
10.1016/j.ahj.2015.02.002
Journal article

Efficacy and safety of canagliflozin by baseline HbA(1c) and known duration of type 2 diabetes mellitus

Wilding, J. P. H., Blonde, L., Leiter, L. A., Cerdas, S., Tong, C., Yee, J., & Meininger, G. (2015). Efficacy and safety of canagliflozin by baseline HbA(1c) and known duration of type 2 diabetes mellitus. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 29(3), 438-444. doi:10.1016/j.jdiacomp.2014.12.016

DOI
10.1016/j.jdiacomp.2014.12.016
Journal article

Impact of bariatric surgery on physical functioning in obese adults

Steele, T., Cuthbertson, D. J., & Wilding, J. P. H. (2015). Impact of bariatric surgery on physical functioning in obese adults. OBESITY REVIEWS, 16(3), 248-258. doi:10.1111/obr.12247

DOI
10.1111/obr.12247
Journal article

Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time

Parikh, S., Wilding, J., Jabbour, S., & Hardy, E. (2015). Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 69(2), 186-198. doi:10.1111/ijcp.12531

DOI
10.1111/ijcp.12531
Journal article

Pathophysiology and aetiology of obesity

Baqai, N., & Wilding, J. P. H. (2015). Pathophysiology and aetiology of obesity. Medicine, 43(2), 73-76. doi:10.1016/j.mpmed.2014.11.016

DOI
10.1016/j.mpmed.2014.11.016
Journal article

An observation of gestational weight gain in obese pregnancies

Abayomi, J. C., Charnley, M. S., Weeks, A., & Wilding, J. P. H. (2015). An observation of gestational weight gain in obese pregnancies. PROCEEDINGS OF THE NUTRITION SOCIETY, 74(OCE4), E255. doi:10.1017/S0029665115002979

DOI
10.1017/S0029665115002979
Journal article

Changes in HbA<sub>1c</sub> and weight in type 2 diabetes patients initiating dapagliflozin treatment in routine UK primary care

Wilding, J. P. H., Bailey, C. J., Rigney, U., Blak, B., Beekman, W., & Emmas, C. E. (2015). Changes in HbA<sub>1c</sub> and weight in type 2 diabetes patients initiating dapagliflozin treatment in routine UK primary care. In DIABETOLOGIA Vol. 58 (pp. S352-S353). Retrieved from https://www.webofscience.com/

Conference Paper

Early Weight Loss Responders to Liraglutide 3.0 mg in the SCALE Obesity and Prediabetes Trial Achieve Greater Reversal of Prediabetes than Placebo

Wilding, J. P. H., Blueher, M., Hermansen, K., Greenway, F., Fujioka, K., Claudius, B., . . . Lau, D. C. W. (2015). Early Weight Loss Responders to Liraglutide 3.0 mg in the SCALE Obesity and Prediabetes Trial Achieve Greater Reversal of Prediabetes than Placebo. In DIABETES Vol. 64 (pp. A568). Retrieved from https://www.webofscience.com/

Conference Paper

Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks

Blueher, M., Hermansen, K., Greenway, F., Fujioka, K., Donsmark, M., Jensen, C. B., & Wilding, J. P. H. (2015). Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. In DIABETOLOGIA Vol. 58 (pp. S310). Retrieved from https://www.webofscience.com/

Conference Paper

In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of Type 2 diabetes: SCALE obesity and pre-diabetes trial

Wilding, J., Astrup, A., Fujioka, K., Greenway, F., Krempf, M., Lau, D., . . . Violante Ortiz, R. (2015). In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of Type 2 diabetes: SCALE obesity and pre-diabetes trial. In DIABETIC MEDICINE Vol. 32 (pp. 71). Retrieved from https://www.webofscience.com/

Conference Paper

Managing patients with type 2 diabetes and obesity.

Wilding, J. (2015). Managing patients with type 2 diabetes and obesity.. The Practitioner, 259(1778), 25-3.

Journal article

Obesity as a disability: a weighty precedent?

Khan, M., Clift, A. K., O'Cinneide, C., & Wilding, J. (2015). Obesity as a disability: a weighty precedent?. CLINICAL OBESITY, 5(4), 163-164. doi:10.1111/cob.12102

DOI
10.1111/cob.12102
Journal article

Optimising clinical care in diabetes through research: a partnership with primary care

Navein, P., & Wilding, J. P. H. (2015). Optimising clinical care in diabetes through research: a partnership with primary care. DIABETIC MEDICINE, 32, 197-198. Retrieved from https://www.webofscience.com/

Journal article

SGLT2 inhibition and ketoacidosis - should we be concerned?

Rajeev, S. P., & Wilding, J. P. H. (2015). SGLT2 inhibition and ketoacidosis - should we be concerned?. BRITISH JOURNAL OF DIABETES AND VASCULAR DISEASE, 15(4), 155-158. doi:10.15277/bjdvd.2015.047

DOI
10.15277/bjdvd.2015.047
Journal article

Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre-diabetes trial

Wilding, J., Lau, D., Astrup, A., Fujioka, K., Greenway, F., Krempf, M., . . . Pi-Sunyer, X. (2015). Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre-diabetes trial. In DIABETIC MEDICINE Vol. 32 (pp. 70). Retrieved from https://www.webofscience.com/

Conference Paper

Serum Adiponectin Determines Circulating Vitamin D Concentration Independently of Other Adipokines

Narayanan, R. P., Boyle, L. D., Ng, S., Kahlon, A., Cross, A., Ding, C., . . . Wilding, J. P. H. (2015). Serum Adiponectin Determines Circulating Vitamin D Concentration Independently of Other Adipokines. In DIABETES Vol. 64 (pp. A574). Retrieved from https://www.webofscience.com/

Conference Paper

2014

Ectopic lipid storage in non-alcoholic fatty liver disease is not mediated by impaired mitochondrial oxidative capacity in skeletal muscle

Cuthbertson, D. J., Irwin, A., Sprung, V. S., Jones, H., Pugh, C. J. A., Daousi, C., . . . Kemp, G. J. (2014). Ectopic lipid storage in non-alcoholic fatty liver disease is not mediated by impaired mitochondrial oxidative capacity in skeletal muscle. CLINICAL SCIENCE, 127(11-12), 655-663. doi:10.1042/CS20130404

DOI
10.1042/CS20130404
Journal article

Liraglutide 3.0 Mg Improves Body Weight and Cardiometabolic Risk Factors in Overweight or Obese Adults without Diabetes: The Scale Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled 56-Week Trial

Le Roux, C., Astrup, A., Fujioka, K., Greenway, F. L., Halpern, A., Krempf, M., . . . Pi-Sunyer, F. X. (2014). Liraglutide 3.0 Mg Improves Body Weight and Cardiometabolic Risk Factors in Overweight or Obese Adults without Diabetes: The Scale Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled 56-Week Trial. In ENDOCRINE REVIEWS Vol. 35. Retrieved from https://www.webofscience.com/

Conference Paper

Obstructive sleep apnea is associated with increased arterial stiffness in severe obesity

Seetho, I. W., Parker, R. J., Craig, S., Duffy, N., Hardy, K. J., & Wilding, J. P. H. (2014). Obstructive sleep apnea is associated with increased arterial stiffness in severe obesity. JOURNAL OF SLEEP RESEARCH, 23(6), 700-708. doi:10.1111/jsr.12156

DOI
10.1111/jsr.12156
Journal article

GUIDELINES Identification, assessment, and management of overweight and obesity: summary of updated NICE guidance

Stegenga, H., Haines, A., Jones, K., & Wilding, J. (2014). GUIDELINES Identification, assessment, and management of overweight and obesity: summary of updated NICE guidance. BMJ-BRITISH MEDICAL JOURNAL, 349. doi:10.1136/bmj.g6608

DOI
10.1136/bmj.g6608
Journal article

Sleep-disordered breathing, type 2 diabetes and the metabolic syndrome

Seetho, I. W., & Wilding, J. P. H. (2014). Sleep-disordered breathing, type 2 diabetes and the metabolic syndrome. CHRONIC RESPIRATORY DISEASE, 11(4), 257-275. doi:10.1177/1479972314552806

DOI
10.1177/1479972314552806
Journal article

Urinary proteomics in obstructive sleep apnoea and obesity

Seetho, I. W., Siwy, J., Albalat, A., Mullen, W., Mischak, H., Parker, R. J., . . . Wilding, J. P. H. (2014). Urinary proteomics in obstructive sleep apnoea and obesity. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 44(11), 1104-1115. doi:10.1111/eci.12346

DOI
10.1111/eci.12346
Journal article

The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors

Wilding, J. P. H. (2014). The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. METABOLISM-CLINICAL AND EXPERIMENTAL, 63(10), 1228-1237. doi:10.1016/j.metabol.2014.06.018

DOI
10.1016/j.metabol.2014.06.018
Journal article

Glucose metabolism and the pathophysiology of diabetes mellitus

Wile, D. B., & Wilding, J. P. H. (2014). Glucose metabolism and the pathophysiology of diabetes mellitus. In Clinical Biochemistry: Metabolic and Clinical Aspects (pp. 273-304). Elsevier. doi:10.1016/b978-0-7020-5140-1.00015-8

DOI
10.1016/b978-0-7020-5140-1.00015-8
Chapter

The clinical management of diabetes mellitus

Seetho, I. W., & Wilding, J. P. H. (2014). The clinical management of diabetes mellitus. In Clinical Biochemistry: Metabolic and Clinical Aspects (pp. 305-332). Elsevier. doi:10.1016/b978-0-7020-5140-1.00016-x

DOI
10.1016/b978-0-7020-5140-1.00016-x
Chapter

CARDIOVASCULAR MORTALITY IN PATIENTS WITH TYPE 2 DIABETES AND RECENT ACUTE CORONARY SYNDROMES FROM THE EXAMINE TRIAL

White, W. B., Kupfer, S., Nissen, S., Cushman, W., Bakris, G., Heller, S., . . . Cannon, C. (2014). CARDIOVASCULAR MORTALITY IN PATIENTS WITH TYPE 2 DIABETES AND RECENT ACUTE CORONARY SYNDROMES FROM THE EXAMINE TRIAL. In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Vol. 63 (pp. A116). doi:10.1016/S0735-1097(14)60116-9

DOI
10.1016/S0735-1097(14)60116-9
Conference Paper

Characteristics and perspectives of night-eating behaviour in a severely obese population.

Cleator, J., Judd, P., James, M., Abbott, J., Sutton, C. J., & Wilding, J. P. H. (2014). Characteristics and perspectives of night-eating behaviour in a severely obese population.. Clinical obesity, 4(1), 30-38. doi:10.1111/cob.12037

DOI
10.1111/cob.12037
Journal article

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

Bolinder, J., Ljunggren, O., Johansson, L., Wilding, J., Langkilde, A. M., Sjostrom, C. D., . . . Parikh, S. (2014). Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes, Obesity and Metabolism, 16(2), 159-169. doi:10.1111/dom.12189

DOI
10.1111/dom.12189
Journal article

Effect of a Cooked Meat Meal on Serum Creatinine and Estimated Glomerular Filtration Rate in Diabetes-Related Kidney Disease

Nair, S., O'Brien, S. V., Hayden, K., Pandya, B., Lisboa, P. J. G., Hardy, K. J., & Wilding, J. P. H. (2014). Effect of a Cooked Meat Meal on Serum Creatinine and Estimated Glomerular Filtration Rate in Diabetes-Related Kidney Disease. Diabetes Care, 37(2), 483-487. doi:10.2337/dc13-1770

DOI
10.2337/dc13-1770
Journal article

1,25-dihydroxyvitamin D3 inhibits macrophage-induced inflammatory response in human adipocytes via NF-κB and MAPK pathways

Ding, C., Bing, C., & Wilding, J. P. (2014). 1,25-dihydroxyvitamin D3 inhibits macrophage-induced inflammatory response in human adipocytes via NF-κB and MAPK pathways. In FEBS JOURNAL Vol. 281 (pp. 86). Retrieved from https://www.webofscience.com/

Conference Paper

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., . . . Guimaraes, A. E. (2014). Alogliptin after acute coronary syndrome in patients with type 2 diabetes. Austrian Journal of Clinical Endocrinology and Metabolism, 7(2), 77.

Journal article

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years

Wilding, J. P. H., Woo, V., Rohwedder, K., Sugg, J., Parikh, S., & Dapagliflozin 006 Study Group. (2014). Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics, 16(2), 124-136. doi:10.1111/dom.12187

DOI
10.1111/dom.12187
Journal article

Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial

Fujioka, K., Wilding, J. P. H., Astrup, A., Greenway, F., Halpern, A., Krempf, M., . . . Pi-Sunyer, X. (2014). Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. DIABETOLOGIA, 57, S368-S369. Retrieved from https://www.webofscience.com/

Journal article

Glycaemic efficacy of canaglilozin by baseline HbA1c and known duration of type 2 diabetes mellitus

Cerdas, S., Leiter, L. A., Blonde, L., Wilding, J., Tong, C., Yee, J., & Meininger, G. (2014). Glycaemic efficacy of canaglilozin by baseline HbA1c and known duration of type 2 diabetes mellitus. In DIABETOLOGIA Vol. 57 (pp. S344). Retrieved from https://www.webofscience.com/

Conference Paper

Liraglutide 3.0 Mg Improves Insulin Secretion and Action in Overweight and Obese Adults without Diabetes: Results from Scale Obesity and Prediabetes, a Randomized, Double-Blind and Placebo-Controlled 56-Week Trial

Wilding, J., Astrup, A., Fujioka, K., Greenway, F. L., Halpern, A., Krempf, M., . . . Pi-Sunyer, F. X. (2014). Liraglutide 3.0 Mg Improves Insulin Secretion and Action in Overweight and Obese Adults without Diabetes: Results from Scale Obesity and Prediabetes, a Randomized, Double-Blind and Placebo-Controlled 56-Week Trial. In ENDOCRINE REVIEWS Vol. 35. Retrieved from https://www.webofscience.com/

Conference Paper

Liraglutide 3.0 Mg Reduces the Prevalence of Prediabetes and Delays Onset of Type 2 Diabetes in Overweight and Obese Adults: Results from Scale Obesity and Prediabetes, a Randomized, Double-Blind and Placebo-Controlled 56-Week Trial

Pi-Sunyer, F. X., Astrup, A., Fujioka, K., Greenway, F. L., Halpern, A., Krempf, M., . . . Wilding, J. (2014). Liraglutide 3.0 Mg Reduces the Prevalence of Prediabetes and Delays Onset of Type 2 Diabetes in Overweight and Obese Adults: Results from Scale Obesity and Prediabetes, a Randomized, Double-Blind and Placebo-Controlled 56-Week Trial. In ENDOCRINE REVIEWS Vol. 35. Retrieved from https://www.webofscience.com/

Conference Paper

Liraglutide 3.0 Mg Reduces the Prevalence of Prediabetes and Delays Onset of Type 2 Diabetes in Overweight and Obese Adults: Results from Scale Obesity and Prediabetes, a Randomized, Double-Blind and Placebo-Controlled 56-Week Trial

Pi-Sunyer, F. X., Astrup, A., Fujioka, K., Greenway, F. L., Halpern, A., Krempf, M., . . . Wilding, J. (2014). Liraglutide 3.0 Mg Reduces the Prevalence of Prediabetes and Delays Onset of Type 2 Diabetes in Overweight and Obese Adults: Results from Scale Obesity and Prediabetes, a Randomized, Double-Blind and Placebo-Controlled 56-Week Trial. In ENDOCRINE REVIEWS Vol. 35. Retrieved from https://www.webofscience.com/

Conference Paper

Liraglutide 3.0 mg improves insulin secretion and action in overweight/obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial

Lau, D. C. W., Wilding, J. P. H., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., . . . Pi-Sunyer, X. (2014). Liraglutide 3.0 mg improves insulin secretion and action in overweight/obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. DIABETOLOGIA, 57, S358. Retrieved from https://www.webofscience.com/

Journal article

Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial

Krempf, M., Astrup, A., le Roux, C., Fujioka, K., Greenway, F., Halpern, A., . . . Pi-Sunyer, X. (2014). Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. DIABETOLOGIA, 57, S368. Retrieved from https://www.webofscience.com/

Journal article

Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial

Pi-Sunyer, X., Fujioka, K., le Roux, C., Astrup, A., Greenway, F., Halpern, A., . . . Wilding, J. P. H. (2014). Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. DIABETOLOGIA, 57, S37. Retrieved from https://www.webofscience.com/

Journal article

Liraglutide in the treatment of obesity

Ng, S. Y. A., & Wilding, J. P. H. (2014). Liraglutide in the treatment of obesity. EXPERT OPINION ON BIOLOGICAL THERAPY, 14(8), 1215-1224. doi:10.1517/14712598.2014.925870

DOI
10.1517/14712598.2014.925870
Journal article

Obstructive sleep apnoea in diabetes - assessment and awareness

Seetho, I. W., O’Brien, S. V., Hardy, K. J., & Wilding, J. P. H. (n.d.). Obstructive sleep apnoea in diabetes - assessment and awareness. British Journal of Diabetes, 14(3), 105. doi:10.15277/bjdvd.2014.025

DOI
10.15277/bjdvd.2014.025
Journal article

Safety and Tolerability of Liraglutide 3.0 Mg in Overweight and Obese Adults: The Scale Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled 56-Week Trial

Lau, D. C., Astrup, A., Fujioka, K., Greenway, F. L., Halpern, A., Krempf, M., . . . Pi-Sunyer, F. X. (2014). Safety and Tolerability of Liraglutide 3.0 Mg in Overweight and Obese Adults: The Scale Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled 56-Week Trial. In ENDOCRINE REVIEWS Vol. 35. Retrieved from https://www.webofscience.com/

Conference Paper

Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial

le Roux, C., Lau, D. C. W., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., . . . Pi-Sunyer, X. (2014). Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. DIABETOLOGIA, 57, S338. Retrieved from https://www.webofscience.com/

Journal article

The importance of weight management in type 2 diabetes mellitus

Wilding, J. P. H. (2014). The importance of weight management in type 2 diabetes mellitus. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 68(6), 682-691. doi:10.1111/ijcp.12384

DOI
10.1111/ijcp.12384
Journal article

URATE IS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNOEA IN OBESE WOMEN

Seetho, I. W., Ahmad, A., Parker, R. J., Craig, S., Duffy, N., Hardy, K. J., . . . Goodson, N. (2014). URATE IS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNOEA IN OBESE WOMEN. In RHEUMATOLOGY Vol. 53 (pp. 163). Retrieved from https://www.webofscience.com/

Conference Paper

2013

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

Wilding, J. P. H., Charpentier, G., Hollander, P., Gonzalez-Galvez, G., Mathieu, C., Vercruysse, F., . . . Meininger, G. (2013). Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 67(12), 1267-1282. doi:10.1111/ijcp.12322

DOI
10.1111/ijcp.12322
Journal article

Correlations between night eating, sleep quality, and excessive daytime sleepiness in a severely obese UK population

Cleator, J., Abbott, J., Judd, P., Wilding, J. P. H., & Sutton, C. J. (2013). Correlations between night eating, sleep quality, and excessive daytime sleepiness in a severely obese UK population. SLEEP MEDICINE, 14(11), 1151-1156. doi:10.1016/j.sleep.2013.04.026

DOI
10.1016/j.sleep.2013.04.026
Journal article

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., . . . Knapp, B. (2013). Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. NEW ENGLAND JOURNAL OF MEDICINE, 369(14), 1327-1335. doi:10.1056/NEJMoa1305889

DOI
10.1056/NEJMoa1305889
Journal article

Canagliflozin (CANA) Lowers A1C and Blood Pressure (BP) Through Weight Loss-Independent (WL-I) and Weight Loss-Associated (WL-A) Mechanisms

Chiasson, J. -L., Wilding, J., Blonde, L., Polidori, D., Meininger, G., & Stein, P. (2013). Canagliflozin (CANA) Lowers A1C and Blood Pressure (BP) Through Weight Loss-Independent (WL-I) and Weight Loss-Associated (WL-A) Mechanisms. Canadian Journal of Diabetes, 37, S29. doi:10.1016/j.jcjd.2013.08.086

DOI
10.1016/j.jcjd.2013.08.086
Journal article

Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes

Boyle, L. D., & Wilding, J. P. H. (2013). Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes. EXPERT OPINION ON EMERGING DRUGS, 18(3), 375-391. doi:10.1517/14728214.2013.831405

DOI
10.1517/14728214.2013.831405
Journal article

How to approach endocrine assessment in severe obesity?

Seetho, I. W., & Wilding, J. P. H. (2013). How to approach endocrine assessment in severe obesity?. CLINICAL ENDOCRINOLOGY, 79(2), 163-167. doi:10.1111/cen.12256

DOI
10.1111/cen.12256
Journal article

Screening for obstructive sleep apnoea in obesity and diabetes potential for future approaches

Seetho, I. W., & Wilding, J. P. H. (2013). Screening for obstructive sleep apnoea in obesity and diabetes potential for future approaches. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 43(6), 640-655. doi:10.1111/eci.12083

DOI
10.1111/eci.12083
Journal article

Acute peripheral administration of synthetic human GLP-1 (7-36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: A potential role for GLP-1 in modulation of the diabetic pro-inflammatory state?

Daousi, C., Pinkney, J. H., Cleator, J., Wilding, J. P., & Ranganath, L. R. (2013). Acute peripheral administration of synthetic human GLP-1 (7-36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: A potential role for GLP-1 in modulation of the diabetic pro-inflammatory state?. REGULATORY PEPTIDES, 183, 54-61. doi:10.1016/j.regpep.2013.03.004

DOI
10.1016/j.regpep.2013.03.004
Journal article

Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus

Fonseca, V. A., Ferrannini, E., Wilding, J. P., Wilpshaar, W., Dhanjal, P., Ball, G., & Klasen, S. (2013). Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 27(3), 268-273. doi:10.1016/j.jdiacomp.2012.11.005

DOI
10.1016/j.jdiacomp.2012.11.005
Journal article

DIFFERENTIAL GENETIC EXPRESSION AND REDUCED LONGITUDINAL FUNCTION IN PATIENTS WITH DIABETES AND SEVERE AORTIC STENSOIS WITH A NORMAL EJECTION FRACTION

Ashrafi, R., Gerges, J. Y., Hart, G., Boyett, M., Davis, G., & Wilding, J. (2013). DIFFERENTIAL GENETIC EXPRESSION AND REDUCED LONGITUDINAL FUNCTION IN PATIENTS WITH DIABETES AND SEVERE AORTIC STENSOIS WITH A NORMAL EJECTION FRACTION. HEART, 99, A125. doi:10.1136/heartjnl-2013-304019.232

DOI
10.1136/heartjnl-2013-304019.232
Journal article

Orlistat: should we worry about liver inflammation?

Wilding, J. (2013). Orlistat: should we worry about liver inflammation?. BMJ-BRITISH MEDICAL JOURNAL, 346. doi:10.1136/bmj.f2777

DOI
10.1136/bmj.f2777
Journal article

1,25-dihydroxyvitamin D<sub>3</sub> Protects against Macrophage-Induced Activation of NFκB and MAPK Signalling and Chemokine Release in Human Adipocytes

Ding, C., Wilding, J. P. H., & Bing, C. (2013). 1,25-dihydroxyvitamin D<sub>3</sub> Protects against Macrophage-Induced Activation of NFκB and MAPK Signalling and Chemokine Release in Human Adipocytes. PLOS ONE, 8(4). doi:10.1371/journal.pone.0061707

DOI
10.1371/journal.pone.0061707
Journal article

Hypothalamic obesity: prevalence, associations and longitudinal trends in weight in a specialist adult neuroendocrine clinic

Steele, C. A., Cuthbertson, D. J., MacFarlane, I. A., Javadpour, M., Das, K. S. V., Gilkes, C., . . . Daousi, C. (2013). Hypothalamic obesity: prevalence, associations and longitudinal trends in weight in a specialist adult neuroendocrine clinic. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 168(4), 501-507. doi:10.1530/EJE-12-0792

DOI
10.1530/EJE-12-0792
Journal article

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial

Wilding, J. P. H., Woo, V., Soler, N. G., Pahor, A., Sugg, J., Rohwedder, K., & Parikh, S. (2013). Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 138, S27-S38. doi:10.1055/s-0032-1305284

DOI
10.1055/s-0032-1305284
Journal article

Canagliflozin (CANA) Lowers A1C and Blood Pressure (BP) Through Weight Loss-Independent (WL-I) and Weight Loss-Associated (WL-A) Mechanisms

Blonde, L., Wilding, J., Chiasson, J. -L., Polidori, D., Meininger, G., & Stein, P. (2013). Canagliflozin (CANA) Lowers A1C and Blood Pressure (BP) Through Weight Loss-Independent (WL-I) and Weight Loss-Associated (WL-A) Mechanisms. In DIABETES Vol. 62 (pp. A288). Retrieved from https://www.webofscience.com/

Conference Paper

Canagliflozin lowers HbA<sub>1c</sub> and blood pressure through weight loss-independent and weight loss-associated mechanisms

Wilding, J., Blonde, L., Chiasson, J. -L., Polidori, D., Meininger, G., & Stein, P. (2013). Canagliflozin lowers HbA<sub>1c</sub> and blood pressure through weight loss-independent and weight loss-associated mechanisms. In DIABETOLOGIA Vol. 56 (pp. S379). Retrieved from https://www.webofscience.com/

Conference Paper

Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin

Wilding, J. P. H., Leonsson-Zachrisson, M., Wessman, C., & Johnsson, E. (2013). Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. DIABETES OBESITY & METABOLISM, 15(8), 750-759. doi:10.1111/dom.12088

DOI
10.1111/dom.12088
Journal article

Effect of Cooked Meat Meal on Creatinine and eGFR in Diabetes Related Kidney Disease

Nair, S., O'Brien, S., Hardy, K. J., & Wilding, J. P. (2013). Effect of Cooked Meat Meal on Creatinine and eGFR in Diabetes Related Kidney Disease. In DIABETES Vol. 62 (pp. A136). Retrieved from https://www.webofscience.com/

Conference Paper

Efficacy and safety of canagliflozin in subjects with type 2 diabetes mellitus inadequately controlled with metformin plus sulphonylurea over 52 weeks

Vercruysse, F., Charpentier, G., Wilding, J., Hollander, P., Gonzalez Galvez, G., Mathieu, C., . . . Meininger, G. (2013). Efficacy and safety of canagliflozin in subjects with type 2 diabetes mellitus inadequately controlled with metformin plus sulphonylurea over 52 weeks. In DIABETOLOGIA Vol. 56 (pp. S373). Retrieved from https://www.webofscience.com/

Conference Paper

Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study

Wilding, J. P. H., Ferrannini, E., Fonseca, V. A., Wilpshaar, W., Dhanjal, P., & Houzer, A. (2013). Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. DIABETES OBESITY & METABOLISM, 15(5), 403-409. doi:10.1111/dom.12038

DOI
10.1111/dom.12038
Journal article

Plasma obestatin and autonomic function are altered in orexin-deficient narcolepsy, but ghrelin is unchanged

Huda, M. S. B., Mani, H., Durham, B. H., Dovey, T. M., Halford, J. C. G., Aditya, B. S., . . . Hart, I. K. (2013). Plasma obestatin and autonomic function are altered in orexin-deficient narcolepsy, but ghrelin is unchanged. ENDOCRINE, 43(3), 696-704. doi:10.1007/s12020-012-9838-1

DOI
10.1007/s12020-012-9838-1
Journal article

Vitamin D reduces cytokine-induced insulin resistance in human adipocytes

Wilding-Steele, T. P., Ding, C., Madi, M., Bing, C., & Wilding, J. P. H. (2013). Vitamin D reduces cytokine-induced insulin resistance in human adipocytes. DIABETIC MEDICINE, 30, 40. Retrieved from https://www.webofscience.com/

Journal article

2012

Vitamin D signalling in adipose tissue

Ding, C., Gao, D., Wilding, J., Trayhurn, P., & Bing, C. (2012). Vitamin D signalling in adipose tissue. BRITISH JOURNAL OF NUTRITION, 108(11), 1915-1923. doi:10.1017/S0007114512003285

DOI
10.1017/S0007114512003285
Journal article

A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus

Thondam, S. K., Cuthbertson, D. J., Aditya, B. S., MacFarlane, I. A., Wilding, J. P., & Daousi, C. (2012). A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus. CLINICAL ENDOCRINOLOGY, 77(4), 635-637. doi:10.1111/j.1365-2265.2012.04368.x

DOI
10.1111/j.1365-2265.2012.04368.x
Journal article

Are the causes of obesity primarily environmental? Yes

Wilding, J. (2012). Are the causes of obesity primarily environmental? Yes. BMJ-BRITISH MEDICAL JOURNAL, 345. doi:10.1136/bmj.e5843

DOI
10.1136/bmj.e5843
Journal article

Night eating syndrome: implications for severe obesity

Cleator, J., Abbott, J., Judd, P., Sutton, C., & Wilding, J. P. H. (2012). Night eating syndrome: implications for severe obesity. NUTRITION & DIABETES, 2. doi:10.1038/nutd.2012.16

DOI
10.1038/nutd.2012.16
Journal article

Anti-obesity drugs: past, present and future

Rodgers, R. J., Tschoep, M. H., & Wilding, J. P. H. (2012). Anti-obesity drugs: past, present and future. DISEASE MODELS & MECHANISMS, 5(5), 621-626. doi:10.1242/dmm.009621

DOI
10.1242/dmm.009621
Journal article

Facing the Challenges for Europe - Research into Action: Liverpool European Congress of Obesity, May 12-15, 2013

Wilding, J. P. H., & Halford, J. C. G. (2012). Facing the Challenges for Europe - Research into Action: Liverpool European Congress of Obesity, May 12-15, 2013. OBESITY FACTS, 5(4), 629-634. doi:10.1159/000342705

DOI
10.1159/000342705
Journal article

Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus

Thondam, S. K., Cross, A., Cuthbertson, D. J., Wilding, J. P., & Daousi, C. (2012). Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus. DIABETIC MEDICINE, 29(8), E205-E210. doi:10.1111/j.1464-5491.2012.03675.x

DOI
10.1111/j.1464-5491.2012.03675.x
Journal article

Response to Monesi <i>et al</i>. Prevalence, incidence and mortality of diagnosed diabetes: evidence from an Italian population-based study

Nair, S., Hardy, K. J., & Wilding, J. P. H. (2012). Response to Monesi <i>et al</i>. Prevalence, incidence and mortality of diagnosed diabetes: evidence from an Italian population-based study. DIABETIC MEDICINE, 29(8), 1086-1087. doi:10.1111/j.1464-5491.2012.03569.x

DOI
10.1111/j.1464-5491.2012.03569.x
Journal article

Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin A Randomized Trial

Wilding, J. P. H., Woo, V., Soler, N. G., Pahor, A., Sugg, J., Rohwedder, K., & Parikh, S. (2012). Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin A Randomized Trial. ANNALS OF INTERNAL MEDICINE, 156(6), 405-U50. doi:10.7326/0003-4819-156-6-201203200-00003

DOI
10.7326/0003-4819-156-6-201203200-00003
Journal article

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

Bolinder, J., Ljunggren, O., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., . . . Parikh, S. (2012). Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 97(3), 1020-1031. doi:10.1210/jc.2011-2260

DOI
10.1210/jc.2011-2260
Journal article

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., . . . Parikh, S. (2012). Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin. The Journal of Clinical Endocrinology &amp; Metabolism, 97(3), 1020-1031. doi:10.1210/jc.2011-2260

DOI
10.1210/jc.2011-2260
Journal article

Canagliflozin (CANA), a Sodium Glucose Co-Transporter 2 Inhibitor, Improves Glycemic Control and Reduces Body Weight in Subjects With Type 2 Diabetes (T2D) Inadequately Controlled With Metformin (MET) and Sulfonylurea (SU)

Wilding, J., Mathieu, C., Vercruysse, F., Usiskin, K., Deng, L., & Canovatchel, W. (2012). Canagliflozin (CANA), a Sodium Glucose Co-Transporter 2 Inhibitor, Improves Glycemic Control and Reduces Body Weight in Subjects With Type 2 Diabetes (T2D) Inadequately Controlled With Metformin (MET) and Sulfonylurea (SU). In DIABETES Vol. 61 (pp. A262). Retrieved from https://www.webofscience.com/

Conference Paper

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycaemia in subjects with type 2 diabetes inadequately controlled with metformin plus sulphonylurea

Wilding, J., Mathieu, C., Deng, L., Black, S., Vercruysse, F., Canovatchel, W., & Meininger, G. (2012). Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycaemia in subjects with type 2 diabetes inadequately controlled with metformin plus sulphonylurea. In DIABETOLOGIA Vol. 55 (pp. S315-S316). Retrieved from https://www.webofscience.com/

Conference Paper

Chronic non-communicable diseases: adding weight to evidence

Purcell, H., Day, C., Ziso, B., Wilding, J., & Daly, C. (2012). Chronic non-communicable diseases: adding weight to evidence. In H. Purcell (Ed.), Chronic non-communicable diseases (pp. 1-12). London: NHSI.

Chapter

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin

Ljunggren, O., Bolinder, J., Johansson, L., Wilding, J., Langkilde, A. M., Sjostrom, C. D., . . . Parikh, S. (2012). Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. DIABETES OBESITY & METABOLISM, 14(11), 990-999. doi:10.1111/j.1463-1326.2012.01630.x

DOI
10.1111/j.1463-1326.2012.01630.x
Journal article

Dapagliflozin has no long-term effect on markers of bone turnover or bone mineral density in patients with inadequately controlled type 2 diabetes on metformin

Ljunggren, O., Bolinder, J., Johansson, L., Wilding, J. P. H., Langkilde, A. M., Sjostrom, C. D., . . . Parikh, S. (2012). Dapagliflozin has no long-term effect on markers of bone turnover or bone mineral density in patients with inadequately controlled type 2 diabetes on metformin. In DIABETOLOGIA Vol. 55 (pp. S306-S307). Retrieved from https://www.webofscience.com/

Conference Paper

Dapagliflozin produces long-term reductions in body weight, waist circumference and total fat mass in patients with type 2 diabetes inadequately controlled on metformin

Bolinder, J., Ljunggren, O., Johansson, L., Wilding, J. P. H., Langkilde, A. M., Sjostrom, C. D., . . . Parikh, S. (2012). Dapagliflozin produces long-term reductions in body weight, waist circumference and total fat mass in patients with type 2 diabetes inadequately controlled on metformin. In DIABETOLOGIA Vol. 55 (pp. S308). Retrieved from https://www.webofscience.com/

Conference Paper

Facing the Challenges for Europe – Research into Action: Liverpool European Congress of Obesity, May 12–15, 2013

Wilding, J. P. H., & Halford, J. C. G. (2012). Facing the Challenges for Europe – Research into Action: Liverpool European Congress of Obesity, May 12–15, 2013. Obesity Facts, 5(4), 629-634. doi:10.1159/000342705

DOI
10.1159/000342705
Journal article

High-fat diet-induced obesity is associated with increased cardiac telomerase expression but not cell proliferation in the rat

Ashrafi, R., Yon, M. A., Yanni-Gerges, J., Hart, G., Boyett, M., Davis, G. K., . . . Wilding, J. P. H. (2012). High-fat diet-induced obesity is associated with increased cardiac telomerase expression but not cell proliferation in the rat. In PROCEEDINGS OF THE NUTRITION SOCIETY Vol. 71 (pp. E242). doi:10.1017/S0029665112003333

DOI
10.1017/S0029665112003333
Conference Paper

High-fat diet-induced obesity is associated with increased cardiac telomerase expression but not cell proliferation in the rat

Ashrafi, R., Yon, M. A., Yanni-Gerges, J., Hart, G., Boyett, M., Davis, G. K., . . . Wilding, J. P. H. (2012). High-fat diet-induced obesity is associated with increased cardiac telomerase expression but not cell proliferation in the rat. In Joint Winter Meeting 2012 (pp. ?). London: Cambridge University Press.

Conference Paper

Long-Term Effectiveness of Dapagliflozin Over 104 Weeks in Patients With Type 2 Diabetes Poorly Controlled With Insulin

Wilding, J. P., Woo, V. C., Rohwedder, K., Sugg, J. E., & Parikh, S. J. (2012). Long-Term Effectiveness of Dapagliflozin Over 104 Weeks in Patients With Type 2 Diabetes Poorly Controlled With Insulin. In DIABETES Vol. 61 (pp. A267-A268). Retrieved from https://www.webofscience.com/

Conference Paper

Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin A Randomized Trial

Wilding, J. P. H., Woo, V., Soler, N. G., Pahor, A., Sugg, J., Rohwedder, K., . . . Dapagliflozin, S. G. (2012). Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin A Randomized Trial. Annals of Internal Medicine, 156(6), 405-U50. doi:10.1059/0003-4819-156-6-201203200-00003

DOI
10.1059/0003-4819-156-6-201203200-00003
Journal article

Long-term effectiveness of dapagliflozin over 104 weeks in patients with type 2 diabetes poorly controlled with insulin

Rohwedder, K., Wilding, J. P. H., Woo, V., Sugg, J., & Parikh, S. (2012). Long-term effectiveness of dapagliflozin over 104 weeks in patients with type 2 diabetes poorly controlled with insulin. In DIABETOLOGIA Vol. 55 (pp. S309). Retrieved from https://www.webofscience.com/

Conference Paper

Nurse led counselling in a hypertension clinic in Malawi leads to improved adherence and blood pressure control

Starichi, Z., Wilding, J., Dawes, S., Lopez, T., Dreyer, G., & Allain, T. (2012). Nurse led counselling in a hypertension clinic in Malawi leads to improved adherence and blood pressure control. JOURNAL OF HUMAN HYPERTENSION, 26(10), 623-624. Retrieved from https://www.webofscience.com/

Journal article

PPAR agonists for the treatment of cardiovascular disease in patients with diabetes

Wilding, J. P. H. (2012). PPAR agonists for the treatment of cardiovascular disease in patients with diabetes. DIABETES OBESITY & METABOLISM, 14(11), 973-982. doi:10.1111/j.1463-1326.2012.01601.x

DOI
10.1111/j.1463-1326.2012.01601.x
Journal article

Risk of Misdiagnosis, Health-Related Quality of Life, and BMI in Patients Who Are Overweight With Doctor-Diagnosed Asthma

Scott, S., Currie, J., Albert, P., Calverley, P., & Wilding, J. P. H. (2012). Risk of Misdiagnosis, Health-Related Quality of Life, and BMI in Patients Who Are Overweight With Doctor-Diagnosed Asthma. CHEST, 141(3), 616-624. doi:10.1378/chest.11-0948

DOI
10.1378/chest.11-0948
Journal article

Sustained reductions in weight and HbA<sub>1c</sub> with dapagliflozin: long-term results from phase III clinical studies in type 2 diabetes

Bailey, C. J., Wilding, J., Nauck, M. A., Ferrannini, E., Ptaszynska, A. A., Apanovitch, A. M., . . . Parikh, S. J. (2012). Sustained reductions in weight and HbA<sub>1c</sub> with dapagliflozin: long-term results from phase III clinical studies in type 2 diabetes. In DIABETOLOGIA Vol. 55 (pp. S295). Retrieved from https://www.webofscience.com/

Conference Paper

The effect of continuous positive airway pressure usage on sleepiness in obstructive sleep apnoea: real effects or expectation of benefit?

Crawford, M. R., Bartlett, D. J., Coughlin, S. R., Phillips, C. L., Neill, A. M., Espie, C. A., . . . Marshall, N. S. (2012). The effect of continuous positive airway pressure usage on sleepiness in obstructive sleep apnoea: real effects or expectation of benefit?. THORAX, 67(10), 920-924. doi:10.1136/thoraxjnl-2012-201622

DOI
10.1136/thoraxjnl-2012-201622
Journal article

Treatment of Diabetes through targeting weight loss

Thondam, S., & Wilding, J. P. H. (2012). Treatment of Diabetes through targeting weight loss. In J. Vora, & J. Buse (Eds.), Evidence-based Management of Diabetes (pp. 111-130). Shrewsbury: TFM Publishing.

Chapter

2011

The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula performs worse than the Modification of Diet in Renal Disease (MDRD) equation in estimating glomerular filtration rate in Type 2 diabetic chronic kidney disease

Nair, S., Hardy, K. J., & Wilding, J. P. H. (2011). The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula performs worse than the Modification of Diet in Renal Disease (MDRD) equation in estimating glomerular filtration rate in Type 2 diabetic chronic kidney disease. DIABETIC MEDICINE, 28(10), 1279. doi:10.1111/j.1464-5491.2011.03344.x

DOI
10.1111/j.1464-5491.2011.03344.x
Journal article

Ghrelin does not orchestrate the metabolic changes seen in fasting but has significant effects on lipid mobilisation and substrate utilisation

Huda, M. S. B., Dovey, T. M., Wong, S. P., English, P. J., Halford, J. C. G., McCulloch, P., . . . Pinkney, J. H. (2011). Ghrelin does not orchestrate the metabolic changes seen in fasting but has significant effects on lipid mobilisation and substrate utilisation. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 165(1), 45-55. doi:10.1530/EJE-10-1122

DOI
10.1530/EJE-10-1122
Journal article

The four-variable modification of diet in renal disease formula underestimates glomerular filtration rate in obese type 2 diabetic individuals with chronic kidney disease

Nair, S., Mishra, V., Hayden, K., Lisboa, P. J. G., Pandya, B., Vinjamuri, S., . . . Wilding, J. P. H. (2011). The four-variable modification of diet in renal disease formula underestimates glomerular filtration rate in obese type 2 diabetic individuals with chronic kidney disease. DIABETOLOGIA, 54(6), 1304-1307. doi:10.1007/s00125-011-2085-9

DOI
10.1007/s00125-011-2085-9
Journal article

Therapeutics Glucagon-like peptide-1 analogues for type 2 diabetes

Wilding, J. P. H., & Hardy, K. (2011). Therapeutics Glucagon-like peptide-1 analogues for type 2 diabetes. BRITISH MEDICAL JOURNAL, 342. doi:10.1136/bmj.d410

DOI
10.1136/bmj.d410
Journal article

Human RBP4 adipose tissue expression is gender specific and influenced by leptin

Kos, K., Wong, S., Tan, B. K., Kerrigan, D., Randeva, H. S., Pinkney, J. H., & Wilding, J. P. H. (2011). Human RBP4 adipose tissue expression is gender specific and influenced by leptin. CLINICAL ENDOCRINOLOGY, 74(2), 197-205. doi:10.1111/j.1365-2265.2010.03892.x

DOI
10.1111/j.1365-2265.2010.03892.x
Journal article

Pathophysiology and aetiology of obesity

Wilding, J. P. H. (2011). Pathophysiology and aetiology of obesity. Medicine, 39(1), 6-10. doi:10.1016/j.mpmed.2010.10.002

DOI
10.1016/j.mpmed.2010.10.002
Journal article

RBP4 adipose tissue expression in humans is gender specific and influenced by leptin

Kos, K., Wong, S., Bee, T., Kerrigan, D., Harpal, S. R., Pinkney, J. H., & Wilding, J. P. H. (2011). RBP4 adipose tissue expression in humans is gender specific and influenced by leptin. Clinical Endocrinology, 74, 197-205.

Journal article

The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula performs worse than the Modification of Diet in Renal Disease (MDRD) equation in estimating glomerular filtration rate in Type 2 diabetic chronic kidney disease

Nair, S., Hardy, K. J., & Wilding, J. P. H. (2011). The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula performs worse than the Modification of Diet in Renal Disease (MDRD) equation in estimating glomerular filtration rate in Type 2 diabetic chronic kidney disease. Diabetic Medicine. doi:10.1111/j.1464-

DOI
10.1111/j.1464-
Journal article

2010

Ghrelin inhibits autonomic function in healthy controls, but has no effect on obese and vagotomized subjects

Huda, M. S. B., Mani, H., Dovey, T., Halford, J. C. G., Boyland, E., Daousi, C., . . . Pinkney, J. (2010). Ghrelin inhibits autonomic function in healthy controls, but has no effect on obese and vagotomized subjects. CLINICAL ENDOCRINOLOGY, 73(5), 678-685. doi:10.1111/j.1365-2265.2010.03865.x

DOI
10.1111/j.1365-2265.2010.03865.x
Journal article

Nurse-led clinics for strict hypertension control are effective long term: a 7 year follow-up study

Woodward, A., Wallymahmed, M., Wilding, J. P., & Gill, G. V. (2010). Nurse-led clinics for strict hypertension control are effective long term: a 7 year follow-up study. DIABETIC MEDICINE, 27(8), 933-937. doi:10.1111/j.1464-5491.2010.03039.x

DOI
10.1111/j.1464-5491.2010.03039.x
Journal article

Nurse‐led clinics for strict hypertension control are effective long term: a 7 year follow‐up study

Woodward, A., Wallymahmed, M., Wilding, J. P., & Gill, G. V. (2010). Nurse‐led clinics for strict hypertension control are effective long term: a 7 year follow‐up study. Diabetic Medicine, 27(8), 933-937. doi:10.1111/j.1464-5491.2010.03039.x

DOI
10.1111/j.1464-5491.2010.03039.x
Journal article

Absence of insulin signalling in skeletal muscle is associated with reduced muscle mass and function: evidence for decreased protein synthesis and not increased degradation

O'Neill, E. D., Wilding, J. P. H., Kahn, C. R., Van Remmen, H., McArdle, A., Jackson, M. J., & Close, G. L. (2010). Absence of insulin signalling in skeletal muscle is associated with reduced muscle mass and function: evidence for decreased protein synthesis and not increased degradation. AGE, 32(2), 209-222. doi:10.1007/s11357-009-9125-0

DOI
10.1007/s11357-009-9125-0
Journal article

SPARC: a key player in the pathologies associated with obesity and diabetes

Kos, K., & Wilding, J. P. H. (2010). SPARC: a key player in the pathologies associated with obesity and diabetes. NATURE REVIEWS ENDOCRINOLOGY, 6(4), 225-235. doi:10.1038/nrendo.2010.18

DOI
10.1038/nrendo.2010.18
Journal article

The adipokine zinc-α2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity

Mracek, T., Ding, Q., Tzanavari, T., Kos, K., Pinkney, J., Wilding, J., . . . Bing, C. (2010). The adipokine zinc-α2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity. CLINICAL ENDOCRINOLOGY, 72(3), 334-341. doi:10.1111/j.1365-2265.2009.03658.x

DOI
10.1111/j.1365-2265.2009.03658.x
Journal article

Dapagliflozin in Patients with Type 2 Diabetes Poorly Controlled on Insulin Therapy-Efficacy of a Novel Insulin-Independent Treatment

Wilding, J. P. H., Woo, V., Soler, N. G., Pahor, A., Sugg, J., & Parikh, S. (2010). Dapagliflozin in Patients with Type 2 Diabetes Poorly Controlled on Insulin Therapy-Efficacy of a Novel Insulin-Independent Treatment. In DIABETES Vol. 59 (pp. A21-A22). Retrieved from https://www.webofscience.com/

Conference Paper

Dapagliflozin lowered rate of insulin uptitration/study discontinuation from lack of glycaemic control in 48-week study of type 2 diabetes patients poorly controlled on insulin therapy

Soler, N. G., Wilding, J. P. H., Woo, V., Pahor, A., Sugg, J., Langkilde, A., & Parikh, S. (2010). Dapagliflozin lowered rate of insulin uptitration/study discontinuation from lack of glycaemic control in 48-week study of type 2 diabetes patients poorly controlled on insulin therapy. In DIABETOLOGIA Vol. 53. Retrieved from https://www.webofscience.com/

Conference Paper

Effect of dapagliflozin, a novel insulin-independent treatment, over 48 weeks in patients with type 2 diabetes poorly controlled with insulin

Wilding, J. P. H., Woo, V., Pahor, A., Sugg, J., Langkilde, A., & Parikh, S. (2010). Effect of dapagliflozin, a novel insulin-independent treatment, over 48 weeks in patients with type 2 diabetes poorly controlled with insulin. In DIABETOLOGIA Vol. 53. Retrieved from https://www.webofscience.com/

Conference Paper

In humans the adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIF-1

Kos, K., Wong, S. P. Y., Huda, M. S. B., Cakir, M., Jernas, M., Carlsson, L., . . . Pinkney, J. H. (2010). In humans the adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIF-1. DIABETES OBESITY & METABOLISM, 12(4), 360-363. doi:10.1111/j.1463-1326.2009.01171.x

DOI
10.1111/j.1463-1326.2009.01171.x
Journal article

Non-invasive Ventilation and Weaning: Principles and Practice

Elliott, M., Nava, S., & Schonhofer, B. (Eds.) (n.d.). Non-invasive Ventilation and Weaning: Principles and Practice. In . CRC Press. doi:10.1201/b13434

DOI
10.1201/b13434
Chapter

Sodium Glucose Co transporter 2 Inhibitors as a New Treatment for Diabetes Mellitus

Nair, S., & Wilding, J. P. H. (2010). Sodium Glucose Co transporter 2 Inhibitors as a New Treatment for Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism (JCEM), 95, 34-42.

Journal article

Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus

Nair, S., & Wilding, J. P. H. (2010). Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 95(1), 34-42. doi:10.1210/jc.2009-0473

DOI
10.1210/jc.2009-0473
Journal article

The Endocrinologist and Respiratory Failure

Wilding, J. P. H. (2010). The Endocrinologist and Respiratory Failure. In M. Elliott, S. Nava, & B. Schönhofer (Eds.), Non-Invasive Ventilation and Weaning: Principals and Practice (pp. 210-230). London: Hodder Arnold.

Chapter

The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women

Halford, J. C. G., Boyland, E. J., Cooper, S. J., Dovey, T. M., Huda, M. S. B., Dourish, C. T., . . . Wilding, J. P. H. (2010). The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. JOURNAL OF PSYCHOPHARMACOLOGY, 24(1), 99-109. doi:10.1177/0269881108095195

DOI
10.1177/0269881108095195
Journal article

2009

New treatments for type 2 diabetes

Kos, K., & Wilding, J. P. H. (2009). New treatments for type 2 diabetes. Journal of the Royal College of Physicians of Edinburgh, 39(3), 227-230.

Journal article

Results of the LEAD-2 study in relation to NICE and ADA/EASD guidelines for the treatment of type 2 diabetes in the UK

Wilding, J. (2009). Results of the LEAD-2 study in relation to NICE and ADA/EASD guidelines for the treatment of type 2 diabetes in the UK. The British Journal of Diabetes &amp; Vascular Disease, 9(4), 177-185. doi:10.1177/1474651409342637

DOI
10.1177/1474651409342637
Journal article

Adipokines: Emerging therapeutic targets

Kos, K., & Wilding, J. P. H. (2009). Adipokines: Emerging therapeutic targets. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 10(10), 1061-1068. Retrieved from https://www.webofscience.com/

Journal article

A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers Applicability of a novel insulin-independent treatment

Wilding, J. P. H., Norwood, P., T'joen, C., Bastien, A., List, J. F., & Fiedorek, F. T. (2009). A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers Applicability of a novel insulin-independent treatment. DIABETES CARE, 32(9), 1656-1662. doi:10.2337/dc09-0517

DOI
10.2337/dc09-0517
Journal article

Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes

Daousi, C., Wilding, J. P. H., Aditya, S., Durham, B. H., Cleator, J., Pinkney, J. H., & Ranganath, L. R. (2009). Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes. CLINICAL ENDOCRINOLOGY, 71(2), 195-201. doi:10.1111/j.1365-2265.2008.03451.x

DOI
10.1111/j.1365-2265.2008.03451.x
Journal article

Regulation of the Fibrosis and Angiogenesis Promoter SPARC/Osteonectin in Human Adipose Tissue by Weight Change, Leptin, Insulin, and Glucose

Kos, K., Wong, S., Tan, B., Gummesson, A., Jernas, M., Franck, N., . . . Wilding, J. P. H. (2009). Regulation of the Fibrosis and Angiogenesis Promoter SPARC/Osteonectin in Human Adipose Tissue by Weight Change, Leptin, Insulin, and Glucose. DIABETES, 58(8), 1780-1788. doi:10.2337/db09-0211

DOI
10.2337/db09-0211
Journal article

Identification of Macrophage Inhibitory Cytokine-1 in Adipose Tissue and Its Secretion as an Adipokine by Human Adipocytes

Ding, Q., Mracek, T., Gonzalez-Muniesa, P., Kos, K., Wilding, J., Trayhurn, P., & Bing, C. (2009). Identification of Macrophage Inhibitory Cytokine-1 in Adipose Tissue and Its Secretion as an Adipokine by Human Adipocytes. ENDOCRINOLOGY, 150(4), 1688-1696. doi:10.1210/en.2008-0952

DOI
10.1210/en.2008-0952
Journal article

Pharmacological Approaches for Treating Obesity

Wilding, J. (2009). Pharmacological Approaches for Treating Obesity. In Unknown Book (pp. 421-446). Wiley. doi:10.1002/9780470712221.ch17

DOI
10.1002/9780470712221.ch17
Chapter

Drug Therapy for the Obese Diabetic Patient

Wilding, J. P. H. (2009). Drug Therapy for the Obese Diabetic Patient. In Unknown Book (pp. 185-202). Wiley. doi:10.1002/9780470741474.ch10

DOI
10.1002/9780470741474.ch10
Chapter

Ghrelin restores 'lean-type' hunger and energy expenditure profiles in morbidly obese subjects but has no effect on postgastrectomy subjects

Huda, M. S. B., Dovey, T., Wong, S. P., English, P. J., Halford, J., Mcculloch, P., . . . Pinkney, J. (2009). Ghrelin restores 'lean-type' hunger and energy expenditure profiles in morbidly obese subjects but has no effect on postgastrectomy subjects. INTERNATIONAL JOURNAL OF OBESITY, 33(3), 317-325. doi:10.1038/ijo.2008.270

DOI
10.1038/ijo.2008.270
Journal article

'Ghrelin inhibits autonomic function in healthy controls, but has no effect on obese and vagotomized subjects'

Huda, M., Mani, H., Dovey, T. M., Halford, J. C., Boyland, E. J., Daousi, C., . . . Pinkney, J. (2009). 'Ghrelin inhibits autonomic function in healthy controls, but has no effect on obese and vagotomized subjects'. Obesity Facts, S2(2), 150.

Journal article

Anti-obesity drugs: from animal models to the clinic

Dourish, C. T., Wilding, J. P. H., & Halford, J. C. G. (2009). Anti-obesity drugs: from animal models to the clinic. In R. A. McArthur, & F. Borsini (Eds.), Animal and translational models of CNS drug discovery - Reward Deficit Disorders (Vol. 3, pp. 271-315). London: Academic Press.

Chapter

Anxiety and Depression amongst Diabetic Foot Ulcer Patients

Thomas, C. M., Thomas, J. C., Ranjan, S., Wallymahmed, M., Wallymahmed, A. H., Benbow, S. J., . . . Gill, G. V. (2009). Anxiety and Depression amongst Diabetic Foot Ulcer Patients. In DIABETES Vol. 58 (pp. A471). Retrieved from https://www.webofscience.com/

Conference Paper

Dapagliflozin Pilot Study in Insulin-Resistant T2DM Patients

Wilding, J. P. H., Norwood, P., T'joen, C., Bastien, A., List, J. F., & Fiedorek, F. T. (2009). Dapagliflozin Pilot Study in Insulin-Resistant T2DM Patients. In DIABETES Vol. 58 (pp. A129). Retrieved from https://www.webofscience.com/

Conference Paper

Dapagliflozin improves glycaemic control in insulin-resistant patients with type 2 diabetes

Wilding, J. P. H., Norwood, P., T'joen, C., Bastien, A., List, J. F., & Fiedorek, F. T. (2009). Dapagliflozin improves glycaemic control in insulin-resistant patients with type 2 diabetes. In DIABETOLOGIA Vol. 52 (pp. S76). Retrieved from https://www.webofscience.com/

Conference Paper

Ghrelin Increases Lipid Mobilization and Respiratory Quotient Variability, Suggesting a Role in Metabolic Flexibility

Huda, M. S., Dovey, T. M., Wong, S., English, P. J., Halford, J. C. G., Hayden, K., . . . Pinkney, J. (2009). Ghrelin Increases Lipid Mobilization and Respiratory Quotient Variability, Suggesting a Role in Metabolic Flexibility. DIABETES, 58, A362. Retrieved from https://www.webofscience.com/

Journal article

Modern management of obesity

Aditya, B. S., & Wilding, J. P. H. (2009). Modern management of obesity. CLINICAL MEDICINE, 9(6), 617-621. doi:10.7861/clinmedicine.9-6-617

DOI
10.7861/clinmedicine.9-6-617
Journal article

Obstructive sleep apnoea in patients with type 2 diabetes: aetiology and implications for clinical care

Idris, I., Hall, A. P., O'Reilly, J., Barnett, A., Allen, M., Andrews, R., . . . Wilding, J. P. (2009). Obstructive sleep apnoea in patients with type 2 diabetes: aetiology and implications for clinical care. DIABETES OBESITY & METABOLISM, 11(8), 733-741. doi:10.1111/j.1463-1326.2009.01045.x

DOI
10.1111/j.1463-1326.2009.01045.x
Journal article

Pharmacological Approaches

Wilding, J. P. H. (2009). Pharmacological Approaches. In G. Williams, & G. Fruhbeck (Eds.), Obesity: Science and Practice (pp. 340-367). Oxford: Wiley.

Chapter

Regulation of the Fibrosis and Angiogenesis Promoter SPARC/Osteonectin in Human Adipose Tissue

Kos, K., Wong, S., Tan, B., Gummesson, A., Jernas, M., Franck, N., . . . Wilding, J. P. H. (2009). Regulation of the Fibrosis and Angiogenesis Promoter SPARC/Osteonectin in Human Adipose Tissue. In DIABETES Vol. 58 (pp. A358). Retrieved from https://www.webofscience.com/

Conference Paper

The human adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIF-1

Kos, K. T., Wong, S., Jernas, M., Kerrigan, D., Carlsson, L., Wilding, J. P. H., & Pinkney, J. H. (2009). The human adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIF-1. In DIABETOLOGIA Vol. 52 (pp. S282). Retrieved from https://www.webofscience.com/

Conference Paper

The human adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIF-1

Kos, K. T., Wong, S., Jernas, M., Kerrigan, D., Carlsson, L., Wilding, J. P. H., & Pinkney, J. H. (2009). The human adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIF-1. Diabetologia, 52, 719.

Journal article

2008

Achieving blood pressure control in patients with type 2 diabetes and diabetic renal disease by a nurse-led protocol based clinic

Mugarza, J. A., Wilding, J. P., Woodward, A., Hayden, K., & Gill, G. V. (2008). Achieving blood pressure control in patients with type 2 diabetes and diabetic renal disease by a nurse-led protocol based clinic. The British Journal of Diabetes &amp; Vascular Disease, 8(6), 279-284. doi:10.1177/1474651408098672

DOI
10.1177/1474651408098672
Journal article

Growth hormone and changes in energy balance in growth hormone deficient adults

Deepak, D., Daousi, C., Boyland, E., Pinkney, J. H., Wilding, J. P. H., & MacFarlane, I. A. (2008). Growth hormone and changes in energy balance in growth hormone deficient adults. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 38(9), 622-627. doi:10.1111/j.1365-2362.2008.01993.x

DOI
10.1111/j.1365-2362.2008.01993.x
Journal article

Sleep-disordered breathing and type 2 diabetes - A report from the International Diabetes Federation Taskforce on Epidemiology and Prevention

Shaw, J. E., Punjabi, N. M., Wilding, J. P., Alberti, K. G. M. M., & Zimmet, P. Z. (2008). Sleep-disordered breathing and type 2 diabetes - A report from the International Diabetes Federation Taskforce on Epidemiology and Prevention. DIABETES RESEARCH AND CLINICAL PRACTICE, 81(1), 2-12. doi:10.1016/j.diabres.2008.04.025

DOI
10.1016/j.diabres.2008.04.025
Journal article

Weight management and cardiovascular disease: implications of recent and ongoing clinical trials

Wilding, J., & Finer, N. (2008). Weight management and cardiovascular disease: implications of recent and ongoing clinical trials. The British Journal of Diabetes &amp; Vascular Disease, 8(4), 170-176. doi:10.1177/1474651408094587

DOI
10.1177/1474651408094587
Journal article

Blood pressure control and ACE inhibitor/angiotensin receptor blocker usage

Woodward, A., Mugarza, J., Khan, M., Smith, E., Wilding, J., & Gill, G. (2008). Blood pressure control and ACE inhibitor/angiotensin receptor blocker usage. Practical Diabetes International, 25(2), 54-58. doi:10.1002/pdi.1203

DOI
10.1002/pdi.1203
Journal article

Is Obesity Realistically Treatable in Type 2 Diabetes?

Wilding, J. (2001). Is Obesity Realistically Treatable in Type 2 Diabetes?. In Unknown Book (pp. 73-87). Wiley. doi:10.1002/9780470757109.ch5

DOI
10.1002/9780470757109.ch5
Chapter

Plasma obestatin levels are lower in obese and post-gastrectomy subjects, but do not change in response to a meal

Huda, M. S. B., Durham, B. H., Wong, S. P., Deepak, D., Kerrigan, D., McCulloch, P., . . . Wilding, J. P. H. (2008). Plasma obestatin levels are lower in obese and post-gastrectomy subjects, but do not change in response to a meal. INTERNATIONAL JOURNAL OF OBESITY, 32(1), 129-135. doi:10.1038/sj.ijo.0803694

DOI
10.1038/sj.ijo.0803694
Journal article

'Acute administration of synthetic human GLP-1 (7-36 amide) in obese patients with type 2 diabetes mellitus decreases circulating IL-6 levels but does not alter plasma leptin and adiponectin'

Daousi, C., Wilding, J. P., Cleator, J., Durham, B. H., & Ranganath, L. (2008). 'Acute administration of synthetic human GLP-1 (7-36 amide) in obese patients with type 2 diabetes mellitus decreases circulating IL-6 levels but does not alter plasma leptin and adiponectin'. In American Endocrine Society (Ed.), 90th Annual Meeting of the American Endocrine Society (pp. 719). San Fransisco, USA: American Endocrine Society.

Conference Paper

'Effects Of 6 Months Growth Hormone Replacement (GHR) On Pro-Inflammatory Cytokines In Adults With Severe Growth Hormone Deficiency'

Deepak, D., Daousi, C., Boyle, E., Halford, J. C., Wilding, J. P., Pinkney, J., & MacFarlane, I. A. (2008). 'Effects Of 6 Months Growth Hormone Replacement (GHR) On Pro-Inflammatory Cytokines In Adults With Severe Growth Hormone Deficiency'. In 90th Annual Meeting of the American Endocrine Society (pp. 387). San Francisco: American Endocrine Society.

Conference Paper

'Plasma Obestatin And Ghrelin Levels During Acute Administration Of Synthetic Human GLP-1(7-36 Amide) And GIP In Obese Patients With Type 2 Diabetes And Lean Healthy Volunteers'

Daousi, C., Ranganath, L., Cleator, J., Durham, B. H., & Wilding, J. P. (2008). 'Plasma Obestatin And Ghrelin Levels During Acute Administration Of Synthetic Human GLP-1(7-36 Amide) And GIP In Obese Patients With Type 2 Diabetes And Lean Healthy Volunteers'. In American Endocrine Society (Ed.), 90th Annual Meeting of the American Endocrine Society (pp. 719). San Fransisco: American Endocrine Society.

Conference Paper

'Plasma obestatin levels are lower in morbidly obese and post-gastrectomy subjects, but do not change in response to a meal '

Huda, M. S. B., Durham, B. H., Wong, S. P., Deepak, D., Kerrigan, D., McCulloch, P., . . . Wilding, J. P. H. (2008). 'Plasma obestatin levels are lower in morbidly obese and post-gastrectomy subjects, but do not change in response to a meal '. International Journal of Obesity, 32, 135-139.

Journal article

'The influence of growth hormone (GH) replacement (GHR) in adults with GH deficiency (GHD) on resting energy expenditure, voluntary physical activity and ingestive behavior'

Deepak, D., Daousi, C., Boyle, E., Halford, J. C., Wilding, J. P., Pinkney, J., & MacFarlane, I. A. (2008). 'The influence of growth hormone (GH) replacement (GHR) in adults with GH deficiency (GHD) on resting energy expenditure, voluntary physical activity and ingestive behavior'. In 90th Annual Meeting of the American Endocrine Society (pp. 386). San Francisco: American Endocrine Society.

Conference Paper

'Weight management and cardiovascular disease: implications of recent and ongoing clinical trials'

Wilding, J., & Finer, N. (2008). 'Weight management and cardiovascular disease: implications of recent and ongoing clinical trials'. British Journal of Diabetes and Vascular Disease, 8, 165-170.

Journal article

A prospective randomised control trial of medical weight loss in obese asthmatics

Scott, S., Albert, P. S., Currie, J., Parry, P., Calverley, P. M. A., & Wilding, J. (2008). A prospective randomised control trial of medical weight loss in obese asthmatics. European Respiratory Journal, 32 (su, 1141.

Journal article

A validated screening tool can be used to identify night-eaters in a UK obesity clinic

Cleator, J., James, M., Wilding, J., Sutton, C. J., & Judd, P. A. (2008). A validated screening tool can be used to identify night-eaters in a UK obesity clinic. In INTERNATIONAL JOURNAL OF OBESITY Vol. 32 (pp. S116). Retrieved from https://www.webofscience.com/

Conference Paper

Adipose tissue derived SPARC and obesity related inflammation in healthy

Kos, K., Wong, S., Kerrigan, D., Wilding, J. P. H., & Pinkney, J. H. (2008). Adipose tissue derived SPARC and obesity related inflammation in healthy. In DIABETOLOGIA Vol. 51 (pp. S330-S331). Retrieved from https://www.webofscience.com/

Conference Paper

Adipose tissue derived SPARC and obesity related inflammation in healthy adults

Kos, K., Wong, S., Kerrigan, D., Wilding, J. P. H., & Pinkney, J. H. (2008). Adipose tissue derived SPARC and obesity related inflammation in healthy adults. Diabetologia, TBC, TBC.

Journal article

Anti-obesity Drugs: From Animal Models to Clinical Efficacy

Dourish, C. T., Wilding, J. P. H., & Halford, J. C. G. (2008). Anti-obesity Drugs: From Animal Models to Clinical Efficacy. In Animal and Translational Models for CNS Drug Discovery (pp. 271-315). Elsevier. doi:10.1016/b978-0-12-373861-5.00028-x

DOI
10.1016/b978-0-12-373861-5.00028-x
Chapter

Current criteria for Night Eating Syndrome (NES) exclude some aspects of night eating behaviour

Cleator, J., Wilding, J., James, M., Sutton, C. J., & Judd, P. A. (2008). Current criteria for Night Eating Syndrome (NES) exclude some aspects of night eating behaviour. In INTERNATIONAL JOURNAL OF OBESITY Vol. 32 (pp. S112). Retrieved from https://www.webofscience.com/

Conference Paper

Depot specific expression of SPARC in human adipose tissue, relation with adipokines and insulin resistance

Kos, K., Wong, S., Kerrigan, D., Pinkney, J. H., & Wilding, J. P. H. (2008). Depot specific expression of SPARC in human adipose tissue, relation with adipokines and insulin resistance. Diabetes, S, P.

Journal article

Depot specific expression of SPARC in human adipose tissue, relation with adipokines and insulin resistance

Kos, K., Wong, S., Kerrigan, D., Pinkney, J. H., & Wilding, J. P. (2008). Depot specific expression of SPARC in human adipose tissue, relation with adipokines and insulin resistance. In DIABETES Vol. 57 (pp. A387). Retrieved from https://www.webofscience.com/

Conference Paper

Distribution and characteristics of adiponectin R1 and R2 receptor in RNA gene expression in human visceral and subcutaneous adipose tissue

Pinkney, J. H., Wong, S. P. Y., Kerrigan, D., Kos, K., & Wilding, J. P. H. (2008). Distribution and characteristics of adiponectin R1 and R2 receptor in RNA gene expression in human visceral and subcutaneous adipose tissue. In DIABETOLOGIA Vol. 51 (pp. S90). Retrieved from https://www.webofscience.com/

Conference Paper

Distribution and characteristics of adiponectin R1 and R2 receptor mRNA

Pinkney, J. H., Wong, S., Kerrigan, D., Kos, K., & Wilding, J. P. H. (2008). Distribution and characteristics of adiponectin R1 and R2 receptor mRNA. Diabetologia, TBC, TBC.

Journal article

Endocrine adaptations to short term fasting are preserved after gastrectomy but impaired in morbid obesity

Huda, M., Dovey, T., Wong, S., English, P., Halford, J., McCulloch, P., . . . Pinkney, J. (2008). Endocrine adaptations to short term fasting are preserved after gastrectomy but impaired in morbid obesity. In INTERNATIONAL JOURNAL OF OBESITY Vol. 32 (pp. S74). Retrieved from https://www.webofscience.com/

Conference Paper

Energy restriction enhances therapeutic efficacy of the PPARγ agonist, rosiglitazone, through regulation of visceral fat gene expression

Moore, G. B. T., Pickavance, L. C., Briscoe, C. P., Clapham, J. C., Buckingham, R. E., & Wilding, J. P. H. (2008). Energy restriction enhances therapeutic efficacy of the PPARγ agonist, rosiglitazone, through regulation of visceral fat gene expression. DIABETES OBESITY & METABOLISM, 10(3), 251-263. doi:10.1111/j.1463-1326.2007.00697.x

DOI
10.1111/j.1463-1326.2007.00697.x
Journal article

Gender differences of RBP4 expression, relation of plasma, VAT and SCAT expression and its relation with insulin resistance and inflammation

Kos, K., Wong, S., Kerrigan, D., Wilding, J. P. H., & Pinkney, J. H. (2008). Gender differences of RBP4 expression, relation of plasma, VAT and SCAT expression and its relation with insulin resistance and inflammation. In INTERNATIONAL JOURNAL OF OBESITY Vol. 32 (pp. S15). Retrieved from https://www.webofscience.com/

Conference Paper

Gender differences of RBP4 expression, relation of plasma, VAT and SCAT expression and its relation with insulin resistance and inflammation

Kos, K., Wong, S., Kerrigan, D., Wilding, J. P. H., & Pinkney, J. H. (2008). Gender differences of RBP4 expression, relation of plasma, VAT and SCAT expression and its relation with insulin resistance and inflammation. European Congress of Obesity, p, OS1.3.

Journal article

How effective is bariatric surgery in diabetes?

Aditya, B. S., Magee, C., Pipara, L., Kerrigan, D., & Wilding, J. P. H. (2008). How effective is bariatric surgery in diabetes?. In DIABETIC MEDICINE Vol. 25. Retrieved from https://www.webofscience.com/

Conference Paper

Is there a stereotyped personality amongst diabetic foot ulcer patients?

Thomas, C. M., Thomas, J., Wallymahamed, A. H., Wallymahamed, M., Benbow, S. J., Wilding, J. P., & Gill, G. V. (2008). Is there a stereotyped personality amongst diabetic foot ulcer patients?. In DIABETES Vol. 57 (pp. A756). Retrieved from https://www.webofscience.com/

Conference Paper

Management of diabetes following bariatric surgery

Aditya, B. S., Andrews, C., Pillai, A., Kerrigan, D., & Wilding, J. P. H. (2008). Management of diabetes following bariatric surgery. In DIABETIC MEDICINE Vol. 25. Retrieved from https://www.webofscience.com/

Conference Paper

Pharmacology of Obesity

Wilding, J. P. H. (2008). Pharmacology of Obesity. M. J. Parnham, & J. Bruinvels (Eds.), Basel: Birkhauser.

Book

Regulation of energy balance — towards rational drug design in obesity

Harrold, J. A., & Wilding, J. P. H. (n.d.). Regulation of energy balance — towards rational drug design in obesity. In Milestones in Drug Therapy (pp. 21-46). Birkhäuser Basel. doi:10.1007/978-3-7643-7425-9_3

DOI
10.1007/978-3-7643-7425-9_3
Chapter

SPARC expression in human adipose tissue is correlated with insulin resistance and fat mass

Kos, K., Wong, S., Kerrigan, D., Pinkney, J. H., & Wilding, J. P. H. (2008). SPARC expression in human adipose tissue is correlated with insulin resistance and fat mass. Diabetic Medicine, S, P1.

Journal article

The RAPSODI trial:: Goals, design, methods, and recruitment for a clinical trial of rimonabant on the time for progression to type 2 diabetes

Sjoestrom, L., Wilding, J. P., Ryan, D., Pi-Sunyer, X., & Fujioka, K. (2008). The RAPSODI trial:: Goals, design, methods, and recruitment for a clinical trial of rimonabant on the time for progression to type 2 diabetes. In DIABETES Vol. 57 (pp. A595). Retrieved from https://www.webofscience.com/

Conference Paper

The endocannabinoid system as a target for obesity treatment

Khan, M., & Wilding, J. P. H. (n.d.). The endocannabinoid system as a target for obesity treatment. In Milestones in Drug Therapy (pp. 69-80). Birkhäuser Basel. doi:10.1007/978-3-7643-7425-9_6

DOI
10.1007/978-3-7643-7425-9_6
Chapter

The expression of the adipokine SPARC is correlated with insulin resistance and fat mass

Kos, K., Wong, S. P. Y., Kerrigan, D., Pinkneyw, J. H., & Wilding, J. P. H. (2008). The expression of the adipokine SPARC is correlated with insulin resistance and fat mass. In DIABETIC MEDICINE Vol. 25. Retrieved from https://www.webofscience.com/

Conference Paper

Unlike subcutaneous expression of IL-6 and IL-18, omental expression of IL-6, IL-18 and MCP-1 are not related to systemic cytokine levels in human obesity

Kos, K., Wong, S., Kerrigan, D., Wilding, J. P. H., & Pinkney, J. H. (2008). Unlike subcutaneous expression of IL-6 and IL-18, omental expression of IL-6, IL-18 and MCP-1 are not related to systemic cytokine levels in human obesity. Society for Endocrinology, 15, P105.

Journal article

2007

Cardiovascular disease risk modification in abdominally obese people with type 2 diabetes

Wilding, J. (2007). Cardiovascular disease risk modification in abdominally obese people with type 2 diabetes. Diabetes and Primary Care, 9(1).

Journal article

Clinical Investigations of Antiobesity Drugs

Wilding, J. (2007). Clinical Investigations of Antiobesity Drugs. In Appetite and Body Weight (pp. 337-III). Elsevier. doi:10.1016/b978-012370633-1/50014-1

DOI
10.1016/b978-012370633-1/50014-1
Chapter

Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects

Huda, M. S. B., Durham, B. H., Wong, S. P., Dovey, T. M., McCulloch, P., Kerrigan, D., . . . Wilding, J. P. H. (2007). Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects. BONE, 41(3), 406-413. doi:10.1016/j.bone.2007.05.006

DOI
10.1016/j.bone.2007.05.006
Journal article

Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.

Wilding, J. P. H., Gause-Nilsson, I., Persson, A., & GALLANT 7 Study Group. (2007). Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.. Diabetes & vascular disease research, 4(3), 194-203. doi:10.3132/dvdr.2007.040

DOI
10.3132/dvdr.2007.040
Journal article

The importance of free fatty acids in the development of Type 2 diabetes

Wilding, J. P. H. (2007). The importance of free fatty acids in the development of Type 2 diabetes. DIABETIC MEDICINE, 24(9), 934-945. doi:10.1111/j.1464-5491.2007.02186.x

DOI
10.1111/j.1464-5491.2007.02186.x
Journal article

Effects of olanzapine in mate rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabotic abnormatities

Cooper, G. D., Pickavance, L. C., Wilding, J. P. H., Harrold, J. A., Halford, J. C. G., & Goudie, A. J. (2007). Effects of olanzapine in mate rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabotic abnormatities. JOURNAL OF PSYCHOPHARMACOLOGY, 21(4), 405-413. doi:10.1177/0269881106069637

DOI
10.1177/0269881106069637
Journal article

Metformin prolongs the postprandial fall in plasma ghrelin concentrations in type 2 diabetes

English, P. J., Ashcroft, A., Patterson, M., Dovey, T. M., Halford, J. C. G., Harrison, J., . . . Wilding, J. P. H. (2007). Metformin prolongs the postprandial fall in plasma ghrelin concentrations in type 2 diabetes. DIABETES-METABOLISM RESEARCH AND REVIEWS, 23(4), 299-303. doi:10.1002/dmrr.681

DOI
10.1002/dmrr.681
Journal article

A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure

Dargie, H. J., Hildebrandt, P. R., Riegger, G. A. J., McMurray, J. J. V., McMorn, S. O., Roberts, J. N., . . . Wilding, J. P. H. (2007). A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 49(16), 1696-1704. doi:10.1016/j.jacc.2006.10.077

DOI
10.1016/j.jacc.2006.10.077
Journal article

An elderly type 1 diabetic patient with life event‐related brittle diabetes

Thomas, C., Majid, S., Wilding, J., Wallymahmed, M., & Gill, G. (2007). An elderly type 1 diabetic patient with life event‐related brittle diabetes. Practical Diabetes International, 24(3), 130-131. doi:10.1002/pdi.1075

DOI
10.1002/pdi.1075
Journal article

Cardiovascular and metabolic effects of CPAP in obese males with OSA

Coughlin, S. R., Mawdsley, L., Mugarza, J. A., Wilding, J. P. H., & Calverley, P. M. A. (2007). Cardiovascular and metabolic effects of CPAP in obese males with OSA. EUROPEAN RESPIRATORY JOURNAL, 29(4), 720-727. doi:10.1183/09031936.00043306

DOI
10.1183/09031936.00043306
Journal article

Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic-pituitary disease

Deepak, D., Furlong, N. J., Wilding, J. P. H., & MacFarlane, I. A. (2007). Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic-pituitary disease. POSTGRADUATE MEDICAL JOURNAL, 83(978), 277-280. doi:10.1136/pgmj.2006.052241

DOI
10.1136/pgmj.2006.052241
Journal article

Treatment strategies for obesity

Wilding, J. P. H. (2007). Treatment strategies for obesity. OBESITY REVIEWS, 8, 137-144. doi:10.1111/j.1467-789X.2007.00333.x

DOI
10.1111/j.1467-789X.2007.00333.x
Journal article

'Does the co-administration of synthetic human GLP-1 (7-36 amide) and GIP restore the diminished insulinotropic action of GIP in obese patients with type 2 diabetes?'

Daousi, C., Wilding, J. P., Cleator, J., & Ranganath, L. (2007). 'Does the co-administration of synthetic human GLP-1 (7-36 amide) and GIP restore the diminished insulinotropic action of GIP in obese patients with type 2 diabetes?'. In 89th Annual Meeting of the American Endocrine Society (pp. 187). Toronto: The Endocrine Society.

Conference Paper

'Effects of synthetic human GLP-1 (7-36 amide) and GIP on energy expenditure and appetite in obese patients with type 2 diabetes mellitus and in lean healthy subjects'

Daousi, C., Ranganath, L., Aditya, S., Cleator, J., & Wilding, J. P. (2007). 'Effects of synthetic human GLP-1 (7-36 amide) and GIP on energy expenditure and appetite in obese patients with type 2 diabetes mellitus and in lean healthy subjects'. In 89th Annual Meeting of the American Endocrine Society (pp. P2-P186). Toronto: The Endocrine Society.

Conference Paper

'Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects'

Huda, M. S. B., Durham, B. H., Wong, S. P., Dovey, T. M., McCulloch, P., Kerrigan, D., . . . Wilding, J. P. H. (2007). 'Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects'. Bone, 41(3), 413-416.

Journal article

A double-blind, placebo-controlled crossover study to quantify the effects of sibutramine on energy intake and energy expenditure in obese subjects during a test meal using a Universal Eating Monitor (UEM) method

Halford, J., Boyland, E., Dovey, T., Huda, M., Dourish, C., Dawson, G., & Wilding, J. (2007). A double-blind, placebo-controlled crossover study to quantify the effects of sibutramine on energy intake and energy expenditure in obese subjects during a test meal using a Universal Eating Monitor (UEM) method. Retrieved from https://www.webofscience.com/

Presentation material

A double-blind, placebo-controlled crossover study to quantify the effects of sibutramine on energy intake and energy expenditure in obese subjects during a test meal using a Universal Eating Monitor (UEM) method.

Halford, J. C. G., Boyland, E., Dovey, T. M., Huda, M., Dourish, C. T., Dawson, G., & Wilding, J. P. H. (2007). A double-blind, placebo-controlled crossover study to quantify the effects of sibutramine on energy intake and energy expenditure in obese subjects during a test meal using a Universal Eating Monitor (UEM) method.. International Journal of Obesity., 1(31), 151.

Journal article

Changes in circulating plasma ghrelin and obestatin in narcolepsy-cataplexy

Huda, M., Mani, H., Durham, B., Dovey, T., Halford, J., Aditya, S., . . . Hart, I. (2007). Changes in circulating plasma ghrelin and obestatin in narcolepsy-cataplexy. In SLEEP Vol. 30 (pp. A218-A219). Retrieved from https://www.webofscience.com/

Conference Paper

Differential vascular dysfunction in response to diets of differing macronutrient composition: a phenomenonological study

Fatani, S., Pickavance, L. C., Sadler, C. J., Harrold, J. A., Cassidy, R., Elliott, J., . . . Naderali, E. K. (2007). Differential vascular dysfunction in response to diets of differing macronutrient composition: a phenomenonological study. Nutrition and Metabolism, 4(15).

Journal article

Effects of S 15511, a therapeutic metabolite of the insulin-sensitizing agent S 15261, in the Zucker Diabetic Fatty rat

Pickavance, L. C., & Wilding, J. P. H. (2007). Effects of S 15511, a therapeutic metabolite of the insulin-sensitizing agent S 15261, in the Zucker Diabetic Fatty rat. DIABETES OBESITY & METABOLISM, 9(1), 114-120. doi:10.1111/j.1463-1326.2006.00586.x

DOI
10.1111/j.1463-1326.2006.00586.x
Journal article

Effects of S 15511, a therapeutic metabolite of the insulin‐sensitizing agent S 15261, in the Zucker Diabetic Fatty rat

Pickavance, L. C., & Wilding, J. P. H. (2007). Effects of S 15511, a therapeutic metabolite of the insulin‐sensitizing agent S 15261, in the Zucker Diabetic Fatty rat. Diabetes, Obesity and Metabolism, 9(1), 114-120. doi:10.1111/j.1463-1326.2006.00586.x

DOI
10.1111/j.1463-1326.2006.00586.x
Journal article

Health related quality of life (HRQL) in patients with and without diabetic foot ulcers

Thomas, C. M., Wong, S. Y., Thomas, J. C., Wallymahmed, M., Wallymahmed, A. H., Benbow, S. J., . . . Gill, G. V. (2007). Health related quality of life (HRQL) in patients with and without diabetic foot ulcers. In DIABETES Vol. 56 (pp. A711). Retrieved from https://www.webofscience.com/

Conference Paper

How can we best modify the risk of cardiovascular disease in type 2 diabetes patients with abdominal obesity?

Wilding, J. P. H. (2007). How can we best modify the risk of cardiovascular disease in type 2 diabetes patients with abdominal obesity?. Diabetes and Primary Care, 9(1), 16-26.

Journal article

Is the modification of diet in renal disease equation suitable for estimating glomerular filtration rate in obese patients with Type 2 diabetes?

Mishra, V., Hayden, K., & Wilding, J. P. H. (2007). Is the modification of diet in renal disease equation suitable for estimating glomerular filtration rate in obese patients with Type 2 diabetes?. In DIABETIC MEDICINE Vol. 24 (pp. 77-78). Retrieved from https://www.webofscience.com/

Conference Paper

Microangiopathic haemolytic anaemia and diabetes mellitus

Joyes, L., Bhutani, R., Daousi, C., DasGupta, R., Gill, G. V., & Wilding, J. P. H. (2007). Microangiopathic haemolytic anaemia and diabetes mellitus. DIABETIC MEDICINE, 24, 109. Retrieved from https://www.webofscience.com/

Journal article

Pharmacotherapy of Obesity

Wilding, J. P. H. (Ed.) (2007). Pharmacotherapy of Obesity. Basel: Birkhauser.

Book

Regulation of energy balance - towards rational drug design in obesity

Harrold, J. A. (2007). Regulation of energy balance - towards rational drug design in obesity. In M. J. Parnham, & J. Bruinvels (Eds.), Pharmacotherapy of Obesity (pp. IN PRESS). Basel: Birkhauser Publishing.

Chapter

Standard tools used to assess eating patterns in obese populations do not encourage the reporting of night eating behaviour

Cleator, J., Wilding, J., Sutton, C., & Judd, P. (2007). Standard tools used to assess eating patterns in obese populations do not encourage the reporting of night eating behaviour. In INTERNATIONAL JOURNAL OF OBESITY Vol. 31 (pp. S128). Retrieved from https://www.webofscience.com/

Conference Paper

2006

Pathophysiology and aetiology of obesity

Wilding, J. P. H. (2006). Pathophysiology and aetiology of obesity. Medicine, 34(12), 501-505. doi:10.1053/j.mpmed.2006.09.004

DOI
10.1053/j.mpmed.2006.09.004
Journal article

Applied physiology: The control of weight

English, P. J., & Wilding, J. P. H. (2006). Applied physiology: The control of weight. Current Paediatrics, 16(6), 439-446. doi:10.1016/j.cupe.2006.08.007

DOI
10.1016/j.cupe.2006.08.007
Journal article

Diabetes and sleep apnoea: a hidden epidemic?

Wilding, J. (2006). Diabetes and sleep apnoea: a hidden epidemic?. THORAX, 61(11), 928-929. doi:10.1136/thx.2006.062513

DOI
10.1136/thx.2006.062513
Journal article

Thiazolidinediones, insulin resistance and obesity: finding a balance

Wilding, J. (2006). Thiazolidinediones, insulin resistance and obesity: finding a balance. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 60(10), 1272-1280. doi:10.1111/j.1742-1241.2006.01128.x

DOI
10.1111/j.1742-1241.2006.01128.x
Journal article

Fasting plasma peptide-YY concentrations are elevated but do not rise postprandially in type 2 diabetes

English, P. J., Ashcroft, A., Patterson, M., Dovey, T. M., Halford, J. C. G., Harrison, J., . . . Wilding, J. P. H. (2006). Fasting plasma peptide-YY concentrations are elevated but do not rise postprandially in type 2 diabetes. DIABETOLOGIA, 49(9), 2219-2221. doi:10.1007/s00125-006-0344-y

DOI
10.1007/s00125-006-0344-y
Journal article

Successful cardiovascular risk reduction in Type 2 diabetes by nurse-led care using an open clinical algorithm

Woodward, A., Wallymahmed, M., Wilding, J., & Gill, G. (2006). Successful cardiovascular risk reduction in Type 2 diabetes by nurse-led care using an open clinical algorithm. DIABETIC MEDICINE, 23(7), 780-787. doi:10.1111/j.1464-5491.2006.01889.x

DOI
10.1111/j.1464-5491.2006.01889.x
Journal article

Gut peptides and the regulation of appetite

Huda, M. S. B., Wilding, J. P. H., & Pinkney, J. H. (2006). Gut peptides and the regulation of appetite. OBESITY REVIEWS, 7(2), 163-182. doi:10.1111/j.1467-789X.2006.00245.x

DOI
10.1111/j.1467-789X.2006.00245.x
Journal article

Obesity and risk of myocardial infarction: the INTERHEART study

Wilding, J., & Finer, N. (2006). Obesity and risk of myocardial infarction: the INTERHEART study. LANCET, 367(9516), 1053. doi:10.1016/S0140-6736(06)68463-8

DOI
10.1016/S0140-6736(06)68463-8
Journal article

Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors

Daousi, C., Casson, I. F., Gill, G. V., MacFarlane, I. A., Wilding, J. P. H., & Pinkney, J. H. (2006). Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. POSTGRADUATE MEDICAL JOURNAL, 82(966), 280-284. doi:10.1136/pmj.2005.039032

DOI
10.1136/pmj.2005.039032
Journal article

'Assessment of the potential efficacy and CNS side effects of novel serotoninergic anti-obesity agents in phase 1 clinical studies'

Dourish, C. T., Boyland, E., Halford, J. C. G., Dawson, R., & Wilding, J. P. H. (2006). 'Assessment of the potential efficacy and CNS side effects of novel serotoninergic anti-obesity agents in phase 1 clinical studies'. Journal of Pharmacological Sciences, 101, 17.

Journal article

'Gut peptides and the regulation of appetite'

Huda, M. S. B., Wilding, J. P. H., & Pinkney, J. H. (2006). 'Gut peptides and the regulation of appetite'. Obesity reviews, 7(2), 780-787.

Journal article

'The influence of growth hormone replacement (GHR) in adults with GH deficiency (GHD) on body composition, basal metabolic rate, physical activity and ingestive behaviour'

Deepak, D., Daousi, C., Pinkney, J., Wilding, J. P., & MacFarlane, I. A. (2006). 'The influence of growth hormone replacement (GHR) in adults with GH deficiency (GHD) on body composition, basal metabolic rate, physical activity and ingestive behaviour'. In 8th European Congress of Endocrinology (pp. 125). Glasgow: Society for Endocrinology.

Conference Paper

Aetiology of type 2 diabetes

Huda, M. S. B., & Wilding, J. P. H. (2006). Aetiology of type 2 diabetes. Best Practice and Research in Diabetes and Endocrinology, 39-52.

Journal article

Assessment of the potential efficacy and CNS side-effects of novel serotonergic anti-obesity agents in phase 1 clinical studies

Dourish, C. T., Boyland, E., Halford, J. C. G., Dawson, G. R., & Wilding, J. P. H. (2006). Assessment of the potential efficacy and CNS side-effects of novel serotonergic anti-obesity agents in phase 1 clinical studies. JOURNAL OF PHARMACOLOGICAL SCIENCES, 101, 17. Retrieved from https://www.webofscience.com/

Journal article

Effect of rimonabant on energy intake, motivation to eat and body weight with or without hypocaloric diet: the REBA study. PRESIDENTS AWARD

Blundell, J. E., Jebb, S., Stubbs, R. J., Wilding, J. P. H., Lawton, C. L., Browning, L., . . . Halford, J. C. G. (2006). Effect of rimonabant on energy intake, motivation to eat and body weight with or without hypocaloric diet: the REBA study. PRESIDENTS AWARD. Obesity Reviews 7, 2(7), 104.

Journal article

Ghrelin increases respiratory quotient in obese subjects. PRESIDENTS AWARD

Huda, M. S. B., Wong, S. P., Dovey, T. M., English, P. J., Halford, J. C. G., Hayden, K., . . . Pinkney, J. (2006). Ghrelin increases respiratory quotient in obese subjects. PRESIDENTS AWARD. Obesity Reviews, 2(7), 102-103.

Journal article

Symptoms are poor indicators for the presence of asthma in obese adults measured by SGRQ and SF36

Scott, S. J., Currie, J., Maharjan, L., Wilding, J. P., & Calverley, P. M. (2006). Symptoms are poor indicators for the presence of asthma in obese adults measured by SGRQ and SF36. Procedings of the American Thoracic Society, 3, A527.

Journal article

The metabolic syndrome - New definition, more controversy

Wilding, J. (2006). The metabolic syndrome - New definition, more controversy. Cardiometabolic Risk and Weight Management, 1(1), 2-3.

Journal article

2005

Improved glycaemic control - an unintended benefit of a nurse-led cardiovascular risk reduction clinic

Woodward, A., Wallymahmed, M., Wilding, J., & Gill, G. (2005). Improved glycaemic control - an unintended benefit of a nurse-led cardiovascular risk reduction clinic. DIABETIC MEDICINE, 22(9), 1272-1274. doi:10.1111/j.1464-5491.2005.01549.x

DOI
10.1111/j.1464-5491.2005.01549.x
Journal article

Improved glycaemic control—an unintended benefit of a nurse‐led cardiovascular risk reduction clinic

Woodward, A., Wallymahmed, M., Wilding, J., & Gill, G. (2005). Improved glycaemic control—an unintended benefit of a nurse‐led cardiovascular risk reduction clinic. Diabetic Medicine, 22(9), 1272-1274. doi:10.1111/j.1464-5491.2005.01549.x

DOI
10.1111/j.1464-5491.2005.01549.x
Journal article

Is there a role for ghrelin and peptide-YY in the pathogenesis of obesity in adults with acquired structural hypothalamic damage?

Daousi, C., MacFarlane, I. A., English, P. J., Wilding, J. P. H., Patterson, M., Dovey, T. M., . . . Pinkney, J. H. (2005). Is there a role for ghrelin and peptide-YY in the pathogenesis of obesity in adults with acquired structural hypothalamic damage?. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 90(9), 5025-5030. doi:10.1210/jc.2004-1874

DOI
10.1210/jc.2004-1874
Journal article

A parametric analysis of olanzapine-induced weight gain in female rats

Cooper, G. D., Pickavance, L. C., Wilding, J. P. H., Halford, J. C. G., & Goudie, A. J. (2005). A parametric analysis of olanzapine-induced weight gain in female rats. PSYCHOPHARMACOLOGY, 181(1), 80-89. doi:10.1007/s00213-005-2224-4

DOI
10.1007/s00213-005-2224-4
Journal article

Reply

Bennett, S. M. A., Heise, M., Jones, N. P., Walker, M., & Wilding, J. P. H. (2005). Reply. Diabetic Medicine, 22(5), 667. doi:10.1111/j.1464-5491.2005.01472b.x

DOI
10.1111/j.1464-5491.2005.01472b.x
Journal article

Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance: does it really work? If yes, is it a novelty?

Ciardullo, A. V. (2005). Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance: does it really work? If yes, is it a novelty?. DIABETIC MEDICINE, 22(5), 666-667. doi:10.1111/j.1464-5491.2005.01502.x

DOI
10.1111/j.1464-5491.2005.01502.x
Journal article

Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance: does it really work? If yes, is it a novelty? Reply

Bennett, S. M. A., Heise, M., Jones, N. P., Walker, M., & Wilding, J. P. H. (2005). Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance: does it really work? If yes, is it a novelty? Reply. DIABETIC MEDICINE, 22(5), 667. doi:10.1111/j.1464-5491.2005.01472b.x

DOI
10.1111/j.1464-5491.2005.01472b.x
Journal article

The dual PPARα/γ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats

Pickavance, L. C., Brand, C. L., Wassermann, K., & Wilding, J. P. H. (2005). The dual PPARα/γ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. BRITISH JOURNAL OF PHARMACOLOGY, 144(3), 308-316. doi:10.1038/sj.bjp.0706041

DOI
10.1038/sj.bjp.0706041
Journal article

'Does impaired satiety contribute to human hypothalamic obesity?'

Daousi, C., English, P. J., Wilding, J. P., MacFarlane, I. A., Dovey, T. M., Halford, J. C., & Pinkney, J. H. (2005). 'Does impaired satiety contribute to human hypothalamic obesity?'. Obesity Research, 12, 322-P.

Journal article

Achievements of blood pressure targets in a stand alone nurse-led clinic in type 2 diabetic patients with microalbuminuria and nephropathy.

Mugarza, J. A., Wilding, J. P. H., Woodward, A., & Gill, G. V. (2005). Achievements of blood pressure targets in a stand alone nurse-led clinic in type 2 diabetic patients with microalbuminuria and nephropathy.. Diabetic Medicine, 22, 75.

Journal article

Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C

Wong, S. P. Y., Huda, M., English, P., Bargiotta, A., Wilding, J. P. H., Johnson, A., . . . Pinkney, J. H. (2005). Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C. DIABETOLOGIA, 48(12), 2641-2649. doi:10.1007/s00125-005-0038-x

DOI
10.1007/s00125-005-0038-x
Journal article

Adult Obesity: Diabetes, Metabolic Syndrome and NASH

Dewan, S., & Wilding, J. P. H. (2005). Adult Obesity: Diabetes, Metabolic Syndrome and NASH. In P. Kopelman, I. Caterson, & B. Dietz (Eds.), 'Obesity and related metabolic disease in adults and children' (pp. 45). Oxford: Blackwell Science.

Chapter

Baseline B-type natriuretic peptide identifies patients with type 2 diabetes and class I/II heart failure at risk of fluid retention when treated with rosigiltazone

Dargle, H., Hildebrandt, P. K., Riegger, G., Wilding, J. P., McMurray, J., McMorn, S., . . . Stewart, M. W. (2005). Baseline B-type natriuretic peptide identifies patients with type 2 diabetes and class I/II heart failure at risk of fluid retention when treated with rosigiltazone. In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Vol. 45 (pp. 139A). Retrieved from https://www.webofscience.com/

Conference Paper

Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults:: a randomized, placebo-controlled trial

Zelissen, P. M. J., Stenlof, K., Lean, M. E. J., Fogteloo, J., Keulen, E. T. P., Wilding, J., . . . Williams, G. (2005). Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults:: a randomized, placebo-controlled trial. DIABETES OBESITY & METABOLISM, 7(6), 755-761. doi:10.1111/j.1463-1326.2005.00468.x

DOI
10.1111/j.1463-1326.2005.00468.x
Journal article

Effects of high-fat feeding and rosiglitazone treatment on hypothalamic MC4-R density

Harrold, J., Cassidy, R., Tarrach, C., Wilding, J., & Williams, G. (2005). Effects of high-fat feeding and rosiglitazone treatment on hypothalamic MC4-R density. In OBESITY RESEARCH Vol. 13 (pp. A106). Retrieved from https://www.webofscience.com/

Conference Paper

Improved glycaemic control ¿ an unintended benefit of a nurse-led cardiovascular risk reduction clinic

Woodward, A., Wallymahmed, M., Wilding, J., & Gill, G. V. (2005). Improved glycaemic control ¿ an unintended benefit of a nurse-led cardiovascular risk reduction clinic. Diabetic Medicine.

Journal article

Insulin resistance and increased markers of systemic inflammation in elderly patients with diastolic heart failure

Wisniacki, N., Lye, M., & Wilding, J. P. H. (2005). Insulin resistance and increased markers of systemic inflammation in elderly patients with diastolic heart failure. Heart, 91(1), 27-31.

Journal article

Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure

Wisniacki, N., Taylor, W., Lye, M., & Wilding, J. P. H. (2005). Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. HEART, 91(1), 32-37. doi:10.1136/hrt.2003.029652

DOI
10.1136/hrt.2003.029652
Journal article

Managing the Patient wiht Newly Diagnosed Type 2 Diabetes

Wilding, J. P. H. (2005). Managing the Patient wiht Newly Diagnosed Type 2 Diabetes. Worthing: Cambridge Medical Publications.

Book

Optimising blood pressure control in the type 2 population is more achievable in the absence of microalbuminuria or nephropathy

Mugarza, J. A., Woodward, A., Wilding, J. P. H., & Gill, G. V. (2005). Optimising blood pressure control in the type 2 population is more achievable in the absence of microalbuminuria or nephropathy. DIABETOLOGIA, 48, A349. Retrieved from https://www.webofscience.com/

Journal article

Optimising blood pressure control in the type 2 population is more achievable in the absence of microalbuminuria or nephropathy

Mugarza, J., Woodward, A., Wilding, J. P. H., & Gill, G. V. (2005). Optimising blood pressure control in the type 2 population is more achievable in the absence of microalbuminuria or nephropathy. Diabetic Medicine, 48, 960.

Journal article

Rat third ventricle ependymal cells possess the ability to produce insulin

Tarrach, C. H. A., Dodson, A. A. R., Foster, C. S., Harrold, J. A., & Wilding, J. P. H. (2005). Rat third ventricle ependymal cells possess the ability to produce insulin. In DIABETES Vol. 54 (pp. A369). Retrieved from https://www.webofscience.com/

Conference Paper

Rosiglitazone (RSG) administered to patients with type 2 diabetes (T2DM) and class I/II congestive heart failure (CHF) does not adversely affect echocardiographic structure or function parameters

Wilding, J., Dargie, H., Hildebrandt, P., Riegger, G., McMurray, J., McMorn, S., . . . Stewart, M. W. (2005). Rosiglitazone (RSG) administered to patients with type 2 diabetes (T2DM) and class I/II congestive heart failure (CHF) does not adversely affect echocardiographic structure or function parameters. In DIABETES Vol. 54 (pp. A20). Retrieved from https://www.webofscience.com/

Conference Paper

Rosiglitazone does not adversely affect cardiac structure and function is determined by echocardiography in patients with type 2 diabetes and class I/II heart failure

Dargie, H., Hildebrandt, P. R., Riegger, G., Wilding, J. P. H., McMurray, J., McMorn, S., . . . Stewart, M. W. (2005). Rosiglitazone does not adversely affect cardiac structure and function is determined by echocardiography in patients with type 2 diabetes and class I/II heart failure. In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Vol. 45 (pp. 186A). Retrieved from https://www.webofscience.com/

Conference Paper

What should we do about the metabolic syndrome?

Wilding, J. P. H. (2005). What should we do about the metabolic syndrome?. Unknown Journal, 1, 6-9.

Journal article

2004

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects

Wilding, J., Van Gaal, L., Rissanen, A., Vercruysse, F., & Fitchet, M. (2004). A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. INTERNATIONAL JOURNAL OF OBESITY, 28(11), 1399-1410. doi:10.1038/sj.ijo.0802783

DOI
10.1038/sj.ijo.0802783
Journal article

Effects of insulin-induced hypoglycaemia on energy intake and food choice at a subsequent test meat

Dewan, S., Gillett, A., Mugarza, J. A., Dovey, T. M., Halford, J. C. G., & Wilding, J. P. H. (2004). Effects of insulin-induced hypoglycaemia on energy intake and food choice at a subsequent test meat. DIABETES-METABOLISM RESEARCH AND REVIEWS, 20(5), 405-410. doi:10.1002/dmrr.471

DOI
10.1002/dmrr.471
Journal article

Reduced ventromedial hypothalamic neuronal nitric oxide synthase and increased sensitivity to NOS inhibition in dietary obese rats: further evidence of a role for nitric oxide in the regulation of energy balance

Sadler, C. J., & Wilding, J. P. H. (2004). Reduced ventromedial hypothalamic neuronal nitric oxide synthase and increased sensitivity to NOS inhibition in dietary obese rats: further evidence of a role for nitric oxide in the regulation of energy balance. BRAIN RESEARCH, 1016(2), 222-228. doi:10.1016/j.brainres.2004.05.007

DOI
10.1016/j.brainres.2004.05.007
Journal article

Response: Postprandial adiponectin revisited

English, P. J., Coughlin, S. R., Hayden, K., Malik, I. A., & Wilding, J. P. H. (2004). Response: Postprandial adiponectin revisited. OBESITY RESEARCH, 12(6), 1032-1034. doi:10.1038/oby.2004.127

DOI
10.1038/oby.2004.127
Journal article

Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome

Coughlin, S. R., Mawdsley, L., Mugarza, J. A., Calverley, P. M. A., & Wilding, J. P. H. (2004). Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. EUROPEAN HEART JOURNAL, 25(9), 735-741. doi:10.1016/j.ehj.2004.02.021

DOI
10.1016/j.ehj.2004.02.021
Journal article

Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance

Bennett, S. M. A., Agrawal, A., Elashat, H., Heise, M., Jones, N. P., Walker, M., & Wilding, J. P. H. (2004). Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. DIABETIC MEDICINE, 21(5), 415-422. doi:10.1111/j.1464-5491.2004.01155.x

DOI
10.1111/j.1464-5491.2004.01155.x
Journal article

AOD-9604 Metabolic.

Wilding, J. (2004). AOD-9604 Metabolic.. Current opinion in investigational drugs (London, England : 2000), 5(4), 436-440.

Journal article

Clinical evaluation of anti-obesity drugs

Wilding, J. (2004). Clinical evaluation of anti-obesity drugs. CURRENT DRUG TARGETS, 5(3), 325-332. doi:10.2174/1389450043490479

DOI
10.2174/1389450043490479
Journal article

'Ghrelin and Peptide-YY (3-36) in human hypothalamic obesity'

Daousi, C., English, P. J., Wilding, J. P. H., Patterson, M., Ghatei, M. A., MacFarlane, I. A., & Pinkney, J. H. (2004). 'Ghrelin and Peptide-YY (3-36) in human hypothalamic obesity'. In 86th Annual Meeting of the American Endocrine Society (pp. 243). New Orleans, USA: American Endocrine Society.

Conference Paper

Body weight and prolactinoma: a retrospective study

Soran, H., Wilding, J., & MacFarlane, I. (2004). Body weight and prolactinoma: a retrospective study. INTERNATIONAL JOURNAL OF OBESITY, 28(1), 183. doi:10.1038/sj.ijo.0802492

DOI
10.1038/sj.ijo.0802492
Journal article

Circulating endothelial cell adhesion molecules in women with gestational diabetes and type 1 diabetes

Dewan, S., Da Silva, N., McTernan, P., Leong, K. S., & Wilding, J. P. H. (2004). Circulating endothelial cell adhesion molecules in women with gestational diabetes and type 1 diabetes. DIABETOLOGIA, 47, A8. Retrieved from https://www.webofscience.com/

Journal article

Does impaired satiety contribute to human hypothalamic obesity?

Daousi, C., English, P., Dovey, T., Macfarlane, I., Wilding, J., Halford, J., & Pinkney, J. (2004). Does impaired satiety contribute to human hypothalamic obesity?. In OBESITY RESEARCH Vol. 12 (pp. A84). Retrieved from https://www.webofscience.com/

Conference Paper

Effects of olanzapine on body weight gain, cumulative food intake and adiposity: A dose-response analysis

Cooper, G. D., Pickavance, L. C., Goudie, A. J., Wilding, J. P. H., & Halford, J. C. G. (2004). Effects of olanzapine on body weight gain, cumulative food intake and adiposity: A dose-response analysis. Int. J. Obes., 28(suppl), S215.

Journal article

Effects of olanzapine on body weight gain, cumulative food intake and adiposity: A dose response analysis

Cooper, G. D., Pickavance, L. C., Goudie, A. J., Wilding, J. P. H., & Halford, J. C. G. (2004). Effects of olanzapine on body weight gain, cumulative food intake and adiposity: A dose response analysis. INTERNATIONAL JOURNAL OF OBESITY, 28, S215. Retrieved from https://www.webofscience.com/

Journal article

Insulin receptors are present in third ventricle ependymal cells suggesting a role in the regulation of energy balance

Tarrach, C., Morris, R., Harrold, J., Williams, G., & Wilding, J. (2004). Insulin receptors are present in third ventricle ependymal cells suggesting a role in the regulation of energy balance. INTERNATIONAL JOURNAL OF OBESITY, 28, S224. Retrieved from https://www.webofscience.com/

Journal article

Insulin resistance (IR) and markers of systemic inflammation (SI) in older patients with systolic and diastolic heart failure (DHF). Predictive value for survival

Wisniacki, N., Taylor, W., Lye, M., & Wilding, J. P. H. (2004). Insulin resistance (IR) and markers of systemic inflammation (SI) in older patients with systolic and diastolic heart failure (DHF). Predictive value for survival. HEART, 90, A49. Retrieved from https://www.webofscience.com/

Journal article

Obesity treatment: the key to managing the type 2 diabetes timebomb?

Wilding, J. (2004). Obesity treatment: the key to managing the type 2 diabetes timebomb?. The British Journal of Diabetes &amp; Vascular Disease, 4(4), 217-219. doi:10.1177/14746514040040040101

DOI
10.1177/14746514040040040101
Journal article

Olanzapine-induced adiposity in male Han Wistar rats: A dose-response analysis

Cooper, G., Pickavance, L., Wilding, J., Goudie, A., & Halford, J. (2004). Olanzapine-induced adiposity in male Han Wistar rats: A dose-response analysis. OBESITY RESEARCH, 12, A127. Retrieved from https://www.webofscience.com/

Journal article

Olanzapine-induced changes in body weight, food intake and adiposity.

Cooper, G. D., Pickavance, L. C., Goudie, A. J., Wilding, J. P. H., & Halford, J. C. G. (2004). Olanzapine-induced changes in body weight, food intake and adiposity.. Appetite, 43, 112.

Journal article

The impact of using meal-replacements verses standard dietetic advice on body weight, appetite, mood and satisfaction during a 12-week weight control program

Halford, J., Ball, M., Pontin, E., Maharjan, L., Dovey, T., Pinkney, J., . . . Mela, D. (2004). The impact of using meal-replacements verses standard dietetic advice on body weight, appetite, mood and satisfaction during a 12-week weight control program. In OBESITY RESEARCH Vol. 12 (pp. A51). Retrieved from https://www.webofscience.com/

Conference Paper

The relationship of ghrelin to biochemical and anthropometric markers of adult growth hormone deficiency

Malik, I. A., English, P. J., Ghatei, M. A., Bloom, S. R., MacFarlane, I. A., & Wilding, J. P. H. (2004). The relationship of ghrelin to biochemical and anthropometric markers of adult growth hormone deficiency. CLINICAL ENDOCRINOLOGY, 60(1), 137-141. doi:10.1111/j.1365-2265.2004.01929.x

DOI
10.1111/j.1365-2265.2004.01929.x
Journal article

The relationship of ghrelin to biochemical and anthropometric markers of adult growth hormone deficiency.

Malik, I. A., English, P. J., Ghatei, M. A., Bloom, S. R., MacFarlane, I. A., & Wilding, J. P. H. (2004). The relationship of ghrelin to biochemical and anthropometric markers of adult growth hormone deficiency.. Clinical endocrinology, 60(1), 137-141. doi:10.1111/j.1365-2265.2004.01929.x

DOI
10.1111/j.1365-2265.2004.01929.x
Journal article

Weight gain, hyperphagia and adiposity following olanzapine treatment does not significantly influence circulating leptin in rats

Cooper, G. D., Pickavance, L. C., Goudie, A. J., Wilding, J. P. H., & Halford, J. C. G. (2004). Weight gain, hyperphagia and adiposity following olanzapine treatment does not significantly influence circulating leptin in rats. Appetite, 42, 349.

Journal article

2003

Assessment of quality of life in adults receiving long-term growth hormone replacement compared to control subjects

Malik, I. A., Foy, P., Wallymahmed, M., Wilding, J. P. H., & MacFarlane, I. A. (2003). Assessment of quality of life in adults receiving long-term growth hormone replacement compared to control subjects. CLINICAL ENDOCRINOLOGY, 59(1), 75-81. doi:10.1046/j.1365-2265.2003.01799.x

DOI
10.1046/j.1365-2265.2003.01799.x
Journal article

Peripheral Injection Of Risperidone, An Atypical Antipsychotic, Alters The Body Weight Gains Of Rats

Goudie, A. J., Halford, J. C. G., Cooper, G. D., Dovey, T., Pickavance, L. C., & Wilding, J. P. H. (2003). Peripheral Injection Of Risperidone, An Atypical Antipsychotic, Alters The Body Weight Gains Of Rats. Clinical and Experimental Pharmacology and Physiology, 30(7), 513-514. doi:10.1046/j.1440-1681.2003.t01-1-03854.x

DOI
10.1046/j.1440-1681.2003.t01-1-03854.x
Journal article

Obesity and type-2 diabetes in the elderly

Dewan, S., & Wilding, J. P. H. (2003). Obesity and type-2 diabetes in the elderly. GERONTOLOGY, 49(3), 137-145. doi:10.1159/000069176

DOI
10.1159/000069176
Journal article

Obesity and diabetes.

Cleator, J., & Wilding, J. (2003). Obesity and diabetes.. Nursing times, 99(15), 54-55.

Journal article

Chronic treatment with the thiazolidinedione, MCC-555, is associated with reductions in nitric oxide synthase activity and β-cell apoptosis in the pancreas of the Zucker Diabetic Fatty rat

Pickavance, L. C., Widdowson, P. S., Foster, J. R., Williams, G., & Wilding, J. P. H. (2003). Chronic treatment with the thiazolidinedione, MCC-555, is associated with reductions in nitric oxide synthase activity and β-cell apoptosis in the pancreas of the Zucker Diabetic Fatty rat. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 84(2), 83-89. doi:10.1046/j.1365-2613.2003.00337.x

DOI
10.1046/j.1365-2613.2003.00337.x
Journal article

P953 The evolution of heart rate variability patterns following acute myocardial infarction in the post-thrombolytic era

MANN, P. (2003). P953 The evolution of heart rate variability patterns following acute myocardial infarction in the post-thrombolytic era. European Heart Journal, 24(5), 159. doi:10.1016/s0195-668x(03)94245-x

DOI
10.1016/s0195-668x(03)94245-x
Journal article

The evolution of heart rate variability patterns following acute myocardial infarction in the post-thrombolytic era

Mann, P., Leong, K., Malik, I., Wilding, J., & Amadi, A. (2003). The evolution of heart rate variability patterns following acute myocardial infarction in the post-thrombolytic era. EUROPEAN HEART JOURNAL, 24, 159. doi:10.1016/S0195-668X(03)94245-X

DOI
10.1016/S0195-668X(03)94245-X
Journal article

Effects of insulin-induced hypoglycaemia on energy intake and food choice at a subsequent test meal.

Dewan, S., Gillett, A., Mugarza, J. A., Dovey, T. M., Halford, J. C. G., & Wilding, J. P. H. (2003). Effects of insulin-induced hypoglycaemia on energy intake and food choice at a subsequent test meal.. DIABETOLOGIA, 46, A306-A307. Retrieved from https://www.webofscience.com/

Journal article

Intensified treatment of type 2 diabetes - positive effects on blood pressure, but not glycaemic control

Gill, G. V., Woodward, A., Pradhan, S., Wallymahmed, M., Groves, T., English, P., & Wilding, J. P. (2003). Intensified treatment of type 2 diabetes - positive effects on blood pressure, but not glycaemic control. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 96(11), 833-836. doi:10.1093/qjmed/hcg143

DOI
10.1093/qjmed/hcg143
Journal article

Is there a role for reduced brown adipose tissue thermogenesis in thiazolidinedione-induced weight gain?

Cassidy, R., Buckingham, R., & Wilding, J. (2003). Is there a role for reduced brown adipose tissue thermogenesis in thiazolidinedione-induced weight gain?. In DIABETES Vol. 52 (pp. A140). Retrieved from https://www.webofscience.com/

Conference Paper

Olanzapine-induced weight gain in female han Wistar rats: A dose-response study

Cooper, G., Pickavance, L., Goudie, A., Wilding, J., & Halford, J. (2003). Olanzapine-induced weight gain in female han Wistar rats: A dose-response study. OBESITY RESEARCH, 11, A74. Retrieved from https://www.webofscience.com/

Journal article

Peripheral injection of risperidone, an atypical antipsychotic, alters the body weight gain of rats

Goudie, A. J., Halford, J. C. G., Cooper, G. D., Dovey, T., Pickavance, L. C., & Wilding, J. P. H. (2003). Peripheral injection of risperidone, an atypical antipsychotic, alters the body weight gain of rats. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 30(7), 513-514. doi:10.1046/j.1440-1681.2003.t01-1-03854.x

DOI
10.1046/j.1440-1681.2003.t01-1-03854.x
Journal article

Plasma adiponectin increases postprandially in obese, but not in lean, subjects

English, P. J., Coughlin, S. R., Hayden, K., Malik, I. A., & Wilding, J. P. H. (2003). Plasma adiponectin increases postprandially in obese, but not in lean, subjects. OBESITY RESEARCH, 11(7), 839-844. doi:10.1038/oby.2003.115

DOI
10.1038/oby.2003.115
Journal article

Topiramate decreases weight and blood pressure in severely obese subjects

Wilding, J., Van Gaal, L., Rissanen, A., Vercruysse, F., Perry, B., & Fitchet, M. (2003). Topiramate decreases weight and blood pressure in severely obese subjects. In OBESITY RESEARCH Vol. 11 (pp. A114). Retrieved from https://www.webofscience.com/

Conference Paper

2002

Neuropeptides and appetite control

Wilding, J. P. H. (2002). Neuropeptides and appetite control. DIABETIC MEDICINE, 19(8), 619-627. doi:10.1046/j.1464-5491.2002.00790.x

DOI
10.1046/j.1464-5491.2002.00790.x
Journal article

Ghrelin: sweet regulation?

English, P. J., & Wilding, J. P. H. (2002). Ghrelin: sweet regulation?. CLINICAL SCIENCE, 103(3), 329-330. doi:10.1042/cs1030329

DOI
10.1042/cs1030329
Journal article

Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK multimorbidity study

Broom, I., Wilding, J., Stott, P., & Myers, N. (2002). Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK multimorbidity study. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 56(7), 494-499. Retrieved from https://www.webofscience.com/

Journal article

<i>Practical Diabetes International</i> 18(9) November December 2001, page 309. ‘Attaining UKPDS management targets in type 2 diabetes’.

Woodward, A., Groves, T., Wallymahamed, M., Wilding, J. P., & Gill, G. V. (2002). <i>Practical Diabetes International</i> 18(9) November December 2001, page 309. ‘Attaining UKPDS management targets in type 2 diabetes’.. Practical Diabetes International, 19(5), 154. doi:10.1002/pdi.371

DOI
10.1002/pdi.371
Journal article

Hypothalamic obesity in humans: what do we know and what can be done?

Pinkney, J., Wilding, J., Williams, G., & MacFarlane, I. (2002). Hypothalamic obesity in humans: what do we know and what can be done?. Obesity reviews : an official journal of the International Association for the Study of Obesity, 3(1), 27-34. doi:10.1046/j.1467-789x.2002.00052.x

DOI
10.1046/j.1467-789x.2002.00052.x
Journal article

Food fails to suppress ghrelin levels in obese humans

English, P. J., Ghatei, M. A., Malik, I. A., Bloom, S. R., & Wilding, J. P. H. (2002). Food fails to suppress ghrelin levels in obese humans. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 87(6), 2984-2987. doi:10.1210/jc.87.6.2984

DOI
10.1210/jc.87.6.2984
Journal article

Obesity: under-diagnosed and under-treated in hospital outpatient departments

Cleator, J., Richman, E., Leong, K. S., Mawdsley, L., White, S., & Wilding, J. (2002). Obesity: under-diagnosed and under-treated in hospital outpatient departments. INTERNATIONAL JOURNAL OF OBESITY, 26(4), 581-584. doi:10.1038/sj.ijo.0801945

DOI
10.1038/sj.ijo.0801945
Journal article

Applied physiology: the control of weight

English, P. J., & Wilding, J. P. H. (2002). Applied physiology: the control of weight. Current Paediatrics, 12(2), 130-137. doi:10.1054/cupe.2001.0264

DOI
10.1054/cupe.2001.0264
Journal article

Involvement of hypothalamic melanocortin receptors in rosiglitazone-induced weight gain

Tarrach, C., Harrold, J., Cassidy, R., Wilding, J., & Williams, G. (2002). Involvement of hypothalamic melanocortin receptors in rosiglitazone-induced weight gain. British Journal of Pharmacology, 137. Retrieved from isi:000179658000142

Journal article

Involvement of hypothalamic melanocortin receptors in rosiglitazone-induced weight gain

Tarrach, C., Harrold, J., Cassidy, R., Wilding, J., & Williams, G. (2002). Involvement of hypothalamic melanocortin receptors in rosiglitazone-induced weight gain. BRITISH JOURNAL OF PHARMACOLOGY, 137. Retrieved from https://www.webofscience.com/

Journal article

Obesity: under-diagnosed and under-treated in hospital outpatient departments

Cleator, J., Richman, E., Leong, K. S., Mawdsley, L., White, S., & Wilding, J. (2002). Obesity: under-diagnosed and under-treated in hospital outpatient departments. International Journal of Obesity, 26(4), 581-584. doi:10.1038/sj.ijo.0801945

DOI
10.1038/sj.ijo.0801945
Journal article

Ragaglitazar improves insulin sensitivity and metabolic profile in dietary obese, pre-diabetic and diabetic ZDF rats.

Pickavance, L., Wassermann, K., Brand, C. L., & Wilding, J. (2002). Ragaglitazar improves insulin sensitivity and metabolic profile in dietary obese, pre-diabetic and diabetic ZDF rats.. Diabetes, 51(suppl.), 576-P, A142.

Journal article

The effect of respiration rate on heart rate variability and baroreflex sensitivity

Delaney, J. P. A., Coughlin, S. R., Brodie, D. A., & Wilding, J. P. H. (2002). The effect of respiration rate on heart rate variability and baroreflex sensitivity. JOURNAL OF PHYSIOLOGY-LONDON, 543, 45P-46P. Retrieved from https://www.webofscience.com/

Journal article

Type 2 diabetes in practice

Pickavance, L., & Wilding, J. (2002). Type 2 diabetes in practice. Unknown Journal, 9, 448.

Journal article

Type 2 diabetes in practice

Pickavance, L., & Wilding, J. (2002). Type 2 diabetes in practice. Br J Cardiol, 9, 448.

Journal article

2001

An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease

Leong, K. S., Walker, A. B., Martin, I., Wile, D., Wilding, J., & MacFarlane, I. A. (2001). An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease. CLINICAL ENDOCRINOLOGY, 54(4), 463-468. doi:10.1046/j.1365-2265.2001.01169.x

DOI
10.1046/j.1365-2265.2001.01169.x
Journal article

Attaining UKPDS management targets in type 2 diabetes: failures and difficulties

Woodward, A., Groves, T., Wallymahamed, M., Wilding, J. P., & Gill, G. V. (2001). Attaining UKPDS management targets in type 2 diabetes: failures and difficulties. Practical Diabetes International, 18(9), 307-310. doi:10.1002/pdi.275

DOI
10.1002/pdi.275
Journal article

Leptin and the control of obesity.

Wilding, J. P. (2001). Leptin and the control of obesity.. Current opinion in pharmacology, 1(6), 656-661. doi:10.1016/s1471-4892(01)00111-4

DOI
10.1016/s1471-4892(01)00111-4
Journal article

The influence of growth hormone replacement on heart rate variability in adults with growth hormone deficiency

Leong, K. S., Mann, P., Wallymahmed, M., MacFarlane, I. A., & Wilding, J. P. H. (2001). The influence of growth hormone replacement on heart rate variability in adults with growth hormone deficiency. CLINICAL ENDOCRINOLOGY, 54(6), 819-826. doi:10.1046/j.1365-2265.2001.01267.x

DOI
10.1046/j.1365-2265.2001.01267.x
Journal article

Dietary obesity in the rat induces endothelial dysfunction without causing insulin resistance: a possible role for triacylglycerols

Naderali, E. K., Brown, M. J., Pickavance, L. C., Wilding, J. P. H., Doyle, P. J., & Williams, G. (2001). Dietary obesity in the rat induces endothelial dysfunction without causing insulin resistance: a possible role for triacylglycerols. CLINICAL SCIENCE, 101(5), 499-506. doi:10.1042/CS20010088

DOI
10.1042/CS20010088
Journal article

Diet-induced endothelial dysfunction in the rat is independent of the degree of increase in total body weight

NADERALI, E. K., PICKAVANCE, L. C., WILDING, J. P. H., & WILLIAMS, G. (2001). Diet-induced endothelial dysfunction in the rat is independent of the degree of increase in total body weight. Clinical Science, 100(6), 635-641. doi:10.1042/cs1000635

DOI
10.1042/cs1000635
Journal article

Diet-induced endothelial dysfunction in the rat is independent of the degree of increase in total body weight

Naderali, E. K., Pickavance, L. C., Wilding, J. P. H., & Williams, G. (2001). Diet-induced endothelial dysfunction in the rat is independent of the degree of increase in total body weight. CLINICAL SCIENCE, 100(6), 635-641. doi:10.1042/CS20000279

DOI
10.1042/CS20000279
Journal article

Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats

Naderali, E. K., Pickavance, L. C., Wilding, J. P. H., Doyle, P. J., & Wiliams, G. (2001). Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats. EUROPEAN JOURNAL OF PHARMACOLOGY, 416(1-2), 133-139. doi:10.1016/S0014-2999(01)00866-4

DOI
10.1016/S0014-2999(01)00866-4
Journal article

Causes of obesity

P.H. Wilding, J. (2001). Causes of obesity. Practical Diabetes International, 18(8), 288-292. doi:10.1002/pdi.277

DOI
10.1002/pdi.277
Journal article

Insulin sensitisation by rosiglitazone: Effects on metabolism and gene exression

Moore, G. B. T., Pickavance, L. C., Clapham, J. C., Carter, S., Briscoe, C., Tadayyon, M., . . . Wilding, J. P. H. (2001). Insulin sensitisation by rosiglitazone: Effects on metabolism and gene exression. DIABETOLOGIA, 44, A28. Retrieved from https://www.webofscience.com/

Journal article

Insulin sensitising effect of rosiglitazone: Effects on metabolism and gene expression.

Moore, G., Pickavance, L., Clapham, J., Carter, S., Bond, B., Buckingham, R., & Wilding, J. P. H. (2001). Insulin sensitising effect of rosiglitazone: Effects on metabolism and gene expression.. Diabetes, 50(suppl.), 2128-PO, A506.

Journal article

Insulin sensitising effect of rosiglitazone: Effects on metablism and gene expression

Moore, G., Pickavance, L., Clapham, J., Carter, S., Bond, B., Buckingham, R., & Wilding, J. P. H. (2001). Insulin sensitising effect of rosiglitazone: Effects on metablism and gene expression. In DIABETES Vol. 50 (pp. A506). Retrieved from https://www.webofscience.com/

Conference Paper

Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia

Pickavance, L. C., Buckingham, R. E., & Wilding, J. P. H. (2001). Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia. DIABETES OBESITY & METABOLISM, 3(3), 171-180. doi:10.1046/j.1463-1326.2001.00120.x

DOI
10.1046/j.1463-1326.2001.00120.x
Journal article

Rosiglitazone improves glycaemic and insulinaemic responses in subjects with impaired glucose tolerance

Elasha, H., Agrawal, A., Jones, N. P., Bennett, S. M. A., Walker, M., & Wilding, J. (2001). Rosiglitazone improves glycaemic and insulinaemic responses in subjects with impaired glucose tolerance. DIABETOLOGIA, 44, A221. Retrieved from https://www.webofscience.com/

Journal article

Rosiglitazone improves insulin sensitivity and 24-hour ambulatory blood pressure in subjects with IGT

Bennett, S. M. A., Jones, N. P., Agrawal, A., Elasha, H., Walker, M., & Wilding, J. (2001). Rosiglitazone improves insulin sensitivity and 24-hour ambulatory blood pressure in subjects with IGT. DIABETOLOGIA, 44, A200. Retrieved from https://www.webofscience.com/

Journal article

Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wister rats independently of hypothalamic neuropeptide Y

Brown, M., Bing, C., King, P., Pickavance, L., Heal, D., & Wilding, J. (2001). Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wister rats independently of hypothalamic neuropeptide Y. BRITISH JOURNAL OF PHARMACOLOGY, 132(8), 1898-1904. doi:10.1038/sj.bjp.0704030

DOI
10.1038/sj.bjp.0704030
Journal article

Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wister rats independently of hypothalamic neuropeptide Y

Brown, M., Bing, C., King, P., Pickavance, L., Heal, D., & Wilding, J. (2001). Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wister rats independently of hypothalamic neuropeptide Y. British Journal of Pharmacology, 132(8), 1898. Retrieved from isi:000168326100031

Journal article

Sleep disordered breathing--a new component of syndrome x?

Coughlin, S., Calverley, P., & Wilding, J. (2001). Sleep disordered breathing--a new component of syndrome x?. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2(4), 267-274. doi:10.1046/j.1467-789x.2001.00045.x

DOI
10.1046/j.1467-789x.2001.00045.x
Journal article

2000

Hypercalcaemia of hypoadrenal crisis mistaken for hypercalcaemia of malignancy in a patient with known bone metastases: a case report.

Stanaway, S. E., & Wilding, J. P. (2000). Hypercalcaemia of hypoadrenal crisis mistaken for hypercalcaemia of malignancy in a patient with known bone metastases: a case report.. European journal of internal medicine, 11(6), 348-350. doi:10.1016/s0953-6205(00)00119-9

DOI
10.1016/s0953-6205(00)00119-9
Journal article

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults

Heymsfield, S. B., Segal, K. R., Hauptman, J., Lucas, C. P., Boldrin, M. N., Rissanen, A., . . . Sjöström, L. (2000). Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. ARCHIVES OF INTERNAL MEDICINE, 160(9), 1321-1326. doi:10.1001/archinte.160.9.1321

DOI
10.1001/archinte.160.9.1321
Journal article

Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and Zucker diabetic fatty rats and effects of rosiglitazone

Cai, X. J., Lister, C. A., Buckingham, R. E., Pickavance, L., Wilding, J., Arch, J. R. S., . . . Williams, G. (2000). Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and Zucker diabetic fatty rats and effects of rosiglitazone. MOLECULAR BRAIN RESEARCH, 77(1), 131-137. doi:10.1016/S0169-328X(00)00041-3

DOI
10.1016/S0169-328X(00)00041-3
Journal article

Management of hypertension (multiple letters)

Wilding, J., Williams, G., Drummond, G., Marshall, T., Rouse, A., Eisenberg, J., . . . Russell, G. (2000). Management of hypertension (multiple letters). British Medical Journal, 320(7234), 576-580.

Journal article

Management of hypertension - Ideal body weight is not realistic goal for lifestyle intervention

Wilding, J., & Williams, G. (2000). Management of hypertension - Ideal body weight is not realistic goal for lifestyle intervention. BRITISH MEDICAL JOURNAL, 320(7234), 576. doi:10.1136/bmj.320.7234.576

DOI
10.1136/bmj.320.7234.576
Journal article

Management of hypertension. Guidelines have serious weaknesses.

Marshall, T., & Rouse, A. (2000). Management of hypertension. Guidelines have serious weaknesses.. BMJ (Clinical research ed.), 320(7234), 576-577. doi:10.1136/bmj.320.7234.576

DOI
10.1136/bmj.320.7234.576
Journal article

Abnormal heart rate variability in adults with growth hormone deficiency

Leong, K. S., Mann, P., Wallymahmed, M., MacFarlane, I. A., & Wilding, J. P. H. (2000). Abnormal heart rate variability in adults with growth hormone deficiency. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 85(2), 628-633. doi:10.1210/jc.85.2.628

DOI
10.1210/jc.85.2.628
Journal article

Effects of chronic <i>in vivo</i> administration of troglitazone on <i>in vitro</i> contractility of rat mesenteric arteries

Naderali, E. K., Pickavance, L., Wilding, J., & Williams, G. (2000). Effects of chronic <i>in vivo</i> administration of troglitazone on <i>in vitro</i> contractility of rat mesenteric arteries. JOURNAL OF PHYSIOLOGY-LONDON, 523, 143P-144P. Retrieved from https://www.webofscience.com/

Journal article

Greater weight loss on sibutramine significantly improves lipid profile: Meta-analysis of six 12-month studies

Williams, G., Wilding, J., & Wickens, M. (2000). Greater weight loss on sibutramine significantly improves lipid profile: Meta-analysis of six 12-month studies. OBESITY RESEARCH, 8, 90S. Retrieved from https://www.webofscience.com/

Journal article

Highly palatable diet-induced vascular dysfunction is independent of the degree of increase in total body weight

Naderali, E. K., Pickavance, L. C., Wilding, J. P. H., Doyle, P. J., & Williams, G. (2000). Highly palatable diet-induced vascular dysfunction is independent of the degree of increase in total body weight. JOURNAL OF PHYSIOLOGY-LONDON, 526, 46P-47P. Retrieved from https://www.webofscience.com/

Journal article

Obesity and Type 2 diabetes mellitus

Wilding, J. (2000). Obesity and Type 2 diabetes mellitus. DIABETIC MEDICINE, 17(5), 400-402. doi:10.1046/j.1464-5491.2000.00292-5.x

DOI
10.1046/j.1464-5491.2000.00292-5.x
Journal article

Obesity and diabetes

Wilding, J. (2000). Obesity and diabetes. CME Bulletin Endocrinology and Diabetes, 3(1), 12-14.

Journal article

Sound familiar?

Wilding, J., Cook, S., & Davis, J. (2000). Sound familiar?. PSYCHOLOGIST, 13(11), 558-562. Retrieved from https://www.webofscience.com/

Journal article

The future of obesity treatment.

Wilding, J. (2000). The future of obesity treatment.. EXS, 89, 181-191. doi:10.1007/978-3-0348-8393-1_11

DOI
10.1007/978-3-0348-8393-1_11
Journal article

1999

Hypothalamic orexin expression - Modulation by blood glucose and feeding

Cai, X. J., Widdowson, P. S., Harrold, J., Wilson, S., Buckingham, R. E., Arch, J. R. S., . . . Williams, G. (1999). Hypothalamic orexin expression - Modulation by blood glucose and feeding. DIABETES, 48(11), 2132-2137. doi:10.2337/diabetes.48.11.2132

DOI
10.2337/diabetes.48.11.2132
Journal article

Clinical presentation of thyroid dysfunction and Addison's disease in young adults with type 1 diabetes

Leong, K. S., Wallymahmed, M., Wilding, J., & MacFarlane, L. (1999). Clinical presentation of thyroid dysfunction and Addison's disease in young adults with type 1 diabetes. POSTGRADUATE MEDICAL JOURNAL, 75(886), 467-470. doi:10.1136/pgmj.75.886.467

DOI
10.1136/pgmj.75.886.467
Journal article

Changes in orexin mRNA during altered energy balance: Influences of leptin and insulin

Cai, X., Tadayyon, M., Buckingham, R., Wilson, S., Arch, J. R. S., Widdowson, P. S., . . . Williams, G. (1999). Changes in orexin mRNA during altered energy balance: Influences of leptin and insulin. BRITISH JOURNAL OF PHARMACOLOGY, 126, U7. Retrieved from https://www.webofscience.com/

Journal article

Hypothalamic neuropeptide Y and its neuroendocrine regulation by leptin

Widdowson, P. S., & Wilding, J. P. H. (2000). Hypothalamic neuropeptide Y and its neuroendocrine regulation by leptin. NEUROENDOCRINOLOGY OF LEPTIN, 26, 71-86. Retrieved from https://www.webofscience.com/

Journal article

Hypothalamic orexin expression - Modulation by blood glucose and feeding

Cai, X. J., Widdowson, P. S., Harrold, J., Wilson, S., Buckingham, R. E., Arch, J. R. S., . . . Williams, G. (1999). Hypothalamic orexin expression - Modulation by blood glucose and feeding. Diabetes, 48(11), 2132. Retrieved from isi:000083267200003

Journal article

Insulin-sensitising action of rosiglitazone is enhanced by food restriction.

Pickavance, L., Buckingham, R., & Wilding, J. (1999). Insulin-sensitising action of rosiglitazone is enhanced by food restriction.. Diabetologia, 42(suppl.), 674, A181.

Journal article

Insulin-sensitising action of rosiglitazone is enhanced by food restriction.

Pickavance, L., Buckingham, R., & Wilding, J. (1999). Insulin-sensitising action of rosiglitazone is enhanced by food restriction.. DIABETOLOGIA, 42, A181. Retrieved from https://www.webofscience.com/

Journal article

Obesity and diabetes

Leong, K. S., & Wilding, J. P. (1999). Obesity and diabetes. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 13(2), 221-237. doi:10.1053/beem.1999.0017

DOI
10.1053/beem.1999.0017
Journal article

Orlistat-induced weight loss improves insulin resistance in obese patients.

Wilding, J. (1999). Orlistat-induced weight loss improves insulin resistance in obese patients.. DIABETOLOGIA, 42, A215. Retrieved from https://www.webofscience.com/

Journal article

The thiazolidinedione, MCC-555, prevents nitric oxide synthase induction in the pancreas of the ZDF rat.

Pickavance, L. C., Widdowson, P. S., Foster, J. R., Ishii, S., Tanaka, H., & Williams, G. (1999). The thiazolidinedione, MCC-555, prevents nitric oxide synthase induction in the pancreas of the ZDF rat.. Br. J. Pharmacol., 128, 116P.

Journal article

Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution

Pickavance, L. C., Tadayyon, M., Widdowson, P. S., Buckingham, R. E., & Wilding, J. P. H. (1999). Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. BRITISH JOURNAL OF PHARMACOLOGY, 128(7), 1570-1576. doi:10.1038/sj.bjp.0702932

DOI
10.1038/sj.bjp.0702932
Journal article

1998

The eat of the land: The obesity epidemic and how overweight Americans can help themselves

Wilding, J. (1998). The eat of the land: The obesity epidemic and how overweight Americans can help themselves. NATURE, 391(6669), 759. doi:10.1038/35793

DOI
10.1038/35793
Journal article

Abdominal obesity, impaired nonesterified fatty acid suppression, and insulin-mediated glucose disposal are early metabolic abnormalities in families with premature myocardial infarction

Kooner, J. S., Baliga, R. R., Wilding, J., Crook, D., Packard, C. J., Banks, L. M., . . . Scott, J. (1998). Abdominal obesity, impaired nonesterified fatty acid suppression, and insulin-mediated glucose disposal are early metabolic abnormalities in families with premature myocardial infarction. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 18(7), 1021-1026. doi:10.1161/01.ATV.18.7.1021

DOI
10.1161/01.ATV.18.7.1021
Journal article

Obesity treatment with orlistat (xenical®) helps to prevent deterioration in glucose tolerance

Wilding, J. P. H., & Stolshek, B. (1998). Obesity treatment with orlistat (xenical®) helps to prevent deterioration in glucose tolerance. DIABETOLOGIA, 41, A126. Retrieved from https://www.webofscience.com/

Journal article

Rosiglitazone therapeutic index: separation of glucose lowering and haemodilution.

Pickavance, L., Widdowson, P. S., Buckingham, R. E., & Wilding, J. P. H. (1998). Rosiglitazone therapeutic index: separation of glucose lowering and haemodilution.. Diabetologia, 41(suppl), 924, A239.

Journal article

Rosiglitazone therapeutic index: Separation of efficacy and haemodilution

Pickavance, L., Widdowson, P. S., Buckingham, R. E., & Wilding, J. P. H. (1998). Rosiglitazone therapeutic index: Separation of efficacy and haemodilution. DIABETOLOGIA, 41, A239. Retrieved from https://www.webofscience.com/

Journal article

Therapeutic index for rosiglitazone in dietary obese rats and effects on body weight and plasma leptin.

Pickavance, L., Tadayyon, M., Widdowson, P., Buckingham, R., & Wilding, J. (1998). Therapeutic index for rosiglitazone in dietary obese rats and effects on body weight and plasma leptin.. British Diabetic Association Meeting, Harrogate., n/a, n/a.

Journal article

1997

Science, medicine, and the future - Obesity treatment

Wilding, J. (1997). Science, medicine, and the future - Obesity treatment. BRITISH MEDICAL JOURNAL, 315(7114), 997-&. doi:10.1136/bmj.315.7114.997

DOI
10.1136/bmj.315.7114.997
Journal article

Necrolytic migratory erythema: a classical cutaneous presentation of the glucagonoma syndrome

Jones, S. A. V., Dunnill, M. G. S., Wilding, J., Liddell, K., Gorsuch, A. N., Bloom, S. R., & Black, M. M. (1997). Necrolytic migratory erythema: a classical cutaneous presentation of the glucagonoma syndrome. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 9(1), 68-73. doi:10.1111/j.1468-3083.1997.tb00231.x

DOI
10.1111/j.1468-3083.1997.tb00231.x
Journal article

Endocrine effects of gastrointestinal tumours

Wilding, J. P. H. (1997). Endocrine effects of gastrointestinal tumours. ENDOCRINE-RELATED CANCER, 4(2), 179-189. doi:10.1677/erc.0.0040179

DOI
10.1677/erc.0.0040179
Journal article

A simple probabilistic approach to classification and routing

Leistensnider, J., & Wilding, J. (1997). A simple probabilistic approach to classification and routing. In MILCOM 97 PROCEEDINGS, VOLS 1-3 (pp. 750-754). Retrieved from https://www.webofscience.com/

Conference Paper

Additive effects of lactation and food restriction to increase hypothalamic neuropeptide Y mRNA in rats

Wilding, J. P. H., Ajala, M. O., Lambert, P. D., & Bloom, S. R. (1997). Additive effects of lactation and food restriction to increase hypothalamic neuropeptide Y mRNA in rats. JOURNAL OF ENDOCRINOLOGY, 152(3), 365-369. doi:10.1677/joe.0.1520365

DOI
10.1677/joe.0.1520365
Journal article

Correction: Science, medicine, and the future: Obesity treatment (British Medical Journal (1997) 18 October (997-1000))

Wilding, J. (1997). Correction: Science, medicine, and the future: Obesity treatment (British Medical Journal (1997) 18 October (997-1000)). British Medical Journal, 315(7122), 1599.

Journal article

Earwitness testimony: Never mind the variety, hear the length

Cook, S., & Wilding, J. (1997). Earwitness testimony: Never mind the variety, hear the length. APPLIED COGNITIVE PSYCHOLOGY, 11(2), 95-111. Retrieved from https://www.webofscience.com/

Journal article

Glucagon-like peptide-1 (GLP-1): A trial of treatment in noninsulin-dependent diabetes mellitus

Todd, J. F., Wilding, J. P. H., Edwards, C. M. B., Khan, F. A., Ghatei, M. A., & Bloom, S. R. (1997). Glucagon-like peptide-1 (GLP-1): A trial of treatment in noninsulin-dependent diabetes mellitus. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 27(6), 533-536. doi:10.1046/j.1365-2362.1997.1490691.x

DOI
10.1046/j.1365-2362.1997.1490691.x
Journal article

Necrolytic migratory erythema: a classical cutaneous presentation of the glucagonoma syndrome

VAUGHANJONES, S., DUNNILL, M., WILDING, J., LIDDELL, K., GORSUCH, A., BLOOM, S., & BLACK, M. (1997). Necrolytic migratory erythema: a classical cutaneous presentation of the glucagonoma syndrome. Journal of the European Academy of Dermatology and Venereology, 9(1), 68-73. doi:10.1016/s0926-9959(97)00602-8

DOI
10.1016/s0926-9959(97)00602-8
Journal article

Neurobiology

Wilding, J., Widdowson, P., & Williams, G. (1997). Neurobiology. BRITISH MEDICAL BULLETIN, 53(2), 286-306. Retrieved from https://www.webofscience.com/

Journal article

Science, medicine, and the future: Obesity treatment (vol 315, pg 997, 1997)

Wilding, J. (1997). Science, medicine, and the future: Obesity treatment (vol 315, pg 997, 1997). BRITISH MEDICAL JOURNAL, 315(7122), 1599. Retrieved from https://www.webofscience.com/

Journal article

1996

Metabolic actions of neuropeptide Y and their relevance to obesity

Wilding, J. P. H. (1996). Metabolic actions of neuropeptide Y and their relevance to obesity. BIOCHEMICAL SOCIETY TRANSACTIONS, 24(2), 576-581. doi:10.1042/bst0240576

DOI
10.1042/bst0240576
Journal article

Reduced NPY induced feeding in diabetic but not steroid-treated rats: Lack of evidence for changes in receptor number or affinity

Morgan, D. G. A., Lambert, P. D., Smith, D. M., Wilding, J. P. H., & Bloom, S. R. (1996). Reduced NPY induced feeding in diabetic but not steroid-treated rats: Lack of evidence for changes in receptor number or affinity. JOURNAL OF NEUROENDOCRINOLOGY, 8(4), 283-290. doi:10.1046/j.1365-2826.1996.04565.x

DOI
10.1046/j.1365-2826.1996.04565.x
Journal article

A role for glucagon-like peptide-1 in the central regulation of feeding

Turton, M. D., OShea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., . . . Bloom, S. R. (1996). A role for glucagon-like peptide-1 in the central regulation of feeding. NATURE, 379(6560), 69-72. doi:10.1038/379069a0

DOI
10.1038/379069a0
Journal article

Reactive (AA) systemic amyloidosis

Allen, A. R., Scott, J., Clutterbuck, E., Walport, M. J., Davies, K., Wilding, J., & Thompson, M. (1996). Reactive (AA) systemic amyloidosis. British Medical Journal, 312(7038), 1087-1089.

Journal article

Reactive (AA) systemic amyloidosis - A cause of refractory nephrotic syndrome

Allen, A. R., Scott, J., Clutterbuck, E., Walport, M. J., Davies, K., Wilding, J., & Thompson, M. (1996). Reactive (AA) systemic amyloidosis - A cause of refractory nephrotic syndrome. BRITISH MEDICAL JOURNAL, 312(7038), 1087-1089. Retrieved from https://www.webofscience.com/

Journal article

1995

ACUTE EFFECTS OF CENTRAL NEUROPEPTIDE-Y INJECTION ON GLUCOSE-METABOLISM IN FASTED RATS

WILDING, J. P. H., KRUSZYNSKA, Y. T., LAMBERT, P. D., & BLOOM, S. R. (1995). ACUTE EFFECTS OF CENTRAL NEUROPEPTIDE-Y INJECTION ON GLUCOSE-METABOLISM IN FASTED RATS. CLINICAL SCIENCE, 89(5), 543-548. doi:10.1042/cs0890543

DOI
10.1042/cs0890543
Journal article

C-FOS EXPRESSION IN THE PARAVENTRICULAR NUCLEUS OF THE HYPOTHALAMUS FOLLOWING INTRACEREBROVENTRICULAR INFUSIONS OF NEUROPEPTIDE-Y

LAMBERT, P. D., PHILLIPS, P. J., WILDING, J. P. H., BLOOM, S. R., & HERBERT, J. (1995). C-FOS EXPRESSION IN THE PARAVENTRICULAR NUCLEUS OF THE HYPOTHALAMUS FOLLOWING INTRACEREBROVENTRICULAR INFUSIONS OF NEUROPEPTIDE-Y. BRAIN RESEARCH, 670(1), 59-65. doi:10.1016/0006-8993(94)01224-6

DOI
10.1016/0006-8993(94)01224-6
Journal article

METABOLIC PHENOTYPES FOR GENETIC-ANALYSIS IN CORONARY HEART-DISEASE

KOONER, J. S., BALIGA, R. R., WILDING, J., PEART, S., AITMAN, T. J., & SCOTT, J. (1995). METABOLIC PHENOTYPES FOR GENETIC-ANALYSIS IN CORONARY HEART-DISEASE. CIRCULATION, 92(8), 76. Retrieved from https://www.webofscience.com/

Journal article

1994

EFFECT OF FOOD-DEPRIVATION AND STREPTOZOTOCIN-INDUCED DIABETES ON HYPOTHALAMIC NEUROPEPTIDE-Y RELEASE AS MEASURED BY A RADIOIMMUNOASSAY-LINKED MICRODIALYSIS PROCEDURE

LAMBERT, P. D., WILDING, J. P. H., TURTON, M. D., GHATEI, M. A., & BLOOM, S. R. (1994). EFFECT OF FOOD-DEPRIVATION AND STREPTOZOTOCIN-INDUCED DIABETES ON HYPOTHALAMIC NEUROPEPTIDE-Y RELEASE AS MEASURED BY A RADIOIMMUNOASSAY-LINKED MICRODIALYSIS PROCEDURE. BRAIN RESEARCH, 656(1), 135-140. doi:10.1016/0006-8993(94)91374-9

DOI
10.1016/0006-8993(94)91374-9
Journal article

GLP-17-36NH(2) IN THE CONTROL OF FOOD-INTAKE IN THE PARTIALLY SATIATED RAT

TURTON, M. D., LAMBERT, P. D., WILDING, J. P. H., GHATEI, M. A., & BLOOM, S. R. (1994). GLP-17-36NH(2) IN THE CONTROL OF FOOD-INTAKE IN THE PARTIALLY SATIATED RAT. REGULATORY PEPTIDES, 51(3), 295. doi:10.1016/0167-0115(94)90113-9

DOI
10.1016/0167-0115(94)90113-9
Journal article

DIETARY ADVICE BASED ON THE GLYCEMIC INDEX IMPROVES DIETARY PROFILE AND METABOLIC CONTROL IN TYPE-2 DIABETIC-PATIENTS

FROST, G., WILDING, J., & BEECHAM, J. (1994). DIETARY ADVICE BASED ON THE GLYCEMIC INDEX IMPROVES DIETARY PROFILE AND METABOLIC CONTROL IN TYPE-2 DIABETIC-PATIENTS. DIABETIC MEDICINE, 11(4), 397-401. doi:10.1111/j.1464-5491.1994.tb00292.x

DOI
10.1111/j.1464-5491.1994.tb00292.x
Journal article

LACK OF ACUTE EFFECT OF AMYLIN (ISLET ASSOCIATED POLYPEPTIDE) ON INSULIN SENSITIVITY DURING HYPERINSULINEMIC EUGLYCEMIC CLAMP IN HUMANS

WILDING, J. P. H., KHANDANNIA, N., BENNET, W. M., GILBEY, S. G., BEACHAM, J., GHATEI, M. A., & BLOOM, S. R. (1994). LACK OF ACUTE EFFECT OF AMYLIN (ISLET ASSOCIATED POLYPEPTIDE) ON INSULIN SENSITIVITY DURING HYPERINSULINEMIC EUGLYCEMIC CLAMP IN HUMANS. DIABETOLOGIA, 37(2), 166-169. doi:10.1007/s001250050088

DOI
10.1007/s001250050088
Journal article

NALOXONE-INDUCED ANOREXIA INCREASES NEUROPEPTIDE-Y CONCENTRATIONS IN THE DORSOMEDIAL HYPOTHALAMUS - EVIDENCE FOR NEUROPEPTIDE-Y OPIOID INTERACTIONS IN THE CONTROL OF FOOD-INTAKE

LAMBERT, P. D., WILDING, J. P. H., ALDOKHAYEL, A. A. M., GILBEY, S. G., GHATEI, M. A., & BLOOM, S. R. (1994). NALOXONE-INDUCED ANOREXIA INCREASES NEUROPEPTIDE-Y CONCENTRATIONS IN THE DORSOMEDIAL HYPOTHALAMUS - EVIDENCE FOR NEUROPEPTIDE-Y OPIOID INTERACTIONS IN THE CONTROL OF FOOD-INTAKE. PEPTIDES, 15(4), 657-660. doi:10.1016/0196-9781(94)90091-4

DOI
10.1016/0196-9781(94)90091-4
Journal article

1993

A ROLE FOR GLP-1(7-36)NH2 IN THE CENTRAL CONTROL OF FEEDING-BEHAVIOR

LAMBERT, P. D., WILDING, J. P. H., GHATEI, M. A., & BLOOM, S. R. (1993). A ROLE FOR GLP-1(7-36)NH2 IN THE CENTRAL CONTROL OF FEEDING-BEHAVIOR. DIGESTION, 54(6), 360-361. Retrieved from https://www.webofscience.com/

Journal article

THE EFFECT OF CENTRAL BLOCKADE OF KAPPA-OPIOID RECEPTORS ON NEUROPEPTIDE Y-INDUCED FEEDING IN THE RAT

LAMBERT, P. D., WILDING, J. P. H., ALDOKHAYEL, A. A. M., GILBEY, S. G., & BLOOM, S. R. (1993). THE EFFECT OF CENTRAL BLOCKADE OF KAPPA-OPIOID RECEPTORS ON NEUROPEPTIDE Y-INDUCED FEEDING IN THE RAT. BRAIN RESEARCH, 629(1), 146-148. doi:10.1016/0006-8993(93)90493-7

DOI
10.1016/0006-8993(93)90493-7
Journal article

A ROLE FOR NEUROPEPTIDE-Y, DYNORPHIN, AND NORADRENALINE IN THE CENTRAL CONTROL OF FOOD-INTAKE AFTER FOOD-DEPRIVATION

LAMBERT, P. D., WILDING, J. P. H., ALDOKHAYEL, A. A. M., BOHUON, C., COMOY, E., GILBEY, S. G., & BLOOM, S. R. (1993). A ROLE FOR NEUROPEPTIDE-Y, DYNORPHIN, AND NORADRENALINE IN THE CENTRAL CONTROL OF FOOD-INTAKE AFTER FOOD-DEPRIVATION. ENDOCRINOLOGY, 133(1), 29-32. doi:10.1210/en.133.1.29

DOI
10.1210/en.133.1.29
Journal article

INCREASED NEUROPEPTIDE-Y MESSENGER-RIBONUCLEIC-ACID (MESSENGER-RNA) AND DECREASED NEUROTENSIN MESSENGER-RNA IN THE HYPOTHALAMUS OF THE OBESE (OB/OB) MOUSE

WILDING, J. P. H., GILBEY, S. G., BAILEY, C. J., BATT, R. A. L., WILLIAMS, G., GHATEI, M. A., & BLOOM, S. R. (1993). INCREASED NEUROPEPTIDE-Y MESSENGER-RIBONUCLEIC-ACID (MESSENGER-RNA) AND DECREASED NEUROTENSIN MESSENGER-RNA IN THE HYPOTHALAMUS OF THE OBESE (OB/OB) MOUSE. ENDOCRINOLOGY, 132(5), 1939-1944. doi:10.1210/en.132.5.1939

DOI
10.1210/en.132.5.1939
Journal article

A role for neuropeptide-Y, dynorphin, and noradrenaline in the central control of food intake after food deprivation.

Lambert, P. D., Wilding, J. P., al-Dokhayel, A. A., Bohuon, C., Comoy, E., Gilbey, S. G., & Bloom, S. R. (1993). A role for neuropeptide-Y, dynorphin, and noradrenaline in the central control of food intake after food deprivation.. Endocrinology, 133(1), 29-32. doi:10.1210/endo.133.1.8100519

DOI
10.1210/endo.133.1.8100519
Journal article

AMYLIN DOES NOT AFFECT INSULIN SENSITIVITY IN HUMANS

WILDING, J. P. H., KHANDANNIA, N., GILBEY, S. G., BENNET, W. M., BEACHAM, J., GHATEI, M. A., & BLOOM, S. R. (1993). AMYLIN DOES NOT AFFECT INSULIN SENSITIVITY IN HUMANS. DIABETOLOGIA, 36, A135. Retrieved from https://www.webofscience.com/

Journal article

INCREASES IN NEUROPEPTIDE-Y CONTENT AND GENE-EXPRESSION IN THE HYPOTHALAMUS OF RATS TREATED WITH DEXAMETHASONE ARE PREVENTED BY INSULIN

WILDING, J. P. H., GILBEY, S. G., LAMBERT, P. D., GHATEI, M. A., & BLOOM, S. R. (1993). INCREASES IN NEUROPEPTIDE-Y CONTENT AND GENE-EXPRESSION IN THE HYPOTHALAMUS OF RATS TREATED WITH DEXAMETHASONE ARE PREVENTED BY INSULIN. NEUROENDOCRINOLOGY, 57(4), 581-587. doi:10.1159/000126410

DOI
10.1159/000126410
Journal article

INTERACTIONS BETWEEN NEUROPEPTIDE-Y AND THE KAPPA-OPIOID SYSTEM IN THE CENTRAL CONTROL OF FOOD-INTAKE

LAMBERT, P. D., WILDING, J. P. H., & BLOOM, S. R. (1993). INTERACTIONS BETWEEN NEUROPEPTIDE-Y AND THE KAPPA-OPIOID SYSTEM IN THE CENTRAL CONTROL OF FOOD-INTAKE. BRITISH JOURNAL OF PHARMACOLOGY, 110, P60. Retrieved from https://www.webofscience.com/

Journal article

Increased neuropeptide-Y messenger ribonucleic acid (mRNA) and decreased neurotensin mRNA in the hypothalamus of the obese (ob/ob) mouse.

Wilding, J. P., Gilbey, S. G., Bailey, C. J., Batt, R. A., Williams, G., Ghatei, M. A., & Bloom, S. R. (1993). Increased neuropeptide-Y messenger ribonucleic acid (mRNA) and decreased neurotensin mRNA in the hypothalamus of the obese (ob/ob) mouse.. Endocrinology, 132(5), 1939-1944. doi:10.1210/endo.132.5.7682936

DOI
10.1210/endo.132.5.7682936
Journal article

1992

INCREASED NEUROPEPTIDE-Y MESSENGER-RNA AND DECREASED NEUROTENSIN MESSENGER-RNA IN THE HYPOTHALAMUS OF THE OBESE (OB OB) MOUSE

WILDING, J. P. H., LAMBERT, P. D., GILBEY, S. G., BAILEY, C. J., BATT, R. A. L., WILLIAMS, G., . . . BLOOM, S. R. (1992). INCREASED NEUROPEPTIDE-Y MESSENGER-RNA AND DECREASED NEUROTENSIN MESSENGER-RNA IN THE HYPOTHALAMUS OF THE OBESE (OB OB) MOUSE. REGULATORY PEPTIDES, 39(2-3), 259. doi:10.1016/0167-0115(92)90566-D

DOI
10.1016/0167-0115(92)90566-D
Journal article

DEXFENFLURAMINE TREATMENT AND HYPOTHALAMIC NEUROPEPTIDES IN DIET-INDUCED OBESITY IN RATS

WILDING, J. P. H., GILBEY, S. G., JONES, P. M., MANNAN, M. M., GHATEI, M. A., & BLOOM, S. R. (1992). DEXFENFLURAMINE TREATMENT AND HYPOTHALAMIC NEUROPEPTIDES IN DIET-INDUCED OBESITY IN RATS. PEPTIDES, 13(3), 557-563. doi:10.1016/0196-9781(92)90089-L

DOI
10.1016/0196-9781(92)90089-L
Journal article

INCREASED NEUROPEPTIDE-Y CONTENT IN INDIVIDUAL HYPOTHALAMIC NUCLEI, BUT NOT NEUROPEPTIDE-Y MESSENGER-RNA, IN DIET-INDUCED OBESITY IN RATS

WILDING, J. P. H., GILBEY, S. G., MANNAN, M., ASLAM, N., GHATEI, M. A., & BLOOM, S. R. (1992). INCREASED NEUROPEPTIDE-Y CONTENT IN INDIVIDUAL HYPOTHALAMIC NUCLEI, BUT NOT NEUROPEPTIDE-Y MESSENGER-RNA, IN DIET-INDUCED OBESITY IN RATS. JOURNAL OF ENDOCRINOLOGY, 132(2), 299-304. doi:10.1677/joe.0.1320299

DOI
10.1677/joe.0.1320299
Journal article

1991

Dexamethasone-induced increase in hypothalamic neuropeptide Y (NPY) is reversed by insulin

Wilding, J. P. H., Gilbey, S. G., Aslam, N., Ghatei, M. A., & Bloom, S. R. (1991). Dexamethasone-induced increase in hypothalamic neuropeptide Y (NPY) is reversed by insulin. Regulatory Peptides, 35(3), 262. doi:10.1016/0167-0115(91)90164-c

DOI
10.1016/0167-0115(91)90164-c
Journal article

1990

ELEVATED HYPOTHALAMIC NEUROPEPTIDE-Y CONCENTRATIONS IN RATS FED A PALATABLE DIET-EFFECT OF D-FENFLURAMINE

WILDING, J., GILBEY, S. G., MANNAN, M., DOMIN, J., ASLAN, N., GHATEI, M. A., & BLOOM, S. R. (1990). ELEVATED HYPOTHALAMIC NEUROPEPTIDE-Y CONCENTRATIONS IN RATS FED A PALATABLE DIET-EFFECT OF D-FENFLURAMINE. REGULATORY PEPTIDES, 30(1), 59. doi:10.1016/0167-0115(90)90182-V

DOI
10.1016/0167-0115(90)90182-V
Journal article

1989

RELATIONS BETWEEN READING AND MUSICAL ABILITIES

BARWICK, J., VALENTINE, E., WEST, R., & WILDING, J. (1989). RELATIONS BETWEEN READING AND MUSICAL ABILITIES. BRITISH JOURNAL OF EDUCATIONAL PSYCHOLOGY, 59, 253-257. doi:10.1111/j.2044-8279.1989.tb03097.x

DOI
10.1111/j.2044-8279.1989.tb03097.x
Journal article

1984

INDEPENDENCE OF SLOPE AND INTERCEPT IN STERNBERG MEMORY-SCANNING PARADIGM

VALENTINE, J., WILDING, J., & MOHINDRA, N. (1984). INDEPENDENCE OF SLOPE AND INTERCEPT IN STERNBERG MEMORY-SCANNING PARADIGM. BRITISH JOURNAL OF MATHEMATICAL & STATISTICAL PSYCHOLOGY, 37(MAY), 122-127. doi:10.1111/j.2044-8317.1984.tb00793.x

DOI
10.1111/j.2044-8317.1984.tb00793.x
Journal article

1982

THE EFFECT OF FORWARD AND BACKWARD-MASKING BY FLASH ON APPARENT SIZE

WILDING, J. (1982). THE EFFECT OF FORWARD AND BACKWARD-MASKING BY FLASH ON APPARENT SIZE. PERCEPTION, 11(2), 153-162. doi:10.1068/p110153

DOI
10.1068/p110153
Journal article

1969

MANAGERIAL GOALS AND INDIVIDUAL NEEDS IN SALESMENS COMPENSATION PLANS

DEWHURST, R. E., WILDING, J., & SUOJANEN, W. W. (1969). MANAGERIAL GOALS AND INDIVIDUAL NEEDS IN SALESMENS COMPENSATION PLANS. ATLANTA ECONOMIC REVIEW, 19(4), 14-16. Retrieved from https://www.webofscience.com/

Journal article

1968

CONSUMER GOALS AND REACTIONS TO A COMMUNICATION SOURCE

WILDING, J., & BAUER, R. A. (1968). CONSUMER GOALS AND REACTIONS TO A COMMUNICATION SOURCE. JOURNAL OF MARKETING RESEARCH, 5(1), 73-77. doi:10.2307/3149797

DOI
10.2307/3149797
Journal article

INDUSTRIAL PURCHASING - SOME INSIGHTS FROM CONSUMER BEHAVIOR

WILDING, J. (1968). INDUSTRIAL PURCHASING - SOME INSIGHTS FROM CONSUMER BEHAVIOR. ATLANTA ECONOMIC REVIEW, 18(6), 6-&. Retrieved from https://www.webofscience.com/

Journal article